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Summary of the Thesis 
 
Lipoproteins play a crucial role in the regulation of biological and cellular 
functions in humans by serving as a mode of transport for the uptake, storage 
and metabolism of lipids. Correlation studies between various lipoproteins have 
indicated that the metabolism of plasma lipoproteins is complex and highly 
interrelated. Dysregulation in lipoprotein metabolism, also known as 
dyslipidaemia, has been found to be strongly correlated to various diseases 
such as cardiovascular disease, diabetes and hypertension, among others. 
Given the prominent role played by lipoproteins in these disease states, 
understanding lipoprotein management is a crucial treatment strategy.  
 
The impact of dyslipidaemia on human health has led physiologists, 
biochemists, pharmacologists and clinicians to contribute a concerted effort in 
lipoprotein research. Although lipoprotein metabolism has been under intense 
investigation over the past 60 years, most of this information is contained in the 
form of natural language in various electronic journals and information sources. 
As the amount of experimental results, clinical data and scientific knowledge 
increases, there is a growing need to promote interoperability of these 
resources, support formal analyses, and utilise this knowledge that may lead to 
novel insights into physiological processes and hypothesis formulation. A 
particularly relevant end-result is translating research outputs from these 
endeavours into improvements in the treatments of dyslipidaemia. 
 
The challenge is to represent and structure lipoprotein knowledge in an explicit 
way in order to produce a knowledge base that is amenable to scientific 
investigation and clinical application. Ontologies serve this purpose by providing 
a controlled vocabulary of well-defined concepts with specified relationships 
between them. They provide a mechanism for sharing a common vocabulary in 
a domain to support information exchange and are the basis for intelligent 
retrieval of information. This facilitates interoperability between research groups 
and information systems, which is essential in the lipoprotein area where there 
exists a multitude of research groups working disparately, in need of a common 
collaboration platform. Ontologies are becoming increasingly relevant in life 
sciences, as evident from the emergence of a number of biomedical ontologies. 
Some of these ontologies include the Gene Ontology, Protein Ontology, Lipid 
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Ontology, among many others. However, to our knowledge, an ontology specific 
to lipoproteins does not exist as yet.  
 
In order to address the issues that have been outlined above, we have 
developed Lipoprotein Ontology, a structured formal framework which 
represents a concise and coherent picture of current, fundamental knowledge in 
the lipoprotein research domain.  Lipoprotein Ontology consists of six sub-
ontologies: Classification, Metabolism, Pathophysiology, Aetiology, Treatment 
and Diagnostic Parameter. Lipoprotein Ontology provides a formal 
representation for lipoprotein concepts and relationships that can be used to 
support the intelligent retrieval of information. Lipoprotein Ontology can also 
facilitate successful collaboration between research groups or software agents 
by providing a common platform of shared and agreed knowledge. Furthermore, 
Lipoprotein Ontology supports the inference of knowledge, which has 
tremendous potential in the development of tools for the diagnosis and treatment 
of dyslipidaemia.  
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Lipids such as cholesterol, triglycerides and fatty acids are essential compounds 
for physiological function in humans. Due to their insolubility in aqueous 
medium, these fat-like substances form a complex with proteins 
(apolipoproteins) in order to be transported in blood through the circulation to 
where they are required. This lipid and protein complex is referred to as 
lipoproteins.  
 
Dysregulation in lipoprotein metabolism, referred to as dyslipidaemia, has been 
found to be a key risk factor for cardiovascular disease, the leading cause of 
deaths worldwide (WHO, 2012). The prevalence of dyslipidaemia is increasing 
to epidemic proportions in industrialised nations as a consequence of sedentary 
lifestyles and high cholesterol/high-fat diet (WHO, 2012). 
 
The impact of dyslipidaemia on human health has led physiologists, 
biochemists, pharmacologists and clinicians to address the complexities 
associated with the disruption of lipoprotein metabolism from different 
perspectives. As clinical data and experimental results from various research 
groups are constantly generated and added to the repository of literature, 
integrating all this information within a collective context proves to be a 
challenge.  
 
This chapter begins with an overview of the lipoprotein research domain, and 
describes the lack of a formal framework for knowledge representation in the 
lipoprotein domain. We then discuss issues in the lipoprotein research domain 
which serve as motivation for the thesis, present the scope of the problem, 




1.2 An Overview of Lipoprotein Research Domain 
 
The lipoprotein transport system is critical for the supply, exchange and 
clearance of essential lipids in the body. Various lipoproteins, apolipoproteins, 
enzymes, transporters, and receptors in this system interact to maintain healthy 
body function. This delicate physiological balance can be impacted by a number 
of factors, including obesity, diet/nutrition, physical exercise and other factors 
such as smoking and alcohol consumption. Dysregulation in lipoprotein 
metabolism, known as dyslipidaemia, has been found to be significantly 
associated with various diseases such as cardiovascular disease, diabetes, and 
hypertension, among others. Treatment of dyslipidaemia is complex and varies 
from individual to individual according to the lipoprotein content.  In order to 
present the lipoprotein domain in a coherent way, we have reviewed and 
organised lipoprotein knowledge from five following aspects: Classification, 




The basic lipoprotein structure comprises of a hydrophobic core of triglycerides 
and cholesteryl esters, surrounded by a hydrophilic outer layer of phospholipids, 
cholesterol and apolipoproteins. Lipoproteins are primarily classified into five 
major classes according to size and density, which are dependent on the 
amounts of lipid and protein components they contain (Alaupovic et al., 1971). 
Ranging from the largest to smallest in size, major lipoprotein fractions include 
chylomicrons, very low density lipoproteins (VLDL), intermediate density 
lipoproteins (IDL), low density lipoproteins (LDL) and high density lipoproteins 




Within the circulation, all lipoproteins are highly dynamic, changing in 
composition and structure as their lipid components and apolipoproteins are 
acquired and catabolised via various lipoprotein metabolism pathways. 
Eventually, lipoproteins are taken up and catabolised in the liver, kidney and 
peripheral tissues via receptor-mediated and other mechanisms. A clear review 
of lipoprotein metabolism in normal physiological condition is crucial to 
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understanding the concepts presented in this thesis as well as the changes in 
diseased states. For the purpose of this introduction, we briefly summarise the 
processes of lipoprotein physiology below, which will be further elucidated in 
Chapter 2.  
 
There are three major pathways involved in lipoprotein metabolism, depending 
on whether the lipoproteins are composed of dietary lipids, whether they are 
synthesised in the liver or whether they involve the synthesis and transport of 
HDL.  
 
The exogenous pathway involves the transport of dietary lipids (triglycerides and 
cholesterol) from the intestines to the liver and peripheral tissues. Following 
intestinal absorption, dietary triglycerides and cholesterol are combined with 
apoB-48, phospholipids and cholesterol to produce nascent chylomicrons. 
These chylomicron particles are then secreted via the lymphatic system into the 
circulation where they acquire apoC and apoE from other lipoproteins 
(Redgrave, 1983). Triglycerides are removed from the chylomicron particles by 
enzymatic action of the lipoprotein lipase (LPL), after which the chylomicron 
particles become smaller and are converted into chylomicron remnants, which 
are then removed from the circulation by hepatic apoE/apoB receptor 
(Redgrave, 1983). 
 
In the endogenous pathway, lipids synthesised in the liver are transported from 
the liver to peripheral tissues. VLDL contains one molecule of apoB-100 and 
acquires cholesteryl esters, apoC and apoE from HDL. The lipolysis of VLDL is 
facilitated by apoC-II and inhibited by the apoC-III content of the lipoprotein 
particles (Shachter, 2001). The triglycerides in VLDL are lipolysed into free fatty 
acids by LPL as VLDL gets broken down to form IDL. The triglycerides in IDL 
are further lipolysed by hepatic lipase to form LDL or taken up by the liver via 
apoE-mediated binding with the LDL receptor (Chappell & Medh, 1998). LDL 
transport mainly cholesterol from the liver to cells of the body and are 
metabolised by apoB-100 mediated binding with the LDL receptor (Twisk et al., 
2000).  
 
The reverse cholesterol transport pathway involves the transport of excess 
cholesterol from the peripheral tissue to the liver via HDL. HDL is synthesised in 
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the liver and intestines and released into the blood-stream. HDL acts as 
cholesterol scavengers, acquiring free cholesterol from cell membranes and 
triglycerides from other lipoproteins and transporting excess cholesterol from the 




Dysregulation in lipoprotein metabolism, known as dyslipidaemia, has been 
identified to be an independent and major risk factor for cardiovascular disease 
(Lorenzo et al., 2007; Wilson et al., 2005). Dyslipidaemia is generally 
characterised by increased plasma triglycerides, increased levels of LDL 
cholesterol (commonly referred to as the "bad cholesterol"), and reduced HDL 
cholesterol (commonly referred to as the "good cholesterol") (Chan et al., 2004). 
Besides being a major risk factor for cardiovascular disease, dyslipidaemia has 
also been found to be present in other disease states such as the metabolic 
syndrome, diabetes and hypertension, among others. Although usually present 
concurrent with other symptoms such as obesity, insulin resistance, the 
importance of dyslipidaemia is that with proper management, it is an eminently 
remediable state. Major clinical trials have reported that manipulating lipoprotein 
levels such as lowering LDL cholesterol slowed the progression of 
atherosclerosis and decreased the incidence of cardiovascular events 
(Christakis et al., 1966). The reduction in the relative risk of cardiovascular 
events has been documented in patients with and without cardiovascular 
disease and also in patients with mild or severe dyslipidaemia. Thus, a better 
understanding of the pathophysiology of lipoprotein metabolism will help health 
care professionals to provide better care in the realm of dyslipidaemia 
management and improve clinical management strategies. 
 
1.2.4 Aetiology of Dyslipidaemia 
 
There are several contributing factors to dyslipidaemia. Lifestyle contributes to 
most cases of dyslipidaemia in adults. The most prominent cause in 
industrialised countries is a sedentary lifestyle with lack of physical exercise and 
excessive dietary intake of saturated fat and cholesterol. Other common causes 
include smoking, alcohol consumption and stress (butMarieb, 2000; Wright, 
2002). Drug interactions may also contribute to lipoprotein dysregulation. Some 
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examples are corticosteroids (Fernández-Miranda et al., 1998; Hochberg & 
Petri, 1991) and beta-blockers (Feher et al., 1988). Genetic mutations may result 
in either the overproduction or defective clearance of LDL cholesterol and 
triglycerides, or the underproduction or excessive clearance of HDL (Clauss & 
Kwiterovich Jr., 2003).  
 
1.2.5 Treatment of Dyslipidaemia 
 
Treatment options to correct dyslipidaemia include lifestyle changes or 
pharmaceutical drugs such as statins, fibrates, bile acid sequestrants and 
cholesterol absorption inhibitors, or a combination of both. The first line 
approach is often lifestyle changes such as weight loss, exercise and dietary 
modification. Studies have found that the incidence of cardiovascular disease is 
lowered 25-60% when therapeutic agents which lower plasma lipids are 
administered to random, middle-aged men (Christakis et al., 1966). In light of 
this, tailoring the most appropriate dietary or drug therapy to individuals with 
specific lipoprotein profiles might be even more beneficial, especially when such 
treatment is administered earlier on. Combination therapy involves the use of 
dual or multiple lipid-regulating agents to treat lipoprotein abnormalities by 
targeting specific lipoproteins and utilising the complementary mechanisms of 
action of the different agents (Jacobson, 2001). This is a more effective 
treatment strategy where lipid-regulating monotherapy (e.g. statins or fibrates) 
may not provide adequate improvement in dyslipidaemia. However, there are 
some contraindications between different treatments. Although beneficial in 
correcting dyslipidaemia, the combinations of statins with fibrates or niacins 
have the potential for interactions that increase the risks of adverse effects, such 
as myositis and hepatotoxicity (Bays & Dujovne, 1998). Hence, treatment of 
lipoprotein dysregulation necessitates a thorough examination of lipoprotein 
profiles of specific individuals. 
 
1.3 Lack of Formal Framework for Lipoprotein Knowledge 
 
The lipoprotein research domain broadly covers the classification of lipoproteins, 
lipoprotein metabolism, lipoprotein dysregulation, causes as well as treatment of 
dyslipidaemia. Lipoproteins and their implication in health have been extensively 
documented and archived in PubMed over the past 60 years. As such, most of 
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this information is contained in the form of natural language in various electronic 
journals and information sources. This poses a challenge for researchers and 
health practitioners in retrieving and integrating relevant knowledge amongst 
massive quantities of heterogeneous information. In addition, as lipoprotein 
research rapidly becomes more advanced and complex with the discovery of 
new relevant components, associations and risk factors, it is becoming 
increasingly difficult even for lipoprotein experts to to assimilate and integrate 
the new information in the context of their existing knowledge. 
 
The lack of formal framework for lipoprotein knowledge also undermines 
collaboration effort between different research groups. As lipoprotein research 
often involves researchers from various sub-disciplines of biomedical science 
such as physiology, biochemistry, pharmacology, etc., the lack of a common 
research platform may lead to duplication in research efforts, inconsistencies in 
research context, among others. As the biomedical community is moving 
towards a systems approach to solving research issues with practical 
implications and a strong emphasis towards improving health, having a formal 
framework for lipoproteins would provide a common platform for collaboration. In 
turn, this allows the effective integration of lipoprotein knowledge across different 
investigation avenues.  
 
1.4 Motivation of Study 
 
Several issues within the lipoprotein domain have been identified as the 
motivation for the thesis. These issues are discussed as follows. 
 
1.4.1 Complex Metabolism Pathways 
 
Correlation studies between various lipoproteins have indicated that the 
metabolism of plasma lipoproteins is complex and highly interrelated (Frayn, 
2003) (Eisenberg, 1983). Understanding the impact of the dysregulation of 
lipoprotein metabolism necessitates knowledge of the synthesis, structure and 
metabolism of lipoproteins and their individual lipid components, including how 
they are incorporated, transported and trafficked within their respective 
lipoprotein classes. It is also important to note that these processes involve a 
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constant and dynamic flow and remodelling of particles where lipid molecules 
and apolipoproteins are gained and lost through highly complex pathways.  
 
The complexity of lipoprotein metabolism pathway presents a need for a 
framework for lipoprotein knowledge representation. Modelling the relations 
between lipoprotein entities leads to a better understanding of the complex 
interrelationships between lipoprotein particles, receptors and enzymes 
necessary for functional lipid distribution in normal physiological conditions as 
well as in diseased states. Because the metabolism of the plasma lipoproteins is 
highly interrelated, one must consider each of the lipoproteins and their 
subclasses to optimise the complete lipid profile for different individuals.  
 
1.4.2 Lipoprotein Dysregulation and its Implications on Disease 
 
Lipoprotein dysregulation, known as dyslipidaemia, occurs as a consequence of 
alterations in the kinetics of lipoproteins. Dyslipidaemia has been found to be 
significantly associated with various diseases such as cardiovascular disease, 
diabetes and hypertension, among others. The key to alleviating this risk is a 
close examination lipoprotein metabolism and the changes in lipoprotein 
components associated with the various disease states.  
 
1.4.3 Causes of Dyslipidaemia 
 
As briefly outlined in Section 1.2.4, there are several contributing factors to 
dyslipidaemia. The challenge is to attempt to map these causes and link them to 
various lipoprotein disorders, in order to enable the extrapolation of the relations 
between these concepts into easily identifiable risk factors for quick 
identification.   
 
1.4.4 Diagnosis and Treatment of Dyslipidaemia 
 
Although several guidelines exist to define dyslipidaemia, diagnostic parameters 
vary among different individuals, according to gender and ethnicity. In addition, 
the diagnosis of dyslipidaemia also takes into consideration other factors such 
as blood pressure, waist circumference, etc. Thus, it can sometimes be 
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challenging for a health practitioner to interpret the correct diagnostic 
parameters for specific individuals and prescribe the appropriate treatment.  
 
There are two issues with the treatment of dyslipidaemia which reinforce the 
need for a framework for lipoprotein knowledge representation.  
 
Firstly, treatment of dyslipidaemia often involves the use of multiple lipid-
regulating agents by targeting specific lipoproteins and utilising the 
complementary mechanisms of action of different agents. However, drug 
interactions may increase the risk to adverse effects and/or morbidity in certain 
individuals (Bays & Dujovne, 1998). These risks may be potentially reduced if 
these interactions can be mapped in a systematic way. 
 
Secondly, studies on the interaction between the medical profession and the 
pharmaceutical industry suggest that health practitioners are affected by the 
influence of gifts and endorsements from the drug industry (Wazana, 2000). 
Bias was also found towards the sponsor's drugs in randomised clinical trials 
which undermine the results of research (Bero et al., 2007). These controversial 
issues present a need for an objective and unbiased representation of treatment 
pathways that are not tied to any sponsorship affiliation.  
 
1.5 Scope of the Problem 
 
Previously, we have discussed several challenges in the lipoprotein domain due 
to the lack of formal framework for lipoprotein knowledge. We attempt to address 
these challenges by developing a framework of lipoprotein concepts and their 
relationships to represent the lipoprotein research domain. The principal subject 
of interest is the lipoprotein research domain. One of the most significant issues 
identified in this thesis is to determine what it is that needs to be represented. 
Based on the challenges in the lipoprotein domain that have been identified, we 
will organise lipoprotein knowledge according to five key areas: Classification, 
Metabolism, Pathophysiology, Aetiology and Treatment. In order to represent 
these key areas, the research questions that need to be addressed are:  
 
1. How can we model lipoprotein concepts and relationships such that they 
can be used as a representation of the lipoprotein research domain? 
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Specifically, how can we represent complex lipoprotein metabolism 
pathways in terms of concepts and relationships? 
2. How can the model be used to aid knowledge integration and management 
in the lipoprotein domain? How can we use this framework to infer 
knowledge to aid diagnosis of lipoprotein dysregulation?  
3. How can such a model facilitate collaboration between users? For 
instance, how can we develop this platform for easy transference of 
research output from different research groups?  
4. How can we validate our framework such that it is consistent and easily 
extensible? 
 
Due to the overwhelming amount of research available on lipoproteins, it is 
necessary to clarify at this stage that the focus of the lipoprotein knowledge 
representation framework is on breadth rather than depth; we limit ourselves to 
the most important lipoprotein concepts, especially focusing on lipoprotein 
metabolism pathways, the pathophysiology of lipoprotein dysregulation and its 
implication on health. Where discrepancy is found in the literature, the common 
approach is adopted and inconsistencies noted.  
 
1.6 Research Objectives 
 
The main objective of this thesis is to establish a framework for the concepts 
within the lipoprotein domain so that the heterogeneous and dispersed 
information in this field can be organised, related and formally represented in a 
meaningful way. In particular, the focus is to address specific challenges within 
the lipoprotein domain that has been outlined in Chapter 1.4. Therefore, the 
objectives of this thesis are aligned with the research questions identified in 
Chapter 1.5. This objective can be achieved through the following 4 sub-
objectives: 
 
• Objective 1. To develop an overall methodology framework towards the 
development of Lipoprotein Knowledge Representation. This is addressed 
in Chapter 5. 
 
• Objective 2. To conceptualise lipoprotein concepts and structure the 
lipoprotein domain into six sub-domains as follows: describing the 
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classification of lipoproteins in healthy individuals (Classification), 
modelling the complex metabolism of lipoproteins through systematic 
relationships between lipoprotein concepts (Metabolism), transferring this 
approach to the classification of lipoproteins in patients with lipoprotein 
disorders (Pathophysiology), mapping the causes of dyslipidaemia 
(Aetiology), modelling treatment options for lipoprotein disorders 
(Treatment) and providing a consistent representation of diagnostic 
parameters for dyslipidaemia (Diagnostic Parameter). This is described in 
Chapter 6. 
 
• Objective 3. To formalise the conceptualisation of lipoprotein knowledge in 
OWL representation language in the following sub-ontologies: 
Classification, Metabolism, Pathophysiology, Aetiology, Treatment and 
Diagnostic Parameter. This is detailed in Chapter 7. 
 
• Objective 4. To evaluate Lipoprotein Ontology through the use of case 
studies, which have been developed to evaluate the robustness and 
consistency of the lipoprotein knowledge framework. These case studies 
will be discussed in Chapter 8. 
 
1.7 Thesis Structure 
 
Chapter 1. Introduction 
 
In this chapter, we present an overview of the lipoprotein research domain and 
the lack of formal framework for lipoprotein knowledge representation. We then 
discuss the challenges in the lipoprotein domain, which serve as motivation for 
the thesis, present the scope of the problem as well as research objectives. 
 
Chapter 2. Current State of Lipoprotein Research Domain 
 
Chapter 2 provides a literature of the lipoprotein research domain. This section 
highlights the necessary lipoprotein concepts, and serves as the basis for 
developing the framework for lipoprotein knowledge representation. We then 




Chapter 3. Problem Definition 
 
The first section of Chapter 3 defines the main concepts in this thesis. We 
provide an overview of the problem, followed by the underlying research issues, 
from which we derive the key research questions. We then present our choice of 
research approach. 
 
Chapter 4. Overview of the Solution 
 
Chapter 4 presents an overview of the solution. We initially define ontology as a 
solution for the research issues identified in Chapter 3 and describe current 
applications of ontologies in the biomedical domain. We conclude this chapter by 
providing an overview of Lipoprotein Ontology and the components involved.  
 
Chapter 5. Methodology 
 
In Chapter 5, some of the commonly used ontology-building methodologies are 
reviewed. Based on the critical review of these methodologies, we develop our 
own methodology towards the development of Lipoprotein Ontology, and 
elaborate on the different stages of development in this section. 
 
Chapter 6. Conceptual Framework of Lipoprotein Ontology 
 
Chapter 6 outlines the conceptualisation and structure of Lipoprotein Ontology. 
Building on the literature review on lipoproteins presented in Chapter 2, we 
extract important concepts within the lipoprotein research domain arranged into 
the appropriate hierarchy or sub-ontologies. 
 
Chapter 7. Formalisation of Lipoprotein Concepts 
 
This chapter describes the formalisation of the lipoprotein concepts obtained in 
Chapter 6 in OWL by means of the ontology tool Protege 4.2. We present a 






Chapter 8. Evaluation of Lipoprotein Ontology 
 
Chapter 8 presents several case studies or scenarios which to evaluate and 
validate the correctness and completeness of Lipoprotein Ontology. 
 
Chapter 9. Conclusion, Recapitulation and Future Work 
 
Finally, Chapter 9 concludes this thesis. We present a summary of the thesis 
and review the objectives originally set out in the beginning of this research. We 




In this chapter, we have provided an overview of the lipoprotein research 
domain. Lipoprotein knowledge is organised into the following categories: 
Classification, Metabolism, Pathophysiology, Aetiology and Treatment. We also 
discussed the need for a formal framework for the structured representation of 
lipoprotein knowledge and raised a number of challenges in the lipoprotein 
research domain. Subsequently, the scope of the problem was identified, 
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This chapter begins with an introduction to lipoproteins, in terms of their 
structure, components and metabolism. Subsequently, the implications of 
lipoprotein dysregulation, also known as dyslipidaemia, on health are presented, 
followed by challenges in the diagnosis and treatment of dyslipidaemia. We then 
raise the issue of the nature of biomedical information and discuss KR 
techniques in the management of biomedical data.  
 
2.2 Lipoproteins: Structure and Metabolism 
 
Lipoproteins are soluble complexes of lipids and proteins, which serve as a 
mode of transport for the uptake, metabolism and storage of lipids in humans. 
Within the circulation, lipoproteins are in a state of constant dynamic flux. They 
undergo enzymatic reactions of their lipid components, facilitated and 
spontaneous lipid exchange, transfers of soluble apolipoproteins, as well as 
conformational changes of apolipoproteins in response to compositional 
changes. Eventually, lipoproteins are taken up and catabolised in the liver, 
kidney and peripheral tissues via receptor-mediated pathways and other 
mechanisms.  
 
In order to gain a better understanding of lipoproteins and how they are 
implicated in human health, it is necessary to provide a clear outline of the 
lipoprotein structure and metabolism pathways. Due to the sheer amount of 
knowledge available on lipoprotein and lipid research, this literature review does 
not claim to be exhaustive of all lipoprotein knowledge. It does, however, attempt 
to provide a general overview of the lipoprotein research domain and highlights 
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the necessary concepts for modelling the domain and capture an accurate 
representation of lipoprotein knowledge.  
 
2.2.1 Classification of Lipoprotein Entities 
 
The basic lipoprotein structure is spherical and comprises of a hydrophobic core 
of triglycerides and cholesteryl esters, surrounded by a hydrophilic outer layer of 
phospholipids, cholesterol and apolipoproteins (Figure 1). 
 
 
Figure 1. Basic lipoprotein structure (Wasan et al., 2008). The hydrophobic core is primarily 
composed of triglycerides and cholesterol esters. They are encased by a hydrophilic 
phospholipid monolayer. Apolipoproteins embedded in the phospholipid layer confer structural 
and functional properties to the molecule.  
 
Lipoproteins are primarily classified into classes according to size, as well as 
their relative contents of protein and lipid that determine the densities and 
functions of these lipoprotein classes.  Ranging from the largest to smallest in 
size, major lipoprotein fractions include chylomicrons, very low density 
lipoproteins (VLDL), intermediate density lipoproteins (IDL), low density 
lipoproteins (LDL) and high density lipoproteins (HDL). Chylomicrons contain 
approximately 1% protein while the protein content of HDL is around 50%. The 
total lipid content is inversely correlated with the density of the lipoproteins, 
chylomicrons being the least dense and HDL the most dense. Lipoprotein(a) 
(Lp(a)) is similar in content to LDL, except it has apolipoprotein(a) attached to it.  
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The lipid content and composition of the major lipoprotein classes are listed in 
Table 1. An enlarged version of this table is shown in Appendix A. While these 
values serve to categorise the different classes of lipoprotein fractions, it is 
important to note that the ratios of the lipids and protein components vary even 
within a given subclass of lipoproteins.  
 
Table 1.  Major lipoprotein classes: A comparison of density, size, electrophoretic mobility, 
percentage of total mass that is triglyceride (TG), cholesterol (C), cholesteryl ester (CE), 




Abbreviations: VLDL, very low density lipoprotein; IDL, intermediate density lipoprotein; LDL, low 
density lipoprotein; HDL, high density lipoprotein; Lp(a), lipoprotein (a). 
 
The functions of the different lipoprotein classes are determined by their lipid 
and apolipoprotein components. Chylomicrons are synthesised in the intestines 
for the transport of dietary triglycerides to various tissues. VLDL are synthesised 
in the liver for the export of endogenous triglycerides, while IDL and LDL are 
derived from the metabolism of VLDL in circulation. The function of LDL is to 
deliver cholesteryl esters to the liver and peripheral tissues. HDL are 
synthesised and assembled in the liver and intestines or formed from the 
metabolism of other lipoproteins in circulation, and from cellular lipids at the cell 
membranes. HDL remove excess cholesterol from cells and transport it to liver 
and other tissues for metabolism and excretion (Chan et al., 2004b). 
 
Because the lipoprotein divisions by density are arbitrary and vary somewhat 
within their own classes, they can also be classified according to their 
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electrophoretic mobility on agarose gels into α, pre-β and β lipoproteins, 
corresponding to HDL, VLDL and LDL lipoprotein fractions respectively. 
Chylomicrons remain at the electrophoretic origin (Snyder, 1977). 
 
2.2.2 Lipoprotein Metabolism 
 
Lipoprotein metabolism involves a constant, dynamic flux and remodelling of 
particles where lipid molecules and apolipoproteins are gained and lost through 
complex pathways involving the catabolism and exchange between particles. It 
is therefore essential to review individual lipoproteins in terms of structure (in 
terms of lipid composition and associated proteins), synthesis, catabolism, 
kinetics (how they interact with each other) and ability to be influenced by other 
metabolites (such as glucose, reactive oxygen species, etc.). This section 
introduces the key components of lipoproteins which are involved in the 
lipoprotein metabolism pathways, and subsequently describes them in the 
context of the various pathways they participate in. A summary of lipoprotein 
metabolism processes, along with the corresponding location and major 
components involved, is presented in Table 2 below. An enlarged version of this 
table is shown in Appendix B. 
 





Abbreviations: VLDL, very low density lipoprotein; IDL, intermediate density lipoprotein; LDL, low 
density lipoprotein; HDL, high density lipoprotein; apo, apolipoprotein. 
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A better understanding of lipoprotein metabolism and its pathophysiology is 
crucial to management of lipoprotein disorders. As plasma LDL concentration is 
positively correlated with the risk to atherosclerosis, it is important to look for the 
factors which cause the high concentrations of LDL particles. Such factors may 
include increased production of LDL or their slow removal from circulation. 
Lipoprotein metabolism is a highly complex and interrelated process. For 
instance, plasma LDL levels are determined not only by LDL receptors but also 
by the rate of VLDL synthesis, the activity of lipoprotein lipase, as well as other 
catabolic processes.  
 
There are three major pathways involved in human lipoprotein metabolism in 
normal physiological conditions, illustrated and described briefly in Figure 2:  
 
1. Exogenous pathway, the transport and metabolism of dietary lipids 
2. Endogenous pathway, the transport of lipids synthesised in the liver 




Figure 2. Overview of lipoprotein metabolism (Hegele, 2009). The three lipoprotein metabolism 
pathways are shown. The main lipids in lipoproteins are free cholesterol (C), cholesteryl ester 
(CE) and triglyceride (TG). In the exogenous transport pathway, hydrolysed dietary fats enter 
intestinal cells or enterocytes via fatty acid (FA) transporters TG is packaged with CE and the 
apolipoprotein (apo) B-48 (B48) into chylomicrons (CM) by microsomal TG-transfer protein 
(MTTP) through a vesicular pathway. CM, secreted via the lymphatic system, enter the vena 
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cava and circulate until they interact with lipoprotein lipase (LPL). CM contain apo, including 
apoA-I (not shown), apo A-II (not shown), apo A-IV (not shown), apo A-V (A5), Apo C-II (C2), 
Apo C-III (C3) and apo E (not shown). Some of the released free FA enter peripheral cells. In 
adipocytes, enzymes including acyl CoA:diacylglycerol acyltransferase (DGAT) resynthesise TG, 
which is hydrolysed by adipose TG lipase (ATGL) and hormone sensitive lipase (HSL). CM 
remnants (CMR) are taken up by hepatic LDL receptor (LDLR), in the absence of LDLR they are 
taken up by LDLR-related protein-1 (LRP1). In the endogenous transport pathway, TG is 
packaged with C and the apo B-100 (B100) into very low-density lipoprotein (VLDL) in the liver 
cells (hepatocytes); the TG contained in VLDL is hydrolysed by LPL, releasing FA and VLDL 
remnants (IDL) that are hydrolysed by hepatic lipase (HL), thereby yielding LDL. In LDL 
cholesterol metabolism, sterols in the intestinal lumen enter enterocytes via the Niemann-Pick 
C1-like 1 (NPC1L1) transporter and some are resecreted by heterodimeric ATP-binding cassette 
transporter G5/G8 (ABCG5/G8). In enterocytes, cholesterol is packaged with TG into CM. In 
hepatocytes, C is recycled or synthesized de novo, with 3-hydroxy-3-methylglutaryl coenzyme A 
reductase (HMGCR) being rate-limiting. LDL transports C from the liver to the peripheral tissues. 
LDL is endocytosed by peripheral cells and hepatocytes by LDLR, assisted by an adaptor 
protein (AP). Proprotein convertase subtilisin/kexin type 9 (PCSK9), when complexed to LDLR, 
short-circuits recycling of LDLR from the endosome, leading to its degradation (X). In the reverse 
cholesterol transport pathway, HDL, via APOA-I (A1), mediates reverse cholesterol transport by 
interacting with ATP-binding cassette A1 (ABCA1) and ABCG1 transporters on non-hepatic 
cells. Lecithincholesterol acyltransferase (LCAT) esterifies C so it can be used in HDL, which, 
after remodelling by cholesterol ester transfer protein (CETP) and by endothelial lipase (LIPG), 
enters hepatocytes via scavenger receptor class B type I (SR-B1). 
 
In the following sections, we discuss the three lipoprotein metabolism pathways 
in further detail, with important concepts highlighted in bold (lipoprotein classes), 
italics (lipoprotein components) and underlined (processes) respectively.  
 
2.2.2.1 Exogenous transport pathway 
 
The exogenous pathway involves the transport of dietary lipids (triglycerides and 
cholesterol) from the intestines to the liver and peripheral tissues. After a meal, 
dietary triglycerides are hydrolysed to monoglycerides and free fatty acids which 
diffuse across the microvillus membrane across the intestines. Triglycerides are 
subsequently resynthesised in the enterocytes, combined with cholesterol, apo 
B-48, apo A-I, apo A-II, apo A-IV and phospholipids to produce nascent 
chylomicrons. These chylomicron particles are secreted via the lymphatic 
system into the circulation where they acquire apoC-II and apoE from plasma 
HDL (Redgrave, 2004). Apo C-II activates lipoprotein lipase (LPL) located on the 
surface of the endothelial cells in adipose and muscle tissues, where 
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triglycerides in chylomicrons are hydrolysed into free fatty acids and glycerol 
by the action of LPL. Liberated glycerol is returned to the liver and kidneys, 
where it is almost exclusively used to produce glycerol-3-phosphate, which can 
enter glycolysis or gluconeogenesis. The free fatty acids are transported into the 
adipose or muscle cells for storage or energy, or can be transported on albumin 
to other parts of the body. Adipocytes can also re-esterify free fatty acids to form 
triglycerides. As the triglycerides are hydrolysed into free fatty acids, 
chylomicrons progressively shrink to form chylomicron remnants. 
Throughout the catabolic process, a substantial portion of phospholipid, apo A 
and apo C-II is transferred to HDL. The loss of apo C-II prevents LPL from 
further degrading the chylomicron remnants. Chylomicron remnants contain 
primarily cholesteryl esters, apo E and apo B-48, and are transported through 
the endothelial cells lining the hepatic sinusoids, into the space of Disse. Here, 
chylomicron remnants are taken up by LDL receptor located on hepatocytes in 
the liver upon activation by apo E. While in the space of Disse, chylomicron 
remnants accumulate additional apo E that is secreted into the space and are 
taken up via the chylomicron remnant receptors which also require activation by 
apo E. In addition, chylomicron remnants can also be taken up via the hepatic 
apo E/apo B-48 receptor (Redgrave, 2004). 
 
2.2.2.2 Endogenous transport pathway 
 
In the endogenous pathway, hepatically synthesised lipids are transported from 
the liver to peripheral tissues (Mahley et al., 1984). Secreted via exocytosis from 
the liver, VLDL carry triglycerides, one molecule of apo B-100, and acquire 
cholesteryl esters, apo C and apo E from HDL. The hydrolysis of VLDL is 
facilitated by apo C-II and inhibited by the apoC-III content of the lipoprotein 
particles (Shachter, 2001). The triglycerides in VLDL are hydrolysed into 
glycerol and free fatty acids by LPL. Free fatty acids are transported into the 
adipose cells to be resynthesised into triglycerides and stored, or oxidised in the 
muscle tissues for energy. As VLDL get catabolised and lose most of their 
triglycerides to peripheral tissues, they transfer a substantial portion of 
phospholipids and apo C to HDL. Subsequently, some VLDL are returned to the 
liver, endocytosed and catabolised through apo E interaction with the remnant 
receptor, while others remain in the circulation as IDL, also known as VLDL 
remnants. At this point, the predominant remaining apolipoproteins associated 
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with IDL are apoB-100 and apo E. The triglycerides in IDL are further 
hydrolysed by hepatic lipase (HL) and lose apo E to form LDL, or taken up by 
the liver via apo B-100 and apo E-mediated binding with the LDL receptor 
(Chappell & Medh, 1998). LDL contain almost exclusively apo B-100 and carries 
the majority of the cholesterol in the blood, amounting to 60 to 80 % of total 
cholesterol. Excess cholesterol may be deposited in artery walls, increasing the 
risk to atherosclerosis. After a plasma half-life of about 2 days, LDL bind to LDL 
receptors located on the plasma membrane of target cells coated with clathrin 
proteins (Brown & Goldstein, 1986). The uptake of LDL to LDL receptors is 
facilitated by apo B-100 and occurs predominantly in the liver (75%), adrenals 
and adipose tissue. Once LDL binds to the LDL receptor, clathrin promotes 
endocytosis and rapidly dissociates the endosomal vesicle. LDL then dissociate 
from the receptors, and the latter are recycled to the cell surface. Upon fusing 
with a lysosome, LDL is then catabolised into its primary components – their 
apolipoproteins are degraded, cholesterol esters are hydrolysed to yield free 
cholesterol, and cholesterol is incorporated into plasma membranes as 
necessary, recycled into newly secreted lipoprotein particles, or degraded into 
bile acids. Excess cholesterol is re-esterified by acyl-CoA-cholesterol 
acyltransferase (ACAT), for intracellular storage (Brown & Goldstein, 1986). 
 
2.2.2.3 Reverse cholesterol transport 
 
HDL-dependent lipid transport is often referred to as reverse cholesterol 
transport (Fielding & Fielding, 1995). It has been shown that HDL removes 
excess cholesterol within the arteries through this pathway; high levels of HDL 
are associated with decreased risk of heart disease (Ghali & Rodondi, 2009). 
HDL is synthesised in the liver and intestines and released into the blood-
stream. Nascent HDL are disk-shaped but they become spherical as they 
acquire free cholesterol from cell membranes and triglycerides from other 
lipoproteins. HDL acts as cholesterol scavengers, transporting cholesterol from 
the tissues back to the liver for excretion or re-utilisation. The transfer of 
cholesterol from the cell membranes to HDL is mediated by ATP-binding 
cassette protein G1 (ABCG1), and free cholesterol in HDL is esterified into 
cholesteryl esters by lecithin:cholesterol acyltransferase (LCAT) upon activation 
by apo A-I. Cholesterol-rich HDL return to the liver, where they bind to the 
scavenger receptor class B type 1 (SR-B1). When HDL binds to SR-B1, the 
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cholesteryl esters of HDL are taken up by the hepatocytes through the caveolae 
while the HDL and SR-B1 remain on the plasma membrane. Cholesteryl esters 
can also be transferred from HDL to apoB-containing lipoproteins (VLDL, IDL 
and LDL) by cholesterol ester transfer protein (CETP) in exchange for 
triglycerides (Tall et al., 1986). This process transforms VLDL and IDL into LDL. 
Thus, HDL has an important role in reverse cholesterol transport: firstly, specific 
HDL subclasses (preβ-HDL) function as primary cholesterol acceptors and are 
able to remove cholesterol from peripheral cells. In addition, after cholesterol 
esterification, cholesterol esters are transferred from HDL to apoB-containing 
lipoproteins in exchange for triglycerides, which can be removed from the 
circulation by hepatic lipase. As HDL grow in size, they acquire apo E which 
increases the binding affinity of HDL towards hepatic receptors, and are 
subsequently catabolised by the liver. 
 
2.3 Impact of Dyslipidaemia on Health 
 
Clinical and epidemiological studies have identified dyslipidaemia, to be a major 
and independent risk factor for cardiovascular disease (Isomaa et al., 2001). 
Dyslipidaemia is the term given to the dysregulation in lipoprotein metabolism; 
this dysregulation can be caused by various factors, which lead to increased 
plasma triglycerides, increased levels of LDL cholesterol (commonly referred to 
as the “bad cholesterol”), and reduced HDL cholesterol (commonly referred to as 
the “good cholesterol”) (Chan et al., 2004a; Chan et al., 2004b). 
 
Dyslipidaemia has also been found to be present in other disease states such as 
the metabolic syndrome, diabetes and hypertension, among others (Alexander 
et al., 2003; Ninomiya et al., 2004). While the progression of each disease state 
is complex and dependent on many factors, managing abnormal lipoprotein 
levels is one of the key clinical targets in treating the associated diseases. 
Studies have found that the incidence of cardiovascular disease is lowered 25-
60% when therapeutic agents which lower plasma lipids are administered to 
dyslipidaemic patients (Christakis et al., 1966). Studies have also found that with 
proper management, dyslipidaemia is an eminently remediable state. In light of 
this, tailoring the most appropriate lifestyle adjustment or drug therapy to 
individuals with specific lipoprotein profiles might be even more beneficial, 
especially when such treatment is administered earlier on.  
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In this section we focus on how changes in lipoprotein levels and their 
associated components alleviate the risk to developing certain disorders. 
 
2.3.1 Key Components in Dyslipidaemia 
 
Prior to describing the pathophysiology of lipoprotein dysregulation, it is 
essential to introduce the clinically relevant components in dyslipidaemia. To 
recapitulate the previous section, the basic lipoprotein structure comprises of a 
hydrophobic core of triglycerides and cholesteryl esters, surrounded by a 
hydrophilic outer layer of phospholipids, cholesterol and apolipoproteins. We 
have also mentioned previously that lipoprotein metabolism involve highly 
complex and dynamic processes which include the transfer, exchange, 
hydrolysis and catabolism of various lipid and apolipoprotein components 
between lipoprotein particles through the action of various receptors and 
enzymes. Even though each and every component is essential for optimal lipid 





Cholesterol is one of the essential lipid components transported by lipoproteins, 
which has several critical physiological functions. It is an essential structural 
component of cell membranes required to establish proper membrane 
permeability and fluidity over a range of physiological temperatures (Brown & 
Goldstein, 1986). Cholesterol is also required in intracellular transport, cell 
signalling and nerve conduction (Brown & Goldstein, 1986). In addition, 
cholesterol is the precursor molecule in several biochemical pathways, and is 
implicated in the manufacture of vitamin D, bile acids, steroid hormones 
including cortisol and aldosterone, as well as sex hormones progesterone, 
oestrogen and testosterone, and their derivatives (Brown & Goldstein, 1986). 
Some research indicates cholesterol may also have antioxidant properties 
(Bandeali & Farmer, 2012). 
 
Although cholesterol is important in human health, high plasma cholesterol has 
been found to be significantly associated with cardiovascular disease. It is 
important to note however, that it is not the total plasma cholesterol level that is 
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clinically relevant to developing the risk to cardiovascular disease, but rather the 
amount of cholesterol bound to the various classes of lipoproteins. We briefly 




Evidence suggests that the propensity towards developing cardiovascular 
disease substantially increases with elevated LDL cholesterol. Excessive LDLs 
lead to potentially lethal cholesterol deposits on the artery walls which increase 




A positive correlation has been found between high plasma concentration of 
Lp(a) and the incidence of cardiovascular disease. Studies have found that 
elevated Lp(a) in plasma can double a man’s risk to cardiovascular events 
before the age of 55 (Marieb, 2000). Lp(a) appears to promote plaque formation 




The risk to cardiovascular disease is inversely related to the concentration of 
HDL in blood; elevated levels of HDL have been found to be associated with a 
low incidence of cardiovascular disease (Natarajan et al., 2010). Further 
research into the role of HDL has shown that HDL containing apo A-I confers 
protective role in cardiovascular disease (Fruchart et al., 1994). In contrast, HDL 
containing apo A-II has been found to increase the risk of cardiovascular 




Triglycerides, the major lipid components of chylomicrons and VLDL, are the 
major type of dietary fat as well as the storage form of fat in the body. Research 
has found that high plasma triglycerides represent a high risk factor for 
cardiovascular disease in both men and women. Furthermore, patients with 
cardiovascular disease and elevated triglycerides have a higher risk of 
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premature death than patients with cardiovascular disease and normal 
triglyceride levels. Studies also suggest that high plasma triglyceride levels are 
associated with low HDL levels and increased amounts of small dense LDL, 




Apolipoproteins are lipid-binding proteins which serve as enzyme modulators 
and receptor ligands that regulate the intravascular metabolism of lipoproteins 
and their tissue uptake. Apolipoproteins have the ability to change conformation 
to adjust to changing lipid contents, compositions and metabolic states of the 
lipoproteins. They also readily disassociate themselves from one lipoprotein and 
bind to another while in circulation; only apolipoprotein Bs, the principal protein 
components of LDL, VLDL and chylomicrons, maintain their association with the 
respective lipoprotein during the cycle of lipoprotein synthesis and metabolism. 
Table 3 lists the major apolipoproteins, their associated lipoprotein classes, 
molecular weight, concentration in plasma, synthesis site and function. An 
enlarged version of this table is shown in Appendix C. 
 
Because apolipoproteins interact directly with various lipoprotein receptors and 
lipases, changes in apolipoprotein levels may therefore potentially have negative 

















Table 3. Major human apolipoproteinsa, associated lipoprotein classes, molecular weight, 




Abbreviations: apo, apolipoprotein, VLDL, very low density lipoprotein; IDL, intermediate density 
lipoprotein; LDL, low density lipoprotein; HDL, high density lipoprotein; Lp(a), lipoprotein (a); 
ABCA1, ATP-binding cassete transporter; TG, triglycerides; TRL, triglyceride-rich lipoprotein; 
LPL, lipoprotein lipase; HL, hepatic lipase; LDLr, LDL receptor; LCAT, lecithin-cholesterol 
acyltransferase; CETP, cholesteryl ester transfer protein; LSR, lipolysis-stimulated lipoprotein 
receptor.  
 
a Other minor apolipoproteins isolated from lipoprotein fractions include apo F, apo H, apo J, apo 
L, and apo M. They are present in plasma in low concentrations and do not have well-defined 
functions in lipoprotein metabolism 
b In bold are the lipoprotein classes containing the highest proportion of the apolipoprotein; in 
italics are secondary lipoprotein classes 
* To a lesser extent 
 
2.3.2 Clinical and Metabolic Features of Dyslipidaemia 
 
Lipid metabolism is a highly dynamic and interrelated process, leading to 
changes in plasma lipoprotein function and/or levels. Although lipoprotein 
concentrations in blood plasma are highly variable, depending on age, sex, 
feeding state, metabolic/hormonal state and disease state of individuals, a 
representative lipoprotein distribution of a fasting, healthy adult male in plasma 
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is approximately 0 mg/dl for chylomicrons, 150 mg/dl for VLDL, 410 mg/dl for 
LDL and 280 mg/dl for HDL. 
 
The dysregulation of lipoprotein metabolism, known as dyslipidaemia, covers a 
wide range of lipid abnormalities, which increase the risk to cardiovascular 
disease. Atherosclerosis, a type of cardiovascular disease, is one of the most 
prevalent diseases leading to mortality in developed countries. It is initially 
caused by the deposition of cholesterol in blood vessels. Most of the cholesterol 
in blood is transported in the form of LDL particles into the arterial wall. In normal 
physiological conditions, cholesterol is removed by HDL and recirculated in 
plasma. Dysregulation in LDL metabolism leads to the increase in the residence 
time of LDL particles in blood, leading to their oxidation and deposition on the 
arterial wall, which is the site for atherogenesis. The inability of macrophages to 
regulate the uptake of oxidised LDL, in conjunction with insufficient removal of 
cholesterol by HDL particles, causes the accumulation of cholesterol and the 
formation of foam cells which gives rise to atherosclerosis (Kannel et al., 1979). 
 
The processes by which lipids and lipoproteins contribute to the formation of 
atherosclerotic plaque and cardiovascular events continue to be an area of 
controversy and research; however the association between elevated levels of 
LDL cholesterol and increased risk to cardiovascular disease is indisputable 
(Kannel et al., 1979; Lorenzo et al., 2007). It is beyond the scope of this thesis to 
elaborate on the events that lead up to atherosclerosis; instead, we focus 
specifically on dyslipidaemia. In general, dyslipidaemia is characterised by 
increased levels of LDL cholesterol and VLDL cholesterol, elevated plasma 
triglycerides, reduced HDL cholesterol. These factors are strongly and 
independently associated with cardiovascular disease (Ginsberg & Stalenhoef, 




Concentrations of LDL cholesterol have been found to be predictive of the risk of 
cardiovascular disease over a wide age range (Kannel et al., 1979). Moreover, 
mortality rates from cardiovascular disease in different communities are directly 
and linearly correlated with plasma concentrations of cholesterol and LDL 
cholesterol (Lewis et al., 1978). Major clinical trials have reported that 
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manipulating lipoprotein levels such as lowering LDL cholesterol slowed the 
progression of atherosclerosis and decreased the incidence of cardiovascular 
events (Frick et al., 1987; Kannel et al., 1979). The reduction in the relative risk 
of cardiovascular events has been documented in patients with and without 
cardiovascular disease and also in patients with mild or severe dyslipidaemia 
(Kannel et al., 1979). Evidence have found that individuals with predominantly 
small dense LDL have a threefold risk of developing cardiovascular disease 
compared with those who have predominantly large LDL  (Lamarche et al., 
1997). 
 
VLDL and Triglycerides 
 
The elevated triglyceride concentration observed in dyslipidaemic patients is 
mainly a consequence of alterations in VLDL metabolism (Chan et al., 2004a; 
Chan et al., 2004b). Dysregulation of VLDL metabolism in hypertriglyceridaemia 
is predominantly caused by the changes in kinetics of various apolipoproteins 
present in plasma lipoproteins. This includes overproduction of plasma apoC-III  
(Batal et al., 2000; Cohn et al., 2004), overproduction of VLDL apoB-100 and 
decreased catabolism of apoB-containing particles (Chan et al., 2004a; Chan et 
al., 2004b), all of which have negative implications on lipid metabolism. In the 
insulin resistant state, increased levels of free fatty acids liberated from 
peripheral fat tissue stimulate the synthesis of triglyceride-rich VLDL particles by 
the liver. This process also lowers HDL cholesterol concentrations via 
stimulation of cholesteryl ester transfer protein (CETP) and the hepatic lipase 
(HL). In turn, LDL particles become triglyceride-enriched and undergo lipolysis 
by HL to form small dense LDL particles, leading to the accumulation of 




The higher the HDL cholesterol concentration to the total cholesterol level, the 
lower the risk. Some factors known to influence cardiovascular risk can be 
related to HDL levels; for example, cigarette smoking lowers HDL, and the HDL 
level is higher in individuals who exercise regularly (Enger et al., 1977). 
Moderate alcohol intake was associated with increased HDL cholesterol and 
reduced cardiovascular risk (Pearson, 1996). Moreover, premenopausal women, 
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who have a lower incidence of cardiovascular disease compared to their male 
counterparts, have a higher concentration of HDL, due to the atherosclerotic-
protective property of the female sex hormone, oestrogen  (Kannel et al., 1976). 
After the production of oestrogen ceases at menopause, the incidence of 




Another predictor of cardiovascular disease is the inverse relationship between 
LDL and HDL. The correlation between LDL/HDL ratio with CVD has been 
studied extensively; these associations are strong, predictive and independent 
of other risk factors (Lewis, 1983). The plasma HDL-cholesterol/total cholesterol 
ratio is also one of the predictors of the risk to developing cardiovascular 




Recently, it was established that a high plasma apo B level combined with a 
high LDL cholesterol concentration, with or without hypertriglyceridaemia, is 
indicative of hyperapobetalipoproteinemia, which increases the risk to premature 
cardiovascular disease (Jellinger et al., 2012). The Apolipoprotein-Related 
Mortality Risk (AMORIS) study presents evidence that plasma apo B level may 
be equivalent or superior to LDL cholesterol, non-HDL cholesterol or other 
cholesterol ratios in predicting risk to cardiovascular disease  (Walldius et al., 
2001). 
 
It is important to note that these risk factors do not exist exclusively on their own, 
but rather, they must be considered within the context of lipoprotein metabolism. 
For example, an increase in LDL cholesterol may be caused by the increased 
production of LDL, and/or their slow removal from the circulation, among other 
factors. It is therefore crucial to model these lipoprotein components in 
hierarchical and associative relations in order to present a clear elucidation of 






2.3.3 Dyslipidaemia and the Metabolic Syndrome 
 
Dyslipidaemia in the metabolic syndrome is often clustered with other factors 
such as insulin resistance, impaired glucose regulation, visceral obesity and 
hypertension (NCEP, 2001; IDF, 2005; WHO, 1998). Studies have shown that 
the clustering of these metabolic abnormalities co-occur beyond chance  
(Aizawa et al., 2006), and that when grouped together, they increase the risk to 
cardiovascular disease, type 2 diabetes and chronic kidney disease (Isomaa et 
al., 2001; Lakka et al., 2002). The prevalence of metabolic syndrome has varied 
significantly amongst different studies, presumably due to the lack of accepted 
criteria for the definition of the syndrome (Cameron et al., 2004). Numerous 
definitions have therefore been established to diagnose “metabolic syndrome” 
(Table 4). An enlarged version of this table is shown in Appendix D. 
 
Table 4. Clinical definitions of the metabolic syndrome. 
 
 
Abbreviations: WHO, World Health Organization; NCEP/ATP III, National Cholesterol Education 
Program Adult Treatment Panel III; IDF, International Diabetes Foundation. 
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The first operational definition of metabolic syndrome was proposed by the 
World Health Organization in 1998 (WHO, 1998). WHO states that the main 
criterion is impaired glucose regulation, and two or more other components, 
such as abdominal obesity, dyslipidaemia, hypertension and microalbuminuria. 
The National Cholesterol Education Program Expert Panel (NCEP/ATP III) 
describes metabolic syndrome as the occurrence of three or more criteria such 
as obesity, hyperglycaemia, dyslipidaemia and hypertension. Although the 
above two definitions include the same core criteria, the cut-off points for each 
component and the mandatory requirements differ, which leads to a difficulty in 
assessing metabolic syndrome within different populations  (NCEP, 2001). To 
resolve this issue, the International Diabetes Federation (IDF) proposed a global 
definition of metabolic syndrome in (IDF, 2005). The IDF definition has increased 
waist circumference as a key requirement, stating central obesity as the main 
feature plus two or more criteria such as hyperglycaemia, dyslipidaemia and 
hypertension. Ethnic-specific cut-off points were also introduced for waist 
measurements due to racial differences between level of adiposity and risk to 
morbidities, allowing for a more accurate diagnosis of metabolic syndrome.   
 
Currently, the two definitions that are most commonly used are the IDF and 
NCEP/ATP III definitions, although some practices still adhere to the WHO 
definition. An update of the NCEP/ATP III guidelines, renamed NCEP/ATP IV 
are still in progress, and expected to be released in 2013 (Martin et al., 2012). 
 
2.4 Management of Dyslipidaemia 
 
Although a number of guidelines currently exists on the appropriate 
lipid/lipoprotein levels, the management of dyslipidaemia remains a challenge. 
Much of this challenge lies in the interpretation of abnormal lipid and lipoprotein 
levels in the context of traditional risk factors such as family history or smoking 
and/or other newer risk factors. To have a better understanding of the 
management of dyslipidaemia, we initially discuss the guidelines which define 
the dyslipidaemic condition, the causes (aetiology) of lipoprotein dysregulation 






2.4.1 Diagnostic Parameters 
 
In clinical practice, dyslipidaemia can be diagnosed by measuring the plasma 
levels of total cholesterol, triglycerides and individual lipoproteins and comparing 
these levels to established guidelines with a strong emphasis towards 
cardiovascular risk. The most frequently used guideline for dyslipidaemia 
management is the National Cholesterol Education Program guideline presented 
by the Third Report of the Expert Panel on Detection, Evaluation, and Treatment 
of High Blood Cholesterol in Adults (NCEP/ATP III) (NCEP, 2001). This 
guideline is currently being updated to its fourth version (NCEP/ATP IV) and is 
expected to be released in 2013 (Martin et al., 2012).  Many other guidelines 
exist, such as the International Diabetes Foundation guidelines (IDF, 2005), the 
World Health Organization guidelines (WHO, 1998), and more recently, the 
American Association of Clinical Endocrinologists (AACE) 2012 guidelines 
(Jellinger et al., 2012) and the American Heart Association (AHA) 2011 
guidelines (Miller et al., 2011). 
 
Although these guidelines exist to assist in the diagnosis of dyslipidaemia, all of 
them also take into consideration other factors such as blood pressure, waist 
circumference, as well as other lipid markers in cardiovascular risk assessment. 
Therefore, establishing accurate guidelines for achieving “ideal” lipid values 
remain to be a very contentious area of research. As it is beyond the scope of 
this research to discuss the correctness of each of these guidelines, we review 
the literature and base our choice of optimal lipid values on three of the most 
commonly used classifications for dyslipidaemia and their associated risk level 
towards developing cardiovascular disease, the NCEP/ATP III, AACE and AHA 
guidelines. Table 5 below summarises the values for various lipids that indicate 
low to high risk for cardiovascular disease; standard fasting blood tests for 
cholesterol and lipid profiles will include values for total cholesterol, HDL 
cholesterol, LDL cholesterol, triglycerides and apo B level. An enlarged version 
of this table is shown in Appendix E. For the purpose of this thesis, we focus 
specifically on the lipid profile values, although for future work, it would be very 
interesting to factor in other risk factors such as blood pressure, and lifestyle 




Table 5. Classification of risk factors of various lipids according to LDL-cholesterol, total plasma 




Abbreviations: NCEP/ATP III, National Cholesterol Education Program Adult Treatment Panel III; 
AACE, American Association of Clinical Endocrinologists; AHA, American Heart Association  
 
 
2.4.2 Aetiology of Dyslipidaemia 
 
There are several contributing factors to dyslipidaemia. Dyslipidaemia can be 
the result of lifestyle, the interaction between genetic predisposition and 
environmental factors, or other diseases, or a combination of both. 
Dyslipidaemia which occur due to genetic causes are referred to as primary 
dyslipidaemia, while secondary dyslipidaemia arise due to other underlying 
causes such as lifestyle, or other disease states. 
 
Lifestyle contributes to most cases of dyslipidaemia in adults. The most 
prominent cause in industrialised countries is a sedentary lifestyle with lack of 
physical exercise and excessive dietary intake of saturated fat and cholesterol. 
Other common causes include smoking, alcohol consumption and stress 
(Marieb, 2000; Wright, 2002). 
 
Genetic mutations may result in either the overproduction or defective clearance 
of LDL cholesterol and triglycerides, or the underproduction or excessive 




Drug interactions may also contribute to lipoprotein dysregulation. Some 
examples are corticosteroids (Fernández-Miranda et al., 1998; Hochberg & 




Lifestyle contributes mainly to the development of dyslipidaemia, referred to as 
secondary dyslipidaemia, due to the increasing trend of high fat/high cholesterol 
diet in the industrialised world. It has been established that high intake of 
saturated fat is significantly associated with the elevation in blood cholesterol 
levels which increase the risk to cardiovascular disease (Gordon, 1988; Wissler 
& Vesselinovitch, 1975). Further studies indicate that trans fatty acids are also 
significantly associated with cardiovascular risk, more so than saturated fats (Hu 
et al., 1997). Reductions in cardiovascular rates have been noted by replacing 
saturated and trans fat with a combination of poly- and mono-unsaturated fat 
than reducing the overall fat intake, with the benefits of polyunsaturated fat 
appearing to be the strongest (Hu et al., 1997). Epidemiological studies 
comparing the rates of cardiovascular disease of migrants from low- to high-risk 
areas indicate that these migrants adopt the rates of the new area (Robertson et 
al., 1977). This evidence indicate strongly that the significant differences in rates 
are not due to genetic factors, but rather, environmental factors and are 
therefore potentially modifiable.  
 
The consumption of alcohol is associated with either a protective or a negative 
effect on the level of circulating LDL. Low-level alcohol consumption, particularly 
red wines which contain the antioxidant resveratrol, appear to be beneficial with 
respect to cardiovascular health. The consumption of resveratrol, a compound 
found largely in the skin of red grapes and other foods, is associated with a 
reduced risk of cardiovascular disease (Vidavalur et al., 2006). One major effect 
of resveratrol in the blood is the prevention of oxidation of LDLs. This has a 
protective effect towards the development of cardiovascular disease as oxidised 
LDLs are significantly associated with atherosclerosis. 
 
Conversely, excess alcohol consumption is associated with increasing the level 
of triglycerides which lead to the development of fatty liver (Di Castelnuovo et 
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al., 2006). This in turn impairs the ability of the liver to take up LDL via the LDL 
receptor resulting in increased LDL in the circulation (Di Castelnuovo et al., 
2006). Clearly a reduction in alcohol consumption will have a significant impact 
on overall cardiovascular and hepatic function.  
 
Cigarette smoking has also been found to lower HDL cholesterol, which 




Primary dyslipidaemia is caused by a number of hereditary factors, which result 
in abnormal quantities of blood fats due to a lack of certain critical components 
involved in lipoprotein metabolism. The most common form of primary 
dyslipidaemia is hyperlipidaemia, can be further defined into various subtypes 
according to the types of lipids which are elevated, such as 
hypercholesterolaemia (elevated cholesterol), hypertriglyceridaemia (elevated 
triglycerides) and combined hyperlipidaemia (a mix of both elevated cholesterol 
and triglycerides). The life long elevation of LDL concentrations in familial 
hypercholesterolemia is associated with a several-fold excess risk of premature 
cardiovascular disease (Stone et al., 1974). On the other hand, cardiovascular 
disease is found to be rare in a familial syndrome characterised by high HDL 
and low LDL concentrations (Glueck et al., 1975) (Glueck et al., 1976). 
 
Primary dyslipidaemia can be classified into various types according to the 
Fredrickson classification through plasma analysis of lipoprotein patterns 
(Fredrickson & Lees, 1965). Table 6 is a summary of primary dyslipidaemia 
classified under the Fredrickson classification system according to the type of 
disorder with respect to its common name (synonym), type of defect, 
electrophoresis pattern, lipoprotein abnormality, concentrations of plasma 
cholesterol and triglycerides, clinical features as well as recommended treatment  
(Beaumont et al., 1970; Fredrickson & Lees, 1965; Levy & Fredrickson, 1968). 






Table 6. Fredrickson/WHO classification of primary hyperlipidaemia according to type with 
respect to its synonym, type of defect, electrophoresis patter, lipoprotein abnormality, 





Abbreviations: VLDL, very low density lipoprotein; IDL, intermediate density lipoprotein; LDL, low 
density lipoprotein. 
 
The Fredrickson classification system has since been adopted by the World 
Health Organisation (WHO) to provide guidelines with respect to the diagnosis 
and treatment of various types of primary dyslipidaemias (Fredrickson, 1971). 
Although the Fredrickson/WHO classification system remains the most widely 
accepted classification system for primary dyslipidaemia, it is by no means the 
most comprehensive classification of lipoprotein disorders. As the Fredrickson 
classification relies on lipoprotein pattern recognition rather than the genetic 
basis of the condition, patients with the same genetic defect may fall into 
different groups or may change groups as the disease progresses or changes 
with treatment. 
 
Recent discoveries of the genetic determinants of variation in plasma lipoprotein 
levels in humans and animal models have enhanced existing knowledge and 
how they have identified new avenues for investigation. Individual variations in 
the levels and structures of lipoproteins in plasma have been found to be 
strongly associated to hereditary influences through classical linkage analysis, 
association studies and animal models. Within the past decade, a small but 
important group of genetic determinants of lipoprotein variation was uncovered 
by resequencing genomic DNA from individuals with extreme lipoprotein 
phenotypes (Cohen et al., 2004). More recently, genome-wide association 
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studies have implicated common variants in numerous loci and genes as being 
the genetic influences underlying the variation that is closer to the population 
median. For example, familial hypercholesterolaemia may be caused by any one 
of over 800 different mutations of the LDL receptor gene (Villéger et al., 2002). 
Mutations of the apolipoprotein B gene have also been found to produce an 
identical syndrome (Myant, 1993).   
 
As these recent advances in genetic research are paving the pathway towards 
new discovery of novel pathways and genetic basis of lipoprotein dysregulation, 
it is becoming increasingly relevant to structure these complex findings within 
the context of existing knowledge. At this stage, it is suffice to classify primary 
dyslipidaemia according to the Fredrickson/WHO Classification, as it is beyond 
the scope of this thesis to explore the intricacies of these genetic causes 
towards primary dyslipidaemia. Although they still need to be investigated 
further, the biological implications of these recent genetic advances may be far-
reaching as they have the potential to broaden our understanding of basic 
metabolic pathways and improve classification, diagnosis and treatment 
strategies.  
 
2.4.2.3 Disease States 
 
In addition to the above genetic causes of blood fat disorders, a number of 
acquired conditions can raise lipoprotein levels. 
 
Diabetes Mellitus is classified under Type I (insulin-dependent) diabetes and 
Type II (non insulin-dependent) diabetes. Type I diabetes provides a clear 
understanding of the relationship between diabetes, insulin deficiency and lipid 
metabolism. Hypertriglyceridaemia and reduced HDL commonly occur in this 
condition, although these can be easily treated with replacement of insulin 
(Ginsberg, 1996). The lipid abnormalities in Type II diabetes, however, cannot 
be easily managed with insulin replacement. These abnormalities include 
elevated triglycerides and reduced HDL cholesterol. In addition, there is also an 
increased amount of small dense LDL which have atherogenic properties 
(Goldberg, 2001). This effect is amplified by obesity (Brunzell & Hokanson, 
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1998). Dyslipidaemia observed in Type II diabetes is often found prior to 
developing the disorder, and is associated with abnormalities in insulin action 
(referred to as insulin resistance) (Goldberg, 2001). In support of this 
hypothesis, some thiazides which improve insulin action leads to significant 
improvements in the lipid profiles of Type II diabetic patients (Ginsberg et al., 
1999). 
 
Hypothyroidism is a common cause of lipid abnormalities as thyroid hormones 
influence all major metabolic pathways, including lipid metabolism. With specific 
regard to lipid metabolism, thyroid hormones regulate the synthesis, mobilisation 
and catabolism of lipids (Pucci et al., 2000). Hypothyroidism is a condition where 
the thyroid hormone is lacking. Most hypothyroid patients have high total 
cholesterol and LDL cholesterol, while some have high levels of triglycerides 
and IDL (Lithell et al., 1981). In addition, one study has documented and 
classified 295 hypothyroid patients according to the Fredrickson classification 
using plasma analysis of lipoprotein patterns (O’Brien et al., 1993). 
 
Chronic renal failure in kidney disease primarily causes the dysregulation of 
HDL and triglyceride-rich lipoprotein metabolism (Vaziri, 2006). This leads to 
hypertriglyceridaemia, reflected in elevated plasma levels of VLDL, IDL and 
chylomicron remnants. 
 
Chronic liver disease can also raise or lower the blood fats depending on the 
classification and severity. In a study comparing the different types of liver 
disease such as chronic hepatitis, liver cirrhosis, hepatocellular carcinoma and 
metastatic liver disease, it was found that different lipid abnormalities were 
present in each liver disease (Ooi et al., 2005). In chronic hepatitis, liver 
cirrhosis, and hepatocellular carcinoma, the cholesterol and triglyceride levels 
decreased while the LDL triglycerides increased, whereas metastatic liver 
cancer patients showed a lower HDL level but higher levels of other parameters 




2.4.2.4 Drug Interaction 
 
Certain medications have been found to elevate lipid levels. Because some of 
these medications are used to treat heart disease, which often occur 
concurrently with dyslipidaemia, it is necessary to reevaluate their usefulness. 
Some of these medications are: 
 
• Thiazides, medication used to treat high blood pressure, can raise both 
cholesterol and triglycerides 
• Beta-blockers, another class of medication used to treat high blood 
pressure, cortisone-like drugs, and oestrogen can raise triglycerides 
• Progesterone, the pregnancy hormone, raises cholesterol 
 
For the purpose of this thesis, the mechanism of these drugs will not be 
discussed in great detail, but will be classified under the general umbrella of the 
concept Drug Interaction.  
 
2.4.3 Treatment of Dyslipidaemia 
 
Treatment options to correct dyslipidaemia include drugs such as statins, 
fibrates, bile acid sequestrants and cholesterol absorption inhibitors, as well as 
lifestyle changes, or a combination of both. Combination therapy involves the 
use of dual or multiple lipid-regulating agents to treat lipoprotein abnormalities by 
targeting specific lipoproteins and utilising the complementary mechanisms of 
action of the different agents (Jacobson, 2001). This is a more effective 
treatment strategy where lipid-regulating monotherapy (e.g. statins or fibrates) 
may not provide adequate improvement in dyslipidaemia. However, there are 
some contraindications between different treatments. Although beneficial in 
correcting dyslipidaemia, the combinations of statins with fibrates or niacins 
have the potential for interactions that increase the risks of adverse effects, such 
as myositis and hepatotoxicity (Bays & Dujovne, 1998). Hence, treatment of 
lipoprotein dysregulation warrants a thorough examination of lipoprotein profiles 






2.4.3.1 Lifestyle Modification 
 
Therapeutic lifestyle interventions are the first line approach to managing 
dyslipidaemia. These include lifestyle changes such as dietary modification, 
weight loss and physical exercise.  
 
Varying the intake of dietary fatty acids may alter the total plasma cholesterol 
levels by influencing the mechanisms for cholesterol balance. The plasma 
cholesterol level tends to be raised by the ingestion of saturated fatty acids 
found predominantly in animal fats and tropical plant oils such as palm oil and 
coconut oil (Cameron et al., 1988). These fatty acids stimulate the synthesis of 
cholesterol and inhibit its conversion to bile salts. On the other hand, 
polyunsaturated fatty acids, the predominant fatty acids of most plants, tend to 
reduce plasma cholesterol levels by enhancing the elimination of both 
cholesterol and cholesterol-derived bile salts in the faeces. Furthermore, dietary 
soluble fibre supplements have also been shown to reduce the level of plasma 
cholesterol, in particular LDL cholesterol, by physically interfering with its 
absorption from the intestine. Thus, dietary manipulations can reduce the 
cholesterol-related risk of cardiovascular disease, but not just by reducing 
cholesterol intake.  
 
Fish consumption, a rich source of n-3 fatty acids, was shown to effectively raise 
HDL cholesterol and reduce triglycerides by up to 40% in overweight 
hypertensive individuals (Mori et al., 2000). Increasing evidence also suggest 
that fish oil consumption protects against coronary disease (Kris-Etherton et al., 
2002). 
 
Antioxidants inhibit the oxidation of toxic LDL and is inversely correlated with 
cardiovascular risk. Recent studies have demonstrated that oxidised LDL is 
more likely than nonoxidised LDL to promote the development of atherosclerotic 
plaques. In related investigations, antioxidant vitamins that prevent LDL 
oxidation, such as vitamin A, vitamin E and vitamin C, have been shown to slow 
plaque deposition. 
 
Additionally, the consumption of red wines which contain the antioxidant 
resveratrol, was associated with increased HDL cholesterol and reduced 
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cardiovascular risk (Pearson, 1996). 
 
Dietary supplements that lower LDL cholesterol levels include fibre supplements 
and products containing plant sterols (phytosterols). Plant sterols reduce LDL 
cholesterol by 10%-15% by inhibiting cholesterol incorporation into micelles, 
decreasing the absorption of total cholesterol (St-Onge et al., 2003). 
 
Evidence suggests that increased physical activity is associated with decreased 
plasma triglycerides and increased HDL cholesterol levels in individuals with the 
metabolic syndrome (Carroll & Dudfield, 2004) 
 
These lifestyle modifications need to be promoted as first line therapies for 
individuals with dyslipidaemia. More effort to integrate educational and lifestyle 
intervention into the regular care of dyslipidaemic patients is essential. Success 
with such interventions will limit the need for pharmacotherapy and may provide 




In addition to lifestyle changes, several lipid-regulating agents may be used to 
improve dyslipidaemia, described briefly in the following section.  
 
Table 7 summarises these agents with respect to their effects on lipid/lipoprotein 
levels, as well as side effects and contraindications (NCEP, 2001). An enlarged 
version of this table is shown in Appendix G. It is important to note that this list is 
not fully exhaustive of all treatments available for improvement of lipid levels. For 
the purpose of this thesis, we have chosen to represent these drug classes that 




















Statins are possibly the treatment of choice for reducing LDL cholesterol as they 
demonstrably reduce cardiovascular mortality. Statins inhibit 3-Hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase, a key enzyme in cholesterol 
synthesis, leading to up-regulation of LDL receptors and increased LDL 
clearance (Goldstein & Brown, 1987) (Horton et al., 2002). They reduce LDL 
cholesterol by up to 60%, produce small increases in HDL and modest 
decreases in triglycerides through the reduction of VLDL (Jones et al., 2003). 
Recent clinical trials have demonstrated that statins can decrease 
cardiovascular events, irrespective of the initial level of cholesterol 
(Scandinavian Simvastatin Survival Group, 1994; Jones et al., 2003). 
 
2.4.3.2.2 Fibrates  
 
Fibrates reduce triglycerides by about 50% and significantly lowers VLDL 
content.  Clinical studies have shown that fibrates can reduce cardiovascular 
events in high- risk subjects (Frick et al., 1987; The Diabetes Atherosclerosis 
Intervention Study, 2001). The mechanisms of action of fibrates on lipoprotein 
metabolism have been elucidated in various experimental studies (Berge & 
Moller, 2002). Fibrates are often used concurrently with statin therapy, although 
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they have also been used as monotherapy agents, especially for patients who 
do not respond to statin therapy or are intolerant of statins (Abourbih et al., 
2009).  
 
2.4.3.2.3 Nicotinic Acid 
 
Nicotinic acid (niacin) blocks the metabolism of fats in adipose tissue, leading to 
a decrease in free fatty acids in the blood and decreased hepatic secretion of 
VLDL and cholesterol (Duffield et al., 1983). Niacin also increases HDL by 
promoting HDL production and inhibiting HDL clearance (Duffield et al., 1983). It 
must be noted however, that despite improvements in lipid and lipoprotein 
concentrations, treatment with nicotinic acid leads to the worsening of 
hyperglycaemia and the development of hyperuricaemia, and therefore cannot 
be used as a first line therapy for patients with type II diabetes mellitus (Garg & 
Grundy, 1990). 
 
2.4.3.2.4 Bile Acid Sequestrants 
 
Bile acid sequestrants have also been proven to reduce cardiovascular mortality. 
They prevent the reabsorption of intestinal bile acid, forcing the up-regulation of 
hepatic LDL receptors to recruit circulating cholesterol for bile synthesis, leading 
to a decrease in LDL levels (Goldfine, 2008). 
 
Bile salts are the principal catabolic end products of cholesterol and increase in 
hepatic bile acid synthesis is accompanied by enhanced cholesterol catabolism. 
A simple method for increasing bile acid synthesis is to prevent bile acid 
reabsorption from the intestine. Consequently, drugs have been developed that 
will reduce the availability of bile acids for intestinal absorption. These agents 
also impair the function of bile acids within the intestinal lumen and thus can 
lead to triglyceride malabsorption.  
 
Colestyramine is a bile acid sequestrant that causes increased excretion of 
these compounds in the faeces (Hashim & Van Itallie, 1965). When used in low 
doses (13mg/day), colestryamine does not induce steatorrhaea in normal 
subjects but after high doses (30mg/day) significant malabsorption of fat was 
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observed. The steatorrhaea could be reversed by the administration of 
polysorbate (Shuster, Spoto, & Jacobs, 1970). 
 
2.4.3.3 Combination Therapy 
 
Combination therapy involves the use of dual or multiple lipid-regulating agents 
to treat lipoprotein abnormalities by targeting specific lipoproteins and utilising 
the complementary mechanisms of action of the different agents (Jacobson, 
2001) 
 
For example, statin-fibrate, statin-niacin, statin-ezetimibe or ezetimibe-fibrate 
may further optimise the lipid profile of subjects with the metabolic syndrome. In 
addition, a combination of fibrates with either metformin or thiazolidinediones 
(TZD) which treats insulin resistance in metabolic syndrome may be beneficial 
as it would simultaneously address both dyslipidaemia and insulin resistance. 
Additionally, combined alpha and gamma peroxisome proliferator-activated 
receptors (PPAR) agonists can also simultaneously improve insulin resistance, 
glucose intolerance, elevated triglycerides and low HDL cholesterol levels 
(Pourcet et al., 2006). 
 
This is a more effective treatment strategy where lipid-regulating monotherapy 
(e.g. statins or fibrates) may not provide adequate improvement in 
dyslipidaemia. However, there are some contraindications between different 
treatments. Although beneficial in correcting dyslipidaemia, the combinations of 
statins with fibrates or niacins have the potential for interactions that increase 
the risks of adverse effects, such as myositis and hepatotoxicity (Bays & 
Dujovne, 1998). Hence, treatment of lipoprotein dysregulation warrants a 
thorough examination of lipoprotein profiles of specific individuals. 
 
2.5 The Nature of Biomedical Information  
 
Discovery in life sciences typically begins with the study of cells, the 
fundamental building blocks of living systems. Although the process of 
investigating the structure and function of individual components remains a core 
in biomedical research, the emphasis of research naturally shifts from cells to 
systems as the repository of knowledge increases. Understanding biological 
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systems and how they function require not just the knowledge of individual parts, 
but how they interact with one another. These metabolic processes are often 
complex and highly dynamic, involving many different components, which 
undergo physiological changes in response to various regulators and inhibitors. 
As much as these pathways have been extensively reviewed in the literature by 
different sources, it is virtually impossible to elucidate the complete extent of the 
interaction of components in biological processes. Therefore, an integrated view 
of biology requires the retrieval of respective knowledge from the literature or 
from various and often heterogeneous databases.  
 
As the degree of complexity of the biological processes under study grows, it is 
becoming increasingly challenging for domain experts to integrate and link this 
information within context. This is in part due to the sheer volume of information 
available, but also because of the loose, heterogeneous nature of biomedical 
data. In addition to the complex nature of biological processes described above, 
the types of research output in the biomedical domain are highly diverse. They 
range from literature publications, laboratory records, epidemiological studies, 
biomedical images, to various experimental techniques as diverse as qualitative 
and quantitative assay, light and electron microscopy, mass spectrometry, 
among others. Moreover, as biological experiments are conducted on different 
individuals in different physiological states and across different species, the 
research output also varies accordingly. For instance, the structure and function 
of organs vary across age and gender, in normal and diseased states, and 
across species.  
 
In context of these challenges, it is becoming necessary to structure biomedical 
information such that biological concepts can be accurately represented and the 
appropriate relationships between these concepts established clearly. This 
framework will be represented in a format that is widely accepted for the 









2.6 Knowledge Representation Techniques 
 
Bioinformatics is a broad discipline which utilises Information and 
Communications Technology (ICT) in response to the research problems 
concerning the nature of biological data in the biomedical science domain. 
Although the adoption of ICT is relatively recent in biomedical science, 
knowledge engineering has been extensively researched in computer science. 
KR techniques have been developed to manage the information explosion by 
structuring a complex domain systematically and relating the concepts within the 
domain. In this section, we review KR techniques currently used in the 
biomedical domain. 
 
2.6.1 Conceptual Schema and Information Modelling Approaches 
 
The advent of high-throughput technologies in biological research has led to a 
prominent increase in the amount of biological data being generated. In an 
attempt to manage these resources, large centralised repositories for data have 
been established such as UniProt KB and Genbank, to manage protein and 
nucleotide sequences respectively. However, managing large quantities of data 
is a challenge in itself. An important aspect of data management is the clear 
representation of the available data. This can be done by modelling the domain 
of interest through conceptual schemas.  Conceptual schemas are the most 
fundamental basis of an information system and provide the structure or 
grammar of the given domain (Halpin, 2001). The main challenge lies in 
modelling the domain clearly and precisely. Two main information modelling 
approaches in bioinformatics are discussed: Entity-Relationship Modelling and 
Object-Oriented Modelling. 
 
2.6.1.1 Entity-Relationship Modelling  
 
Entity-Relationship (ER) modelling is one of the most widely used approaches 
for data modelling. There are many different versions of ER but in general, ER 
models describe the world in terms of entities that have attributes and participate 
in relationships. These entities and relationships are illustrated in terms of 
symbols, notations and lines within an ER diagram (Bornberg-Bauer & Paton, 
2002). In Figure 3 below, entity types are encased within a rectangle: Enzyme, 
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Protein, DNA, Reaction and Bipolymer. The attributes of the entity type 
Bipolymer are depicted in ovals: accno (accession number), name, species 




Figure 3. ER notation for some biological concepts. Every enzyme is a protein, which is depicted 
by the IsA relationship between Enzyme and Protein. Both Protein and DNA are kinds of 
Biopolymer, also depicted by the IsA relationship. Reaction is related to Enzyme via many-to-
many relationship.  
 
Hierarchical relationships between entities can be represented by arrows from 
the more specialised type to the more general type through a circle containing 
IsA: both Protein and DNA are shown to be kinds of Biopolymer. These 
relationships have two principal roles. Firstly, the properties of a supertype are 
inherited by its subtypes, thereby leading to more concise models. For example, 
the attributes of Biopolymer are inherited by Protein and DNA through the IsA 
relationship. Secondly, the IsA relationship makes subsumption relationships 
explicit. For example, every instance of Enzyme is an instance of Protein, and 
every instance of Protein is an instance of Biopolymer.  
 
Any relationship other than the IsA relationship between two entities is depicted 
by a rhombus between the related entity types: the Catalysis relationship 
between Enzyme and Reaction indicates reactions catalysed by enzymes. For 
example, an instance of an enzyme may catalyse many reactions and at the 
same time be catalysed by many other enzymes. This many-to-many 
relationship is depicted by the M and N in the figure, which denote the number of 
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participants in the relationship. This cardinality value can be left blank, or 
specified to a particular value.  
 
Based on the attributes described above, the ER model offers an advantage in 
representing the domain in an objective way. An example of a database which is 
based on the ER model is PRINTS, a database for fingerprints. Through this 
model, the relationship between sequences, their similarity and function is easily 
represented, thus enabling the efficient and accurate prediction of fingerprint 
match. Although the ER model offers an objective representation of the domain 
that is independent of the application platform, it can be limited in its description 
which may result in missing constraints. In addition, the notation is not 
conducive to the validation process with domain experts compared to natural 
language (Halpin, 2001). 
 
2.6.1.2 Object-Oriented Modelling  
 
Object-oriented modelling is an approach that encapsulates both data and 
behaviour within objects. Although used mainly in object-oriented programs, it 
can also be used as the basis for database models. Out of many object-oriented 
approaches, the most popular is Unified Modelling Language (UML). UML class 
diagrams are used to specify operations, attributes as well as associations, and 
can be seen as an extended version of ER (Halpin, 2001). Figure 4 shows an 
example of a UML class diagram for protein structure. Protein is the topmost 
class with attributes: name, pdbcode and molecularWeight. Each Protein 
consists of one or more Chains, which can be made of a type of Residue or a 
type of SecondaryStructureElement (Bornberg-Bauer & Paton, 2002).  
 
The class Residue provides information about the primary structure with 
attributes name, position within the Chain, as well as tertiary structure 
information modelled using the class Coordinates. The class 
SecondaryStructureElement depicted in italics is an abstract class which has 
no instances, but play an organisational role in the diagram by serving as the 






Figure 4. UML class diagram for protein structure. 
 
Like the ER model, the UML class diagrams are independent of the application 
platform. However, the UML class diagram differs from the ER model in having 
ternary associations instead of binary. In addition, UML does not require 
conceptual identification schemes for its entities; instead, entity instances are 
identified by internal object identifiers (Halpin, 2001). The UML class diagram 
has been successful in describing sequence information for fully sequenced 
eukaryotic genomes (Hu et al., 1998). In addition, the UML class diagram has 
also been implemented using the POET database, which makes use of Java 
class definitions at the same time. A disadvantage to UML is that there are 
currently no standard notations for some attributes. Furthermore, validation of 
UML class diagrams with domain experts are still rife with issues (Halpin, 2001).   
 
2.6.2 Controlled Vocabularies 
 
Controlled vocabularies define a set of standardised terms for labelling entities 
for specific purposes, such as indexing the literature or annotating gene 
functions, among others. Biomedical literature often contains many synonymous 
terms, acronyms and abbreviations which refer to the same concept. For 
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example, in different texts, “high density lipoproteins” is sometimes referred to 
as “HDL” or “α lipoproteins” or “apoA containing lipoproteins”. The inconsistent 
labelling of terms poses a challenge for the integration of information from 
various heterogeneous resources and databases. By providing a standardised 
term for each entity it represents, controlled terminology allows the labelling of 
biomedical entities in a consistent way.  
 
An example of a controlled vocabulary is the Medical Subject Headings (MeSH), 
created by the National Library of Medicine for the indexing of biomedical 
literature and the MEDLINE/PubMed article database (Lowe & Barnett, 1994). 
MeSH provides a standard set of term used to describe the main topics covered 
in papers, the species studies, funding source, and other attributes. The 
standard names provided by MeSH are particularly useful for text processing, 
extraction, and classification (Rubin et al., 2007). Articles can be annotated with 




Although information models and controlled vocabularies offer many advantages 
in terms of structuring information, they have limitations with respect to inferring 
knowledge. In recent years, ontologies have become a topic of interest in the 
knowledge engineering community.  Ontology is defined in the literature as a 
“formal, explicit specification of a shared conceptualisation” (Studer et al., 1998). 
Conceptualisation refers to an abstract model of some phenomenon in the world 
by having identified the relevant concepts of that phenomenon. Explicit means 
that the type of concepts used, and the constraints on their use are explicitly 
defined. Formal refers to the fact that the ontology should be machine-readable. 
Shared reflects the notion that an ontology captures consensual knowledge. 
 
Applications of ontologies are becoming particularly prevalent in biomedical 
science as more scientists are starting to adopt ontology-based s to model their 
research domain (Bard & Rhee, 2004) (Stevens et al., 2000). In contrast to 
information models which operate under a Closed World Assumption (that is, 
models are developed using predefined information), ontologies operate under 
an Open World Assumption which supports the inference of new knowledge 
through automatic reasoning. In addition, most ontologies are based on formal 
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semantics (Description Logics or DL) and articulated by OWL as the 
specification language. Not only are ontologies often regarded for conceptual 
analysis and domain modelling, they are also used to analyse the meaning of an 
object in the world, or a particular domain, and provide a formal specification to 
describe the object (Guarino, 1998).  
 
One advantage of ontologies over controlled vocabularies and terminological 
systems is to support reasoning. The formal structure and rules of inference 
provided by logic may be coupled with the properties of the relations among 
things in an ontology in order to draw inferences. While controlled vocabularies 
are typically created with a specific purpose in mind, ontologies aim at 
representing what exists independent of any specific use. Both can be shared, 
however ontologies can often be reused, sometimes in widely differing 
applications from the ones for which they were originally designed.  
 
The distinguishing feature of an ontology is to explicitly represent various 
concepts and relationships between them in formal categories and classification 
systems. This way, the ontology can be used as a core component in 
knowledge-based information systems in order to aid information retrieval, 
automatic text processing, content management, inference of new knowledge. In 
addition, ontology facilitates interoperability between computer systems by 
providing a common language used in software agents, and can therefore be 
considered to be the basis for which diverse applications within a knowledge 
domain can be managed. It is important to note that the process of ontology 
development varies depending on factors such as the purpose of the ontology 




In this chapter, we presented the current state of the lipoprotein research 
domain. We introduced various lipoprotein concepts, including the different 
lipoprotein classes, components and metabolism pathways. The implications of 
dyslipidaemia on health were discussed, followed by challenges in the diagnosis 
and treatment of dyslipidaemia. We then described the nature of biomedical 
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In Chapter 1, we provided an overview of lipoproteins, raised a number of issues 
within the lipoprotein research domain and highlighted the need for a formal 
framework for the management of lipoprotein knowledge. The lipoprotein 
research domain was extensively reviewed in Chapter 2, followed by a 
discussion on KR techniques in the biomedical domain. In this chapter, we first 
define the key concepts which will appear throughout this thesis, and discuss 
problems within the lipoprotein domain which motivate us to conduct this work. 
The underlying research issues are identified, from which we derive some key 
research questions which will be addressed in the thesis. Finally, the choice of 
research approach to address these research questions will be presented. 
 
3.2 Concept Definition 
 
The main objective of this thesis is to address KR issues in the lipoprotein 
research domain. In order to introduce the main concepts within the lipoprotein 
research domain and to avoid ambiguity, the key concepts in this thesis will be 
defined in this section. First and foremost, we define our domain of study. 
 
Lipoprotein Domain Concept 
 
Definition: Lipoprotein domain concept is defined as a set of lipoprotein concepts 
and relations. In order to represent the lipoprotein domain knowledge in a 
coherent way, these concepts and relations are organised in a hierarchical 
structure, under five distinct superclasses: Classification, Metabolism, 
Pathophysiology, Aetiology and Treatment. These superclasses are further 






Definition: Classification is defined as the classification of Lipoprotein Entity. 
Lipoprotein Entity is defined as a soluble complex of lipids and proteins. 
Depending on the lipid and protein content, lipoprotein entities are classified 
accordingly into various subclasses. Examples of Lipoprotein Entity are: 




Definition: Lipoprotein Metabolism is defined as the chemical processes which 
involve the synthesis and/or catabolism of Lipoprotein Entity. In this thesis, we 
classify “things” associated lipoprotein metabolism into three classes: Physical 
Entity, Occurring Entity, and Participant Role. These subclasses will be further 




Definition: Pathophysiology is defined as the pathophysiology related to the 
dysregulation in lipoprotein disorders. Pathophysiology can be further 
categorised into two classes: Disorder and Symptom. These subclasses will be 




Definition: Aetiology is defined as the causes of lipoprotein disorder. Aetiology 
can be further categorised into three classes: Lifestyle, Genetic and Drug 




Definition: Treatment is defined as the treatment of lipoprotein disorder. 
Treatment can be further categorised into three classes: Lifestyle Change, Drug 





3.2.6 Diagnostic Parameter 
 
Definition: Diagnostic Parameter is defined as the requirement of diagnosis 
specific to the characteristics of an individual. 
 
 
3.3 Problem Overview: Lack of Framework for Lipoprotein Concepts 
 
The past 60 years of lipoprotein research has yielded a great deal of information 
regarding the structure and metabolism of lipoproteins, the implication of 
lipoprotein dysregulation on health, causes of dyslipidaemia as well as its 
management and treatment. Despite the vast amount of research available, a 
large number of the world’s population still suffers from lipoprotein disorders. 
The issue with dyslipidaemia is that it covers a wide variety of clinical findings 
and underlying disorders which involve a range of causes and processes. The 
lack of an inclusive framework for lipoprotein related concepts has 2 
implications: research and clinical, described below.  
 
3.3.1 Research Implications 
 
The semantics of biomedical information are usually not explicitly stated but 
implicitly expressed in biomedical literature. This is because the definitions of 
concepts within the domain are often well understood among domain experts, 
thus eliminating the need for semantics to be explicitly defined. Biomedical 
literature often contains many synonymous terms, acronyms and abbreviations 
which refer to the same concept. Although domain experts are expected to be 
familiar with important lipoprotein concepts, the inconsistent representation of 
terms can sometimes present a challenge in the retrieval and integration of 
information. In addition, the biomedical community is composed of many 
different units of small, focused research groups investigating different aspects 
of a common domain, that would benefit from sharing a common platform for the 
consistent representation of the research domain. For example, in the 
lipoprotein research domain, physiologists may specialise in investigating the 
processes of lipoprotein metabolism, pharmacologists may be interested in 
examining the effect of certain drugs towards the reduction of a certain 
lipoprotein class, epidemiologists may be concerned about longitudinal studies 
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on the dyslipidaemic factors (such as increased LDL levels) which contribute to 
developing the risk to cardiovascular disease. A framework for lipoprotein 
knowledge representation provides unambiguous references to domain 
concepts. This is particularly important when there are tens of thousands of 
concepts, including information about genes, diseases, chemicals and 
organisms. Having unambiguous terms is essential for organising information 
generated in different laboratories. The standardisation of terms is also essential 
for locating publications; having unambiguous names makes retrieving 
appropriate information much easier.  
 
3.3.2 Clinical Implications 
 
The clinical implications of this research may be far-reaching and have 
tremendous potential in opening new possibilities for the development of 
decision-based support systems for the diagnosis and treatment of 
dyslipidaemia. Often, researchers and clinicians want to obtain inclusive 
information about lipoproteins, such as the effect of statins on the different 
lipoprotein parameters, I.e. LDL, HDL, apolipoprotein C-III, etc., in order to 
prescribe a treatment that would best suit individuals with specific lipid profiles. 
Using current information resources and clinical manuals, it is hardly likely that 
one will find all aspects of the different classes of statins in one place. An 
inclusive framework for lipoprotein knowledge representation brings together as 
much information as possible under predefined lipoprotein concepts and their 
relations. This framework can potentially serve as the basis for the development 
of software agents or applications which can utilise the structured knowledge to 
derive and infer information for diagnostic and treatment recommendation 
purposes.  
 
3.4 Motivation of Study 
 
Currently there does not exist a formal framework for the conceptualisation and 
classification of lipoprotein-related information, to our knowledge. There is an 
increasing need to create standardised systems for the formal representation of 
lipoprotein knowledge, in order to facilitate the collaboration among a community 
of domain experts. It is not envisaged that such systems could overtake the role 
of human experts; rather, they can alleviate information integration issues and 
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aid in decision-making. Therefore, this thesis aims to design a formal 
conceptualisation framework for the description, organisation and classification 
of lipoprotein-related information. We discuss specific challenges in the 
lipoprotein domain in the following section that serve as the motivation for this 
work. 
 
3.4.1 Modelling Complex Metabolism Pathways 
 
Lipoprotein metabolism is complex, highly interrelated and involves many 
different pathways under certain physiological conditions (Frayn, 2003) 
(Eisenberg, 1983). Understanding the impact of the dysregulation of lipoprotein 
metabolism necessitates knowledge of the synthesis, structure and metabolism 
of lipoproteins and their individual lipid components, including how they are 
incorporated, transported and trafficked within their respective lipoprotein 
classes. It is also important to note that these processes involve a constant and 
dynamic flow and remodelling of particles where lipid molecules and 
apolipoproteins are gained and lost through highly complex pathways.  
 
Numerous studies have been carried out investigating various aspects of 
lipoprotein metabolism, and stored within a large number of information sources. 
This information can be overwhelming even amongst lipoprotein experts as new 
discoveries are made every day. Currently there is no classification system in 
the field of lipoproteins, which offers an inclusive view of links and 
interconnections between lipoprotein concepts. This has led to difficulties in 
obtaining an integrated view of lipoprotein knowledge. 
 
The complexity of lipoprotein metabolism pathway presents a need for a 
framework for lipoprotein knowledge representation. Modelling the relations 
between lipoprotein entities leads to a better understanding of the complex 
interrelationships between lipoprotein particles, receptors and enzymes 
necessary for functional lipid distribution in normal physiological conditions as 
well as in diseased states. Because the metabolism of the plasma lipoproteins is 
highly interrelated, one must consider each of the lipoproteins and their 





3.4.2 Lipoprotein Dysregulation and its Implications on Disease 
 
Lipoprotein dysregulation, known as dyslipidaemia, covers a wide range of lipid 
abnormalities. Dyslipidaemia occurs as a consequence of alterations in the 
kinetics of lipoproteins, and has been found to be significantly associated with 
various diseases such as cardiovascular disease, diabetes and hypertension, 
among others. Therefore, the key to alleviating this risk is a close examination 
lipoprotein metabolism and the changes in lipoprotein components associated 
with the various disease states.   
 
Although the processes by which lipids and lipoproteins contribute to 
cardiovascular events are complex and may also be dependent on other 
external factors and/or disease states (e.g. hypertension), studies have 
established the significant correlation between certain lipid and lipoprotein 
abnormalities and increased risk to cardiovascular disease (Frick et al., 1987; 
Kannel et al., 1979). Therefore, presenting these abnormalities in terms of the 
lipoprotein components involved in dyslipidaemia in relation to the risk allows a 
better understanding of these associations in context of one another.  
 
In addition, dyslipidaemia observed in the metabolic syndrome is often clustered 
with other factors such as insulin resistance, impaired glucose regulation, 
visceral obesity and hypertension (NCEP, 2001; IDF, 2005; WHO, 1998). 
Although it is beyond the scope of this thesis to describe the pathophysiology of 
each of these risk factors, the framework can be extended to include these 
factors for future work. 
 
3.4.3 Determining the Causes of Dyslipidaemia 
 
Another challenging issue in the lipoprotein research domain is determining the 
causes of dyslipidaemia. Dyslipidaemia can be broadly classified into two 
categories: primary and secondary dyslipidaemias.  
 
Primary dyslipidaemia is relatively more straightforward as it is defined to be 
lipid and lipoprotein abnormalities caused by genetic factors. Although at this 
stage it is beyond the scope of this thesis to delve into the specific genetic 
defects associated with certain dyslipidaemic conditions, the framework can be 
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extended in the future to include gene concepts from other closely-related 
ontologies such as the Gene Ontology.  
 
The aetiology of secondary dyslipidaemia is much more complex, as it takes into 
account various environmental factors and other disease states or disorders, or 
a combination of either. The challenge is to attempt to map these causes and 
link them to various lipoprotein disorders, in order to enable the extrapolation of 
the relations between these concepts into easily identifiable risk factors for quick 
identification. Again, it must be reiterated that although these aetiology concepts 
will be mapped to various lipoprotein components and disorders, it is beyond the 
scope of this thesis to explore the mechanisms of these pathways. Hence, we 
will be representing aetiology concepts as stand-alone concepts with the 
possibility of extending these concepts and merging them with other 
neighbouring ontologies, for future work. For example, the concept of “Diet” 
under the subclass “Lifestyle” can be merged with concepts from Nutrition 
Ontology in order to trace the effects of dietary concepts such as “Saturated 
Fatty Acids” on various lipoprotein components.  
 
3.4.4 Issues in the Diagnosis and Treatment of Dyslipidaemia 
 
In clinical practice, dyslipidaemia can be diagnosed by measuring the plasma 
levels of total cholesterol, triglycerides and individual lipoproteins and comparing 
these levels to established guidelines with a strong objective towards reducing 
cardiovascular risk.  Therefore, the diagnosis and treatment of dyslipidaemic 
patients is a prominent component of cardiovascular care. Although guidelines 
exist to define dyslipidaemia, diagnostic parameters vary among different 
individuals, according to gender and ethnicity. In addition, the diagnosis of 
dyslipidaemia also takes into consideration other factors such as blood 
pressure, waist circumference, etc. Thus, it can sometimes be challenging for a 
health practitioner to interpret the correct diagnostic parameters for specific 
individuals and prescribe the appropriate treatment.  
 
We have identified two issues with the treatment of dyslipidamia which reinforce 




Firstly, treatment of dyslipidaemia often involves the use of multiple lipid-
regulating agents by targeting specific lipoproteins and utilising the 
complementary mechanisms of action of different agents. However, drug 
interactions may increase the risk to adverse effects and/or morbidity in certain 
individuals (Bays & Dujovne, 1998). These risks may be potentially reduced if 
these interactions can be mapped in a systematic way. 
 
Secondly, controversy exists over the interaction between the medical 
profession and the pharmaceutical industry. Studies have found that the 
interaction between health practitioners and the pharmaceutical companies 
appears to affect prescribing and professional behaviour due to the influence of 
gifts and various forms of sponsorship and endorsements from the drug industry 
(Wazana, 2000). In addition, it was also found that the type of sponsorship for 
randomised controlled trials of statins was strongly linked to the results of those 
studies (Bero et al., 2007). Head-to-head comparisons of statins with other 
drugs are more likely to report conclusions that are favourable to the sponsor’s 
drug compared to comparison drugs. This could be due to various reasons such 
as using lower dosages for the competitor drugs or selective reporting of results. 
However, regardless of the reasons, the implications suggest that the evidence 
base relating to statins may be substantially biased. Therefore, these 
controversial issues present a need for an objective and unbiased 
representation of treatment pathways that are not tied to any sponsorship 
affiliation. Modelling the direct relations between treatment with respect to their 
actions on the associated lipoprotein classes can minimise this bias to a certain 
extent. 
 
3.5 Underlying Research Issues 
 
In the previous section we have identified the main problems associated with the 
lack of a framework for lipoprotein-related concepts. In order to resolve these 








3.5.1 Information Explosion and Unstructured Domain Knowledge 
 
Since the advancement of technology and the emergence of the World Wide 
Web, modern biomedical research has evolved to be information-intensive. To 
this effect, the amount of published literature has increased exponentially. Up to 
1980, the search term “lipoprotein” generated 16,129 results in PubMed, 
compared to 69,232 in 2000; currently, as of 2013, the same term fetches 
approximately 150,000 articles. This information explosion clearly poses a 
challenge for researchers to retrieve and integrate knowledge relevant to their 
research.  
 
The premise of biomedical research primarily involves identifying biological 
components (concepts), and investigating the interaction (relations) between 
these components in both normal physiological and diseased states. These 
pathways are highly complex and interrelated, involving many different 
components. As the amount of published literature grows at a tremendous rate 
daily, integrating newly discovered components and pathways in context to 
previously known knowledge is a challenge that is beyond the expertise of a 
single domain expert. For example, a search of the literature for causes of 
lipoprotein dysregulation may return 1,203 articles. Not only is it challenging for 
a single researcher to go through each of these 1,203 articles, but it would be 
practically impossible to manually represent the information contained in these 
articles within a structured framework of concepts and relations.  
 
As such, there is a pressing need to structure these concepts and relations in a 
formal way in order to provide contextual meaning to the available knowledge. 
By providing a vocabulary of well-defined terms with specified relationships 
between them, the formal conceptual model alleviates the issues that 
researchers face in extracting and analysing these concepts. In addition, this 
framework also makes this knowledge amenable to automatic processing by 
computer systems. 
 
3.5.2 Heterogeneity of Biomedical Information 
 
Another underlying issue of this work is the proliferation of research output being  
represented in the form of natural language, from numerous information 
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sources, all of which function autonomously. This autonomy has led to different 
information sources having different contents and dissimilar formats, and is 
collectively referred to as information heterogeneity.  
 
Information heterogeneity can be classified into three broad types: syntactic 
heterogeneity, schematic heterogeneity and semantic heterogeneity (Sheth, 
1998). Syntactic heterogeneity refers to the use of different representation 
languages or models. Schematic heterogeneity refers to schematic or structural 
differences between different information systems. Semantic heterogeneity 
results from the lack of well-defined semantics or meaning of information items.  
 
The emergence of markup languages such as XML (Extensible Markup 
Language) has resolved the problem of syntactic heterogeneity, and to a certain 
extent, schematic heterogeneity. By defining a set of rules for encoding 
documents in a format that is readable by both humans and computer systems, 
XML supports integration at the syntactic and schematic levels.  
 
Schematic heterogeneity results as a consequence from the proliferation of a 
variety of data, ranging from structured databases to unstructured (textual or 
visual) data. Techniques which have been successful in alleviating schematic 
heterogeneity problems include, but are not exclusive to, the use of object 
modelling standards such as UML (Unified Modelling Language) as well as RDF 
(Resource Descriptive Framework) for general purpose description of 
information systems (Sheth, 1998). 
 
Semantic heterogeneity remains to be one of the most challenging issues in 
interoperability (Kashyap & Sheth, 1996). For the purpose of this thesis, we will 
discuss semantic heterogeneity problems specifically within the lipoprotein 
domain as follows: 
 
3.5.2.1 Inconsistent Terminologies  
 
Biomedical literature often contains many synonymous terms, acronyms and 
abbreviations which refer to the same concept. For example, in the lipoprotein 
research domain, “high density lipoproteins” is sometimes referred to as “HDL” 
or “α lipoproteins” or “apoA containing lipoproteins”. It is challenging to integrate 
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information in a consistent way when the biological relevance of the same entity 
is labeled differently in different resources. 
 
3.5.2.2 Differences in Scope and Granularity 
 
Due to the importance of lipoproteins in the regulation of biological and cellular 
functions in humans, as well as the impact of lipoprotein dysregulation on health, 
lipoprotein research involves many sub-domains of biomedical science such as 
physiology, biochemistry, pharmacology and medicine. For example a 
physiologist may specialise in studying the kinetics of lipoprotein metabolism, 
whereas a biochemist may focus on the various components involved in 
lipoprotein metabolism pathways, a pharmacologist may investigate the action of 
a drug on a specific lipoprotein component, and a health practitioner may be 
more concerned with parameters of lipoprotein components which indicate risk 
to developing cardiovascular disease. The differences in scope and granularity 
of lipoprotein research can lead to challenges in the meaningful representation 
of lipoprotein knowledge. As such, there is a need to structure concepts and 
relations in a system of hierarchy, where lower level, more specific concepts can 
be generalised to broader, high level concepts, in order to present the domain 
knowledge in a systematic way.  
 
3.5.2.3 Differences in Research Output 
 
In addition to the complex nature of biological processes, the types of research 
methodologies and output in the biomedical domain are highly diverse. They 
range from literature publications, laboratory records, epidemiological studies, 
biomedical images, to various experimental techniques as diverse as qualitative 
and quantitative assay, light and electron microscopy, mass spectrometry, 
among others. Moreover, as biological experiments are conducted on different 
individuals in different physiological states and across different species, the 
research output also varies accordingly. For instance, the structure and function 
of organs vary across age and gender, in normal and diseased states, and 
across species. This presents a challenge towards the integration of these 





3.5.3 Information Integration 
 
One of the most challenging issues in the biomedical domain is analysing and 
integrating the rapidly expanding information generated from various sub-
domains – from physiology to pharmacology to clinical care. As the amount of 
experimental data and scientific knowledge increases, there is a need to 
promote the interoperability of these resources and provide a platform where 
information can be shared and utilised efficiently.  
 
The effective integration of information is particularly important in translating 
research outputs into applications in the management and treatment of 
diseases. However, researchers often face difficulties in retrieving relevant 
literature embedded in a diverse range of text or electronic resources. Moreover, 
the effective and efficient retrieval of particular information from one single 
information resource through a key word based search engine is a difficult, if not 
impossible process. For example, a search for the term LDL in PubMed 
generates more than 31,000 results. This diversity of results, by nature, 
incorporates both relevant and irrelevant data from various research works, as 
discussed in the problem of information heterogeneity in the previous section. 
Such a widespread compilation of data about LDL is highly unlikely to offer 
associations, interrelations, similarities and differences between related 
concepts and theories although most of these studies have investigated the 
same particle, shared many metabolism pathways with each other. Therefore, in 
order to integrate the knowledge available from diverse, autonomous information 
sources, these important concepts and their relations must be structured in a 
shared, common manner through a formalised framework. 
 
Defining the semantics of lipoprotein concepts and relations in a formalised 
framework also allows automation of knowledge retrieval and integration. By 
formalising these concepts, software agents are able to analyse and elicit the 
desired information embedded within various sources in a precise and 
integrative manner. At this stage, we must emphasise that developing these 
software agents is beyond the scope of this thesis. However, this framework can 
serve the underlying basis for the design of semantic search engines in the 




3.5.4 Inference of Knowledge 
 
Traditionally, knowledge from science is derived from observations, which are 
used to form hypotheses. Scientists seek to prove or disprove these hypotheses 
through experiments, which are documented in natural language and 
communicated with other scientists through manuscripts. This knowledge is 
subsequently used to make inferences about other uncharacterised 
observations, which lead to the formation of new hypotheses. Eventually, a 
collection of proven hypotheses encompasses the scientific paradigm or domain 
knowledge.  
 
As modern experimental techniques are rapidly expanding the knowledge base 
in biomedical science, the lack of formal framework for lipoprotein concepts and 
relations is also proving to be a challenge in the development of new 
hypotheses. The investigation of new components or pathways is generally 
dependent on an integrated view of the domain, as it involves many different 
interrelated factors. However, the size of the existing knowledge base has 
become too large even for experienced researchers to extract the complete and 
relevant information that they need. As such, critical information that may have 
been embedded in obscure experiments may be missed.   
 
There is an increasing need to manage knowledge in a structured form, in order 
for the vast range of web-accessible information to be more effectively exploited 
by both humans and automated tools. Structuring concepts and relations in a 
formal way enables the automatic processing and inference of knowledge which 
might have otherwise been missed by human capabilities. This can then 
potentially lead to novel insights into biological processes and hypothesis 
formulation.  
 
3.6 Key Research Questions 
 
One of the most significant issues identified in this thesis is to determine what it 
is that needs to be represented. Based on the challenges in the lipoprotein 
domain that have been identified, we will organise lipoprotein knowledge 
according to five key areas: Classification, Metabolism, Pathophysiology, 
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Aetiology and Treatment. In order to represent these key areas, the research 
questions that need to be addressed are:  
 
1. How can we model lipoprotein concepts and relationships such that they can 
be used as a representation of the lipoprotein research domain? Specifically, 
how can we represent complex lipoprotein metabolism pathways in terms of 
concepts and relationships? 
 
2. How can the model be used to aid knowledge integration and management in 
the lipoprotein domain? How can we use this framework to infer knowledge to 
aid diagnosis of lipoprotein dysregulation?  
 
3. How can such a model facilitate collaboration between users? For instance, 
how can we develop this underlying framework to enable the efficient 
transference of research output from different research groups?  
 
4. How can we validate our framework such that it is consistent and easily 
extensible? 
 
3.7 Choice of Research Approach 
 
Based on the literature review of KR techniques in Chapter 2, we propose the 
ontology approach to solve the issues defined in this thesis. Ontologies provide 
well-defined meaning to Web-accessible information through formal, structured 
vocabularies of concepts and relationships between them. These common 
frameworks facilitate the integration of knowledge in a machine-processable 
format, in order to allow information to be shared and used effectively by 
researchers as well as automatically through software tools (Cuenca Grau et al., 
2008). The use of ontologies has become increasingly common in the 
biomedical domain, as domain experts have adopted ontologies as a method for 
representing the domain knowledge in a systematic way, as well as to support 
knowledge discovery and interoperability among different research groups. 
However, to this date, to our knowledge there does not exist an ontological 




We propose Lipoprotein Ontology as our choice of framework to address the 
issues that have been defined in this chapter. This thesis will focus on the 
development and validation of an ontological framework for lipoprotein 
knowledge representation. The objective is to present lipoprotein concepts and 
their relationships in a hierarchical and associative manner. Our main research 
approach follows the category of the science and engineering based research 
methodology, which focuses on a systematic, investigative approach to problem 
solving (Galliers, 1992). There are three broad steps to this approach, illustrated 
in detail in Figure 5:  
 
• Conceptual level: The creation of new concepts through systematic 
literature review 
• Perceptual level: The formulation of new methodology and new 
framework design through implementation  
• Practical level: The evaluation of this framework through real world 




Figure 5. Science and engineering-based research approach. 
 
Our first approach is to identify the research problems. This is followed by an 
extensive review of the literature in our domain of study, which in this case is the 
lipoprotein research domain. From the literature review, we extract the key 
concepts, and integrate these key concepts in the research design, from which 
we derive a conceptual solution. In the next phase, we proceed to design the 
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system architecture based on the conceptual solution. Subsequently, we 
incorporate aspects of existing methodologies towards the design of a new 
prototype. Once the prototype design has been developed, we evaluate this 
framework with case studies, followed by further testing and verification by 
domain experts. Based on the results of the case studies, we can then refine our 




The main research issue identified in this thesis is the lack of a formal 
conceptualisation framework for the description, organisation and classification 
of lipoprotein-related information. We initially defined the key concepts in the 
lipoprotein research domain and discussed specific challenges within the 
domain which will serve as the motivation for the research. The underlying 
research issues were identified, including the issues of information explosion 
and unstructured domain knowledge, the heterogeneity of biomedical 
information, and difficulty in information retrieval. In response to these issues, 
we developed some key research questions which this thesis will aim to solve, in 
the context of lipoprotein research domain. With these key research questions in 
mind, we have chosen to develop Lipoprotein Ontology, a formal framework for 
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In order to address the research issues elucidated in the previous chapter, we 
propose Lipoprotein Ontology, a formal framework for the description, 
organisation and classification of lipoprotein-related information. We begin this 
chapter with a brief review on ontology and its definitions. Subsequently, we 
revisit the underlying research issues associated with the representation of 
lipoprotein knowledge. We then discuss the role of ontology in addressing the 
research issues identified in this thesis, by providing examples of current 
applications of ontologies in the biomedical domain. Finally, this chapter 
provides an overview of Lipoprotein Ontology and introduces the key concepts 
and relations in the ontology.  
 
4.2 Ontology Definition and Characteristics 
 
The term ontology has its roots in the branch of philosophy known as 
metaphysics, and can be defined as the science of what exists, dealing with all 
categories and structures of objects, processes, events and their associations in 
every field of reality (Smith et al., 2005). The scheme of metaphysical ontology 
has inspired researchers of information sciences and knowledge engineering to 
develop shared and consistent representation framework for different domains 
of knowledge. In computer science, ontologies are engineering artefacts, which 
consist of sets of logical axioms that form a certain subset of reality or domain of 
discourse (Maedche, 2003). These rich conceptual schemas contain classes 
(concepts), properties (attributes) and relationships between the classes. By 
explicating the relationships between terms, ontologies represent a particular 




Since its incorporation into the knowledge engineering community, various 
groups have attempted to define ontology. As such, the definition of ontology 
has undergone much iteration over time. It is not the purpose of this section to 
provide an exhaustive list of ontological definitions, but to highlight some of the 
most significant and most commonly used definitions, in order to provide some 
guidelines towards ontology development. 
 
One of the first definitions of an ontology was given as “the basic terms and 
relations comprising the vocabulary of a topic area as well as the rules for 
combining terms and relations to define extensions to the vocabulary” (Neches 
et al., 1991). This definition identifies components of an ontology such as terms 
(classes), relations (properties) and rules (restrictions), and implies that 
knowledge can be inferred from the combination of explicitly defined terms and 
relations.  
 
Ontology is most commonly defined in the literature as “the explicit specification 
of a conceptualisation” (Gruber, 1993). Several versions have been proposed 
based on this definition, but by far the most thorough is elucidated by Studer et 
al.: ‘‘An ontology is a formal, explicit specification of a shared conceptualisation. 
Conceptualisation refers to an abstract model of some phenomenon in the world 
by having identified the relevant concepts of that phenomenon. Explicit means 
that the type of concepts used, and the constraints on their use are explicitly 
defined. Formal refers to the fact that the ontology should be machine-readable. 
Shared reflects the notion that an ontology captures consensual knowledge, that 
is, it is not private of some individual, but accepted by a group’’ (Studer et al., 
1998). 
 
Another core definition of ontology is stated as follows: “An ontology refers to an 
engineering artefact, constituted by a specific vocabulary used to describe a 
certain reality, plus a set of explicit assumptions regarding the intended meaning 
of the vocabulary. Usually a form of first-order-logic theory is used to represent 
these assumptions, vocabulary appears as unary and binary predicates, called 
concepts and relations, respectively.” (Maedche, 2003).   
 
All the definitions above describe ontology as a technology used to represent 
and share knowledge about a domain by modelling concepts in that domain and 
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the relationships between those concepts (Gruber, 1991). For the purpose of 




Definition: Ontology in this thesis is defined as a formal, explicit specification of a 




Definition: Formal refers to the representation of knowledge, composed of 
domain concepts and the relationships between them, in a formal or 
specification language in order to be machine-readable. Formalisation of the 




Definition: Explicit refers to the correctness and clarity of the defined concepts, 





Definition: Shared refers to the notion that the ontology reflects consensual 




Definition: Conceptualisation is defined as materialisation of an abstract model 
or portion of reality. This can be achieved by describing the entities within a 








4.3 Ontology as the Proposed Solution 
 
In section 3.3, we discussed several challenges in the lipoprotein domain due to 
the lack of formal framework for lipoprotein knowledge. Consequently, we 
identified the underlying research issues as follows: 
 
• Information Explosion and Unstructured Domain Knowledge 
• Heterogeneity of Biomedical Information 
• Information Integration 
• Inference of Knowledge 
 
The use of ontologies has proven to be effective in the process of data 
organisation and information management, especially in biomedical domains 
(Bodenreider, 2008; Rubin et al., 2007). Therefore, we attempt to address the 
underlying research issues with Lipoprotein Ontology, a formal framework of 
lipoprotein concepts and their relationships. In this section, we elaborate on how 
such an ontological framework can resolve the above-mentioned problems. To 
justify our approach, we provide examples of current applications of ontologies 
in the biomedical domain to the corresponding issues.  
 
4.3.1 Solution for Information Explosion and Unstructured Domain 
Knowledge 
 
Lipoprotein Ontology addresses the issues of information explosion and 
unstructured domain knowledge by formally representing lipoprotein knowledge 
in terms of concepts (lipoprotein components) and relations (interactions 
between components) in a hierarchical and associative manner. As we have 
defined in the previous section, ontologies can be seen as a structured 
framework of concepts and relationships used to describe certain aspects of 
reality, and a set of explicit assumptions regarding the intended meaning of the 
vocabulary (Gruber, 1991; Guarino, 1998). Compared to various other 
classification schemes and structures, including thesauri and taxonomies, 
ontologies represent domain models in a more complete and precise manner 
(Huhns & Singh, 1997). Due to their machine-readability feature, ontological 
frameworks of concepts and relationships can be used to support the intelligent 
management of information by human users or computer systems. The formal 
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structure of ontologies also facilitates the process for classification and 
description of domain concepts and the relationships between them, thus 
providing some structure to domain knowledge. Based on these features, 
ontologies can be used as a reference for applications to obtain knowledge. 
These ontologies are generally referred to as reference ontologies and are 
applicable to many different functions. An example of such ontologies is the 
Foundational Model of Anatomy (FMA) (Rosse & Mejino Jr., 2003).  
 
The FMA is a comprehensive reference ontology for human anatomy. 
Developed in collaboration with anatomists and knowledge engineers for the 
purpose of providing an electronically-accessible encyclopaedic reference for 
anatomic knowledge, FMA presents knowledge in the domain of anatomy as a 
set of entities with rich declarative relationships between them (Figure 6). 
Software applications which require anatomic knowledge about particular organs 
can then navigate to the corresponding entities and relations in FMA, in order to 
retrieve detailed information about anatomic structures needed by the 




Figure 6. Foundational Model of Anatomy (FMA) is a reference ontology representing detailed 
knowledge in the anatomy domain. This screenshot, derived from the FMA Foundational Model 
Explorer page (http://fme.biostr.washington.edu/FME/index.html), shows that anatomic 
knowledge is modelled by specifying a large set of relations among the anatomic concepts. For 
example, the Heart is shown to have many relationships to other entities in the FMA, such as 
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Orientation, Containment, Vascular Supply (Arterial and Venous), as well as Nerve Supply. In 
addition, the ontology also shows hierarchical/subsumption relations between lower concepts 
and upper concepts via the part-Of hierarchy relations. For example, Wall of Right Atrium is part-
Of Right Atrium, which is part-Of Right Side of Heart, and therefore part-Of Heart. 
 
As an anatomic reference, FMA is particularly useful where anatomy might not 
be completely visualised in imaging procedures due to limited spatial resolution 
or to individual patient characteristics. Such detailed anatomic knowledge can 
serve as the basis to build various applications such as helping radiologists to 
interpret images and identify abnormalities in adjacent anatomic structures, 
informing health practitioners about diagnostic possibilities that might have been 
overlooked, or even predicting the anatomic consequences of penetrating injury 
(Rubin et al., 2006). In addition, FMA can also be used as the basis for providing 
anatomic context to other biomedical information (Brinkley, 1991). 
 
4.3.2 Solution for Heterogeneity of Biomedical Information 
 
By providing a controlled vocabulary of lipoprotein concepts, Lipoprotein 
Ontology alleviates heterogeneity issues in the lipoprotein domain. Ontologies 
clarify scientific discussions by serving as controlled terminologies for 
researchers to communicate their results consistently and effectively. As 
biomedical literature often contains many synonymous terms, acronyms and 
abbreviations which refer to the same concept, controlled terminologies 
establish a set of standardised terms for labelling concepts within a given 
domain, in order to ensure the consistent representation of the same concept 
among different agents. To further elaborate, ontologies provide a single 
identifier known as class or concept, to describe information about each entity. 
Ontologies can thus be used as a controlled terminology to describe biomedical 
entities in terms of their functions, disease involvement, etc., in a consistent 
way. In addition, ontologies can be augmented with terminological knowledge 
such as synonyms, abbreviations and acronyms. Therefore, ontologies enable 
the community to integrate resources by providing the ability to reliably identify a 
particular entity or a group of entities based on their biological relevance. These 
controlled sets of terms and relations are crucial for organising the information 
generated by different research groups in a consistent way, thereby facilitating 
communication and enabling interoperability between people as well as 
computer systems. There are a number of ontologies that were developed for 
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the purpose of resolving issues of heterogeneity. We provide some examples of 
biomedical ontologies which were developed towards specific purposes which 
correspond to heterogeneity issues defined in Chapter 3: inconsistent 
terminologies, differences in scope and granularity, differences in research 
output. 
 
4.3.2.1 Inconsistent Terminologies 
 
The Gene Ontology (GO) (GO Consortium, 2000) was designed for the 
standardised representation of various types of genes and gene products 
contained in different databases. Developed by the GO Consortium in 1998, the 
initial structure incorporated a collaborative amalgamation of three model 
organism databases of the Sacchamyces Genome Database, the Mouse 
Genome Database, and FlyBase. The GO now includes many other annotation 
groups.  
 
The primary motivation behind GO was the observation that different databases 
describe the same biological processes, functions and cell components of gene 
products using different terms. Thus, GO serves to eliminate ambiguity across 
databases by providing a controlled vocabulary of terms, categorised under 3 
non-overlapping ontologies: biological processes, molecular functions, and 
cellular components of gene products (GO Consortium, 2000). The GO terms 
have is-a, part-of and the “regulates” relations to other entities, which represents 
the relationship between biological concepts. These relations allow computer 
reasoning applications to infer subsumption or composition by tracing these 
relations respectively.  
 
As whole genomes became readily available through high throughput studies, it 
was discovered that similar genes often have conserved functions in different 
organisms. Nucleic acid and polypeptide sequence data allowed easy 
comparative studies; however, while sequence comparison was easy, 
comparing functional annotation of those data was difficult. The GO facilitates 
the annotation process by associating genes and gene products to GO terms 
(Figure 7), thus making it possible to integrate and query knowledge from 
different databases in order to infer the functionality of newly discovered genes 






Figure 7. Gene Ontology (GO) used to create annotations based on biomedical text (Packard & 
Shepherd, 1997). In the excerpt from biomedical text shown, the molecular function (metabolic 
channel), cellular component (VLDL, IDL and LDL), and biological process (pathogenesis) of 
atherosclerosis, are annotated using the appropriate GO terms from each of the three GO 
ontologies. 
 
In addition, GO annotations can be used to analyse the results of high 
throughput experiments. Each GO annotation has a source, allocated as 
evidence codes, attributed to it (du Plessis et al., 2011). These evidence codes 
promote further analysis of data by highlighting a cluster of genes with similar 
experimental results, which might infer common characteristics or functionality 
shared by that group of genes (Khatri & Draghici, 2005). There are various 
methods by which gene function can be measured quantitatively (du Plessis et 
al., 2011). One method is to measure the similarity as a function of the distance 
between the terms in an ontology graph (Pandey et al., 2008) or the number of 
common parents (Pekar & Staab, 2002). The most common approach is to 
calculate the distance between genes, taking into account all possible pairs of 
GO terms that are associated with both genes (du Plessis et al., 2011). Although 
slightly different in their approach, these measures ultimately enable the 







4.3.2.2 Differences in Scope and Granularity 
 
Originally developed as a classification system, the International Classification of 
Diseases (ICD) is the oldest and most important classification still in use (WHO, 
2004). It is currently in its 10th revision (ICD-10), and has recently been 
formalised in OWL (Möller et al., 2013). Developed and maintained by the World 
Health Organisation, the ICD-10 are detailed classifications of known diseases 
and injuries. The ICD-10 is strongly goal-oriented, has a hierarchical structure 
and focuses upon major aetiological factors, diseases of worldwide importance, 
and causes of serious morbidity and mortality. The value of the hierarchical 
structure is in its support of abstraction, which is the process whereby lower 
level, more specific concepts can be generalised into broader, high level 
concepts to allow reasoning. The goal-oriented characteristic of the ICD-10 
provides context for the abstraction, and the purpose of abstraction within the 
ICD-10 is to enable statistical analysis at the appropriate level, which can be 
used to support causal hypothesising or to identify potential health problems 
within a community. ICD-10 is also used internationally for morbidity and 
mortality statistics (Quan et al., 2005), clinical billing systems (Alexander et al., 
2003) and automated decision support in medicine (Jao & Hier, 2010).  
 
4.3.2.3 Differences in Research Output 
 
By sharing the standard terms used by large databases, controlled terminologies 
facilitate the integration of data from different resources. An example is the 
National Cancer Institute (NCI) Metathesaurus, developed by the National 
Cancer Institute, which was designed to integrate molecular and clinical data in 
cancer research (Hartela et al., 2005). The NCI Metathesaurus provides a 
common vocabulary for cancer terms and relates them to each other in a DL 
framework, thus extending the inferential power of the ontology. By doing so, 
researchers are able to label experimental results in a systematic manner, as 
well as link their research findings to disease and other patterns (Sioutos & al., 
2007). Annotating research data with ontology terms also enables efficient 






4.3.3 Solution for Information Integration 
 
Lipoprotein Ontology addresses information integration issues in a number of 
ways. As we have previously discussed in the problem definition, the amount of 
biomedical information available is massive. In the setting of the current 
information explosion, the knowledge contained within a domain is practically 
beyond the capability of a single domain expert to manually process. Yet, 
biomedical discovery commonly occurs by integrating related, yet diverse 
information from different sources. Ontologies can streamline the process of 
integrating and accessing information across diverse resources. As described 
earlier, ontologies provide a means to make the semantics of a domain explicit 
by providing rich relations among its entities. Specifying the semantics of data in 
a variety of databases can enable researchers to integrate heterogeneous data 
across different databases. Ontologies can play several roles in information 
integration applications: they can provide a formally defined vocabulary for 
semantic annotations, they can be used to describe the structure of existing 
sources and the information that they store, and they can provide a 
comprehensive domain model by which information can be retrieved or 
integrated (Horrocks, 2008). Queries can be performed by DL reasoners through 
semantic annotations and formalised knowledge to retrieve and combine 
information from multiple sources (Stevens et al., 2000). In addition, it is possible 
for a single user or application to utilise different ontologies for different 
purposes. An example is the Open Biological and Biomedical Ontologies (OBO) 
Foundry, which is a library of ontologies designed to facilitate information 
sharing and integration in the biomedical domain.  
 
With an increasing number of biologists recognising the value of ontologies, the 
proliferation of domain ontologies is becoming just as overwhelming as the 
original problem of information explosion. In an attempt to integrate these 
ontologies under one framework and facilitate collaboration within the bio-
ontology community, the OBO Foundry was established. The OBO Foundry 
(Smith et al., 2007) aims to promote semantic interoperability between a group 
of ontologies covering different domains of biomedical reality, on the basis of an 





Upper ontologies represent concepts that are universal and provide a 
standardised approach to KR at the topmost level of organisation in order to 
allow the integration of knowledge. They are not specific to a particular domain, 
and are often generic in order to deal with high-level abstraction and broad 
requirements of different domains, such as the theories of part and whole, 
dependence and boundaries. An example of upper ontologies in the biomedical 
domain is the Basic Formal Ontology (BFO). Of these upper ontologies, BFO 
was specifically developed to serve as an upper ontology for the integration of 
biomedical ontologies under the Open Biomedical Ontologies (OBO) consortium. 
The BFO operations on a distinction between continuants and occurrents; 
continuants are classified as entities in reality that continue to exist through time 
even while undergoing changes, whereas occurrents incorporate temporal 
dimension or time. The former typically encompass entities such as organisms 
which exist even as they undergo changes throughout metabolic processes. On 
the other hand, the latter usually refer to processes which occur through a period 
of time such that they can be divided into temporal parts or phases depending 
on the state that they are in (Smith et al., 2007).  
 
With respect to this basic distinction, the BFO framework is divided into two 
types of ontologies: SNAP ontologies, which are a snapshot of continuant 
entities or all entities existing at a time, and SPAN ontologies, which describe 
processes which unfold through a given interval of time (Grenon & Smith, 2004). 
The interrelations between the two types of ontologies are defined such that 
BFO has the capability to deal with both static/spatial and dynamic/temporal 
features of reality. Both types of ontologies serve as the basis for other sub-
ontologies, each of which contribute a certain portion of reality at a given level of 
granularity.  
 
Such a framework provides guidance for the development of new ontologies 
based on simple guidelines and best practice models, and is particularly 
beneficial in avoiding common mistakes, especially for inexperienced ontology 
developers. Moreover, an upper ontology promotes coherence between 
neighbouring ontologies by providing the meta-level structures shared by the 
biomedical domain. Ultimately, the purpose of the OBO Foundry is to develop 
“an expanding family of ontologies designed to be interoperable and logically 
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well formed and to incorporate accurate representations of biological reality” 
(Smith & Brochhausen, 2010). Shown in Figure 8, OBO ontologies are roughly 
arranged from genotype to phenotype (Bodenreider, 2006).   
 
 
Figure 8. Open Biological and Biomedical Ontologies (OBO) arranged along a spectrum of 
genotype to phenotype, according to their main topic (Bodenreider, 2006). 
 
In this way, OBO provides context to any specific ontology being queried, in 
relation to the genotype, anatomical location, stage of development, among 
others. Thus, by providing a common language across many resources, these 
non-overlapping and interoperable ontologies can have a potentially significant 
impact not only towards the holistic integration of biological knowledge, but also 









4.3.4 Solution for Inference of Knowledge 
 
Lipoprotein Ontology also supports the inference of knowledge and can provide 
the underlying basis for a wide variety of computational applications. Ontologies 
are particularly effective for the management of scientific knowledge as they 
offer several advantages. As ontologies operate on the basis of an open world 
assumption, relations which are not explicitly stated within the ontology can be 
inferred from the relations between explicitly defined terms. This way, ontologies 
extend the functionality of information models and terminological systems by 
supporting automated reasoning. Their formal structure, coupled with the 
properties of the relations between concepts, as well as rules of inference 
provided by DL, provide a justification towards the inference of knowledge that 
cannot be achieved by information modelling approaches or controlled 
vocabularies. Most importantly, information models which are represented by 
ontologies in the OWL format can be applied to Semantic Web search engines, 
thus increasing the processing and inferential capabilities of domain knowledge 
(Horrocks, 2002). In other words, biomedical ontologies enable machines to 
derive meaning from information and complete tasks with reduced human 
intervention. In this section, we discuss several examples of how ontologies can 
be used as the basis for various computational applications and support the 
inference of knowledge.  
 
4.3.4.1 Data Mining 
 
Ontologies can be used to infer new knowledge through data mining. The 
machine-readability feature of ontologies facilitates the process by which 
applications or software agents can access the information contained within the 
ontology, such as data mining tools. Data mining involves the extraction of 
information, and detection of patterns from a large body of information for further 
use, such as finding hidden patterns in the data and establishing predictive 
models based on this data  (Fayyad et al., 1996). Some work has been done in 
the biomedical domain on integrating data across various bioinformatics 
databases and enable mining across various conceptual levels of biological 
information, culminating in a complex set of networks from which information 
can be derived (Gopalacharyulu et al., 2008). A more straightforward example of 
the application of data mining techniques on ontologies is the International 
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Classification of Diseases (ICD) discussed in Section 4.3.2. The availability of a 
large range of disease concepts and relations between diseases represented in 
the ICD enables data mining tools to detect rare events, such as adverse 
reaction to drugs, using ICD-9 (Jinjuvadia et al., 2007). 
 
4.3.4.2 Decision-Based Support Systems 
 
Computer-based information systems are increasingly being used by clinicians 
to aid in the diagnoses of diseases. Clinical systems are qualitatively different 
from the more general information systems used in health care administration or 
population studies, as they must cope with issues of scalability, detail and 
complexity of the information required for clinical decision. At the same time, the 
system needs to be intuitive and offer ease of use across a range of clinical 
settings. To address these requirements, the behaviour of such “intelligent” 
information systems needs to be influenced by semantic context or meaning of 
the information it is manipulating. Through the representation of concepts and 
their relations in formal languages, ontologies therefore serve as the semantic 
basis to enable easy access, retrieval and integration of information by clinical 
systems. In addition, DL reasoners are used in ontology applications due to their 
precision and reliability; this is particularly crucial in medical information 
management, where incorrect reasoning can have an adverse impact on patient 
care (Horrocks, 2008). Having ontologies as a core greatly increases the 
inferential power of any application. For example, if several different websites 
which contain medical information or provide medical services share the same 
underlying ontology, then software agents are able to extract and integrate 
information from these different sites. These agents can then use the 
aggregated information to answer complex user queries through reasoning. By 
making comparisons between the logical definitions of each concept and their 
relations, DL reasoners applied to ontologies are capable of inferring relations 
between concepts. Thus, ontologies can facilitate complex query processing in 
clinical systems (Huff, 2007). 
 
4.4 Critical Review of Biomedical Ontologies 
 
In the previous section, we have established how biomedical ontologies can be 
used to solve a number of research issues. This section presents a critical 
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review of some of these ontologies, as well as several others, to further validate 
the need to creating a new ontology rather than building on existing ontologies, 
and to justify the ontology design we have chosen in the lipoprotein research 




Most of the biomedical ontologies discussed in the previous section do not 
contain any lipoprotein concepts. Of the ontologies that do, none provide 
adequate representations of lipoprotein concepts and their relations. For 
example, the Gene Ontology has a small section on Lipoproteins and 
Lipoprotein Metabolism (GO Consortium, 2000); however these concepts do not 
contain associative relations between them other than the hierarchical structure 
that they are organised in.  
 
The Unified Medical Language System (UMLS) (http://umlsks.nlm.nih.gov), 
developed and maintained by the US National Library of Medicine, consists of a 
multitude of medical concepts from various categorisation systems which makes 
up the Metathesaurus base. Building on top of the Metathesaurus is the UMLS 
Semantic Network which draws both hierarchical and associative relationship 
types between each Metathesaurus concept. However, its associative 
relationship types are limited to five key categories: “physically related to”, 
“spatially related to”, “temporally related to”, “functionally related to” and 
“conceptually related to”. Such relationships do not represent the richness of the 
theories and pathways involved in lipoprotein metabolism. Therefore, the UMLS 
can only be used as a reference resource.  
 
The two ontologies that are most closely associated with Lipoprotein Ontology 
are Lipid Ontology (Baker et al., 2008) and Protein Ontology (Natale et al., 
2011). Although lipoproteins are essentially a lipid and protein complex, and 
both Lipid Ontology and Protein Ontology constitute a repository of lipid and 
protein concepts respectively, merging the two ontologies to form Lipoprotein 
Ontology is not a consideration, as they have not been designed for the 
organisation of lipoprotein concepts in particular. As a result, they lack many 
relevant concepts related to lipoproteins. However, it is possible to merge these 
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two ontologies under Lipoprotein Ontology in the future, in order to utilise the 
information they contain as the fine-grain details of Lipoprotein Ontology.  
One of the main motivations for this thesis is to formalise concepts of lipoprotein 
dysregulation. As lipoprotein dysregulation is classified as a form of disease or 
disorder, we explored the ICD-10 (WHO, 2004) further and found a match for a 
subclass for lipoprotein disorders. Again, we face the same issue that these 
hierarchically structured concepts do not contain the rich associative relations 
that Lipoprotein Ontology offers. We will, however, map these concepts to 




Ontologies used in classification systems are mostly hierarchical. The value of 
the hierarchical structure is in its support of abstraction, which is the process 
whereby lower level, more specific concepts can be generalised into broader, 
high level concepts to allow reasoning. For example, the ICD is a classification 
system for diseases which is strongly goal-oriented in its hierarchy and primarily 
serves as an epidemiological tool, although work to formalise the system in 
OWL is underway (Möller et al., 2013). The ICD focuses upon major aetiological 
factors, diseases of worldwide importance, and causes of serious morbidity and 
mortality. Views on disease models and prevalence are embedded in the system 
and cannot be changed in any way by the users. The purpose of abstraction 
within ICD is to enable statistical analysis at the appropriate level, which can be 
used to support causal hypothesis or to identify potential health problems within 
a community. The goal-oriented characteristic of the ICD provides context for the 
abstraction, which, as mentioned previously, cannot be modified. This can serve 
as a problem when the ICD utilised for different purposes, the classification will 
only be satisfactory when used in a setting where its aims are compatible with 
the embedded assumptions. Because of this reason, it has been considered 
inappropriate for use in general practice (GMSC-RCGP, 1988). If a classification 
does not represent an appropriate choice of concepts or embody a relevant 
abstraction, the appropriate response is to construct another classification. 
However, this can result in a serious fragmentation of medical terminology with a 
lack of standards. In an attempt to reconcile the numerous classifications 
currently in use, the Unified Medical Language System (UMLS) was developed. 
Another major shortcoming of classification systems is that they are often 
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enumerative and lack compositional features. Therefore, adding extensions to 
the content usually results in a combinatorial explosion of terms. This is not a 
serious issue when the classification systems are used for epidemiological and 
statistical purposes. However, when qualifiers and modifiers are included in a 
clinical system to increase the expressive power such as to represent the 
severity or progress of a disease, the total number of terms exponentially 
increase with respect to the modifier. For example, consider a classification 
system in which there are 100 diseases. If we add a modififer concept such as 
severity of a disease and limit this to three degrees of severity (mild, moderate 
and severe), then the total number of terms representing diseases becomes: 
100 diseases x 3 severities + 100 original terms = 400 terms. If we introduce 
another modifier concept such as progress of a disease (better, same and 
worse), the result is now 1,600 terms.  
 
As we have established, the ICD-10 is a traditional medical classification based 
on a single hierarchical structure, which represents a basic model of the domain 
knowledge (WHO, 2004). However, as new concepts are added to the ontology, 
it becomes increasingly difficult to reconcile the new perspective with respect to 
the purpose of the classification. The strong purpose specification of an ontology 
are greatly beneficial when used in an appropriate setting. In fact, one of the 
methodologies that we will discuss in the next section advocates the early 
establishment of purpose and scope in ontology development. However, at the 
same time, a deeply embedded goal can be detrimental to adaptation and 
management of the ontology. Therefore, in an attempt to resolve this problem, a 
semantic model can be built using a multi-axial approach to separate the basic 
concepts within the domain from the more complex ideas embedded in the 
hierarchical structure (Wingert et al., 1989). An example of multi-axial approach 
is the SNOMED CT (Systematized Nomenclature Of Medicine Clinical Terms), a 
systematically organised computer processable collection of medical terms 
(Wingert et al., 1989). The SNOMED CT comprises of six principal axes, which 
are based on a broad view of biomedical science such as topography, 







4.5 Methodologies for Ontology Development 
 
Numerous methodologies have been proposed for ontology development. We 
have reviewed these methodologies in detail, but due to keeping this section 
concise, we will be presenting a comparison of these methodologies. For the full 
review of the methodologies, please refer to Appendix H. Although these 
methodologies vary in their approach and purpose, they have basic 
commonalities with respect to different stages of purpose identification, domain 
conceptualisation, formalisation and evaluation of ontology. Some 
methodologies offer supplementary stages in order to fulfil certain requirements 
and be effective in different applications. It must also be mentioned that the 
process of ontology development is subjective and can be comparable to a 
design activity (Noy & McGuinness, 2001). Given the same set of requirements 
within the same domain, two ontology developers are most likely to produce 
ontologies that are quite different to one another. However, in spite of these 
differences, an ontology building methodology can be described to have a three-
layered structure:  
 
1. Top layer: An outline of the whole ontology development process that is 
similar to a software development process 
2. Middle layer: Generic constraints and guidelines which specify the major 
steps 
3. Bottom layer: Identification of concept and attributes 
 
Of all the methodologies reviewed, the Knowledge Engineering Methodology 
(Noy & McGuinness, 2001) and the methodology proposed by Uschold & King 
(Uschold & King, 1995) are the only two methodologies which describe the steps 
of ontology development at the bottom and middle layers. Both methodologies 
are very similar in nature in that they both specify the purpose and scope of the 
ontology at the initial stage and include similar processes such as domain 
conceptualisation and formalisation of concepts. The only difference between 
the two is that the Uschold & King methodology offers additional steps, which 
are the evaluation and documentation processes. 
 
Other methodologies are aimed mainly towards the middle and top layers by 
developing the ontology within the context of a management process. Therefore, 
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they are generally more focused towards the evaluation and maintenance of the 
ontology. For example, the TOVE methodology includes the incorporation of 
formal competency questions as an evaluation criterion for the effectiveness and 
completeness of the designed ontology (Gruninger & Fox, 1995). 
METHONTOLOGY focuses on the maintenance and quality of the ontology by 
incorporating project management activities (Fernández-López & Gomez-Perez, 
2002) while the OnToKnowledge methodology works especially well for 
knowledge management applications (Staab et al., 2001). Respectively, the 
DILIGENT methodology focuses on user centrality and highlights the need to 
adapt the established ontology to its applicants’ requirements (Pinto et al., 
2004). The DOGMA methodology separates the domain axiomatisation 
(ontology base) from the application axiomatisation (commitment layer) in order 
to provide space for both ontology specific applications and their reusability 
(Spyns et al., 2008).  
 
Some methods also differ in the conceptualisation process. As they are focused 
towards the bottom and middle layers of ontology development, the Knowledge 
Engineering Methodology and Uschold & King methodology provide some 
guidelines towards the top down, bottom up, middle out approaches, providing 
the justification for each approach. Generally, methodologies commit to the 
middle or top layers commit to a specific approach, whether top down, bottom up 
or middle out approaches. For example, comparing the KACTUS (Bernaras et 
al., 1996) and SENSUS (Swartout et al., 1997) methods, the former involves 
developing the ontology by means of an abstraction process from an initial 
knowledge base, whereas in the latter, domain-specific ontologies are generated 
from a broad ontology.  
 
Having reviewed a number of ontology building methodologies, it can be 
concluded that none of the approaches proposed are fully mature compared to 
software engineering methodologies (Corcho, 2003; Fernández-López & 
Gomez-Perez, 2002). In addition, these approaches are ad-hoc and do not 
necessarily serve as a standard methodology for ontology development (Noy & 
McGuinness, 2001). Rather, it is upon the ontology developer to consider the 
different approaches and adopt the features of these methodologies selectively 




We have chosen to develop our Lipoprotein Ontology based on the Knowledge 
Engineering Methodology due to its focus on conceptual design. However, we 
will also be incorporating various aspects of other methodologies to suit the 
purpose of our ontology, which will be discussed in the next chapter. 
 
4.6.1 Overview of Lipoprotein Ontology 
 
The main objective of this thesis is to address KR issues in the lipoprotein 
research domain. In this section, we provide an overview of Lipoprotein 
Ontology and highlight the important upper concepts of the ontology. The 
ontology will be elucidated in detail in Chapter 6.  
 
Lipoprotein Domain Concept 
 
Definition: Lipoprotein domain concept is defined as a set of lipoprotein concepts 
and relations. In order to represent the lipoprotein domain knowledge in a 
coherent way, these concepts and relations are organised in a hierarchical 
structure, under five distinct superclasses: Classification, Metabolism, 
Pathophysiology, Aetiology and Treatment. These superclasses are further 




Definition: Classification is defined as the classification of Lipoprotein Entity. 
Lipoprotein Entity is defined as a soluble complex of lipids and proteins. 
Depending on the lipid and protein content, lipoprotein entities are classified 
accordingly into various subclasses. Examples of Lipoprotein Entity are: 




Definition: Lipoprotein Metabolism is defined as the chemical processes which 
involve the synthesis and/or catabolism of Lipoprotein Entity. In this thesis, we 
classify “things” associated lipoprotein metabolism into three concepts: Physical 




4.6.2.1 Physical Entity 
 
Definition: Physical Entity is defined as the representation of an entity that may 
participate in an interaction, a process or a relationship of significance. Physical 
Entity can be further categorised into two classes: Functional Entity and 
Structural Entity. 
 
Functional Entity is a real thing involved in lipoprotein metabolism, defined by its 
properties or the function it performs. Some examples of Functional Entity are: 
Lipid, Protein. 
 
Structural Entity is defined as a real thing, defined by its physico-chemical 
structure, and can be further divided into two classes: Macro Organic Structure 
(systems) and Micro Organic Structure. Examples of Macro Organic Structure 
are: Body Part, Organ. Examples of Micro Organic Structure are: Cell, Tissue. 
 
4.6.2.2 Occurring Entity 
 
Definition: Occurring Entity is defined as the representation of an entity that 
manifests, unfolds or develops through time, such as a discrete event, or a 
mutual or reciprocal action or influence that happens between participating 
physical entities, and/or other occurring entities. Occurring Entity can be further 
categorised into two classes: Process and Pathway. 
 
Process is defined as the representation of the action which brings about a 
change from one entity to another entity. Examples of Process are: Hydrolysis, 
Synthesis. 
 
Pathway is defined as the representation of a sequence of reactions which 
occurs whereby the products of one reaction are the substrates for subsequent 








4.6.2.3 Participant Role 
 
Definition: Participant Role is defined as the function of a physical or conceptual 
entity, that is its role, in the execution of an event or process. Examples of 
Participant Role are: Action Role (Drug Action Role, Enzyme Action Role), 




Definition: Pathophysiology is defined as the pathophysiology related to the 
dysregulation in lipoprotein disorders. Pathophysiology can be further 




Definition: Disorder is defined as disease or abnormality of function. Examples of 




Definition: Symptom is defined as the subjective indication of a disorder or 




Definition: Aetiology is defined as the causes of lipoprotein disorder. Aetiology 
can be further categorised into four classes: Lifestyle Cause, Genetic Cause, 
Disease States Cause and Drug Interaction. 
 
4.6.4.1 Lifestyle Cause 
 
Definition: Lifestyle Cause is defined as the causes of lipoprotein disorder due to 






4.6.4.2 Genetic Cause 
 
Definition: Genetic Cause is defined as the causes of lipoprotein disorder due to 
hereditary factors. Genetic causes are further categorised into two types: Defect 
(LPL Activity, LDL Clearance) and Deficiency (LDLr Deficiency, LPL Deficiency). 
 
4.6.4.3 Disease State Cause 
 
Definition: Disease State Cause is defined as the causes of lipoprotein disorder 
due to the disease states. Examples of these drugs are: Diabetes, Renal Failure. 
 
4.6.4.5 Drug Interaction 
 
Definition: Drug Interaction is defined as the causes of lipoprotein disorder due 





Definition: Treatment is defined as the treatment of lipoprotein disorder. 
Treatment can be further categorised into three classes: Lifestyle Change, Drug 
and Combination Therapy. 
 
4.6.5.1 Lifestyle Change 
 
Definition: Lifestyle Change is defined as the treatment of lipoprotein disorder 





Definition: Pharmacotherapy is defined as treatment of lipoprotein disorder with 






4.6.5.3 Combination Therapy 
 
Definition: Combination Therapy is defined as the treatment of lipoprotein 
disorder with a combination of treatment options. 
 
4.6.6 Diagnostic Parameter 
 
Definition: Diagnostic Parameter is defined as the requirement of diagnosis 




In this chapter, we introduced Lipoprotein Ontology, a framework for the 
conceptualisation and formal representation of lipoprotein knowledge, as the 
solution to the underlying research issues that were identified in Chapter 3. We 
initially provided some definitions of ontology and presented a clear argument on 
the role of ontologies in addressing the corresponding research issues. This is 
followed by a critical review of other biomedical ontologies, where we present 
validation that current ontologies in health and biomedical domains do not fulfil 
the requirements for a specific ontology for lipoproteins. We also reviewed 
existing methodologies on ontology development. This chapter concluded with 
an overview of Lipoprotein Ontology and defined the key concepts and relations 
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In the previous chapter, we provided justifications for Lipoprotein Ontology as 
the solution to the corresponding research issues that were identified in Chapter 
3. We presented a critical review of biomedical ontologies, as well as a 
comparison of existing methodologies on ontology development. Subsequently, 
we arrived at the conclusion that ontology building is a subjective process, and 
that features from different ontology development methods can be adopted to 
suit the purpose of the ontology. This chapter details the steps we have 
undertaken in developing Lipoprotein Ontology. The methodology used to build 
Lipoprotein Ontology is based on the Knowledge Engineering Methodology; 
however, we will also incorporate various features of other methodologies in our 
ontology development process.  
 
5.2 Overview of the Methodology 
 
In developing Lipoprotein Ontology, our methodology covers four broad 
processes: specification, conceptualisation, formalisation and evaluation (Chen 
& Hadzic, 2010). Knowledge acquisition occurs throughout the four stages. 
Detailed steps for these four processes are shown in Figure 9 and elaborated in 









The specification phase involves 3 sub-phases: 
 
• Identification of purpose and scope 
• Literature review 
• Formulation of competency questions 
 
5.3.1 Identification of Purpose and Scope 
 
The first step to developing Lipoprotein Ontology was to identify the key 
objective, followed by the purpose of the ontology. The aim of this thesis is to 
develop an ontology for the lipoprotein domain which formally represents 
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knowledge about lipoprotein-related concepts and their relationships. This 
ontology will serve the following purposes which correspond to the underlying 
research issues defined in Chapter 3:  
 
• Formal representation of lipoprotein research domain 
• Controlled vocabulary for lipoprotein concepts to alleviate issues of 
information heterogeneity 
• Lipoprotein knowledge integration and management 
• Inference of lipoprotein knowledge 
 
Subsequently, we established the scope of Lipoprotein Ontology. This is to 
ensure that the ontology created is purpose-driven and contain the right level of 
granularity for knowledge-based queries (Noy & McGuinness, 2001). Here, we 
defined the domain and range of our work, as well as some of the features of the 
ontology.  
 
The scope of Lipoprotein Ontology is focused mainly on the organisation of 
lipoprotein concepts and coverage of the concepts and theories in the lipoprotein 
research domain. However, further refinement and evolution of Lipoprotein 
Ontology could consider other issues such as the adaptation of the ontology to 
various communities of users. 
 
The domain of this work is the lipoprotein research domain, which was 
extensively reviewed in Chapter 2. The range of the project starts from the 
specification phase, followed by the conceptualisation of lipoprotein knowledge, 
ontology design, formal representation of the conceptual model, as well as 
evaluation of Lipoprotein Ontology. We specified the areas of lipoprotein 
knowledge that the ontology aims to represent, and identified the resources and 
databases from which we extracted knowledge for the development of our 
ontology (Spyns et al., 2008). For the lipoprotein domain, we used PubMed as 
the literature database from which we extracted lipoprotein concepts from peer-
reviewed journal articles and conference proceedings, as well as other 
biomedical textbooks and articles concerning lipoproteins. The selected 
resources must be representative of the domain-related concepts and theories 
which are used by domain experts and researchers. Lipoprotein Ontology was  
formalised in OWL and visualised in Protégé 4.2.  
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Some key features of Lipoprotein Ontology include: 
 
• Evidence-based: The concepts in Lipoprotein Ontology were manually 
extracted  from peer-reviewed journal articles and conference proceedings 
from PubMed as well as biomedical textbooks. 
• Reusability: The concepts and relations in Lipoprotein Ontology should be 
reusable for purposes beyond those anticipated in the ontology model. 
• Extensibility: Lipoprotein Ontology also has to have the potential to evolve 
to accommodate new concepts that extend well beyond the current 
concepts. It is imperative to structure the ontology in such a way that 
allows for legacy use to consider ontology evolution.  
• Completeness: Although ontologies operate on the basis of an open world 
assumption and can therefore never be classified as entirely “complete”, 
Lipoprotein Ontology will attempt to model the lipoprotein domain as 
described in the literature review.  
• Compatibility: Some of the concepts in Lipoprotein Ontology will be 
adopted from neighbouring ontologies such as Lipid Ontology and Protein 
Ontology. However, as ontology alignment is a significant research area in 
itself, it is beyond the scope of this thesis to align entire ontologies with 
Lipoprotein Ontology. As a compromise, we have reused concepts in our 
ontology from its neighbouring ontologies whenever possible. This gives us 
the potential to merge Lipoprotein Ontology and other ontologies for future 
work. 
 
5.3.2 Literature Review 
 
In the next part of the specification phase, a broad literature survey on 
lipoproteins was conducted to define the most important lipoprotein concepts. 
First, we identified the resources and databases from which we can extract 
knowledge for the development of our ontology. The selected resources must be 
representative of the domain-related concepts which are used by domain 
experts and researchers. Therefore, we chose to curate our resources from 
PubMed, the largest online repository for biomedical literature from MEDLINE, 
biomedical science journals, and other online books (PubMed, 2013). PubMed is 
developed and maintained by the National Center for Biotechnology Information 
(NCBI), at the US National Library of Medicine (NLM).  
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For our work, we manually extracted lipoprotein concepts from peer-reviewed 
journal articles and conference proceedings from the PubMed database, as well 
as other biomedical textbooks and articles concerning lipoproteins. We initially 
searched for review articles for a general overview of the lipoprotein research 
domain, using the search term “lipoproteins” in PubMed. The relevant texts and 
statements from various knowledge resources were selected and recorded, to 
define the basic concepts for Lipoprotein Ontology. From our review of the 
literature, we identified the core motivations behind lipoprotein research and 
subsequently categorised them according into five sub-concepts: Classification, 
Metabolism, Pathophysiology, Aetiology and Treatment. These concepts 
provided the structure for the formulation of competency questions in the next 
step. 
 
5.3.3 Formulation of Competency Questions 
 
The formulation of competency questions supports the iterative process of 
knowledge acquisition and also serves as a validation technique for the 
correctness and consistency of the ontology. These competency questions 
cover the six sub-ontologies of Lipoprotein Ontology: Classification, Metabolism, 




The conceptualisation phase involves 2 sub-phases: 
 
• Defining the domain conceptual model 
• Identification of classes, properties and relations 
 
5.4.1 Defining the Domain Conceptual Model 
 
The primary aim of the conceptualisation phase is to create an abstract model of 
the lipoprotein domain knowledge. In the literature review step of the 
specification phase, we identified five important concepts as the sub-ontologies 
under which the corresponding lipoprotein concepts can be categorised: 
classification of lipoproteins, lipoprotein metabolism pathways, pathophysiology 
of lipoprotein dysregulation (dyslipidaemia), aetiology (causes) of dyslipidaemia 
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and treatment of dyslipidaemia. These concepts constitute the initial framework 
for the lipoprotein conceptual model.  
 
We developed the initial lipoprotein conceptual model using the multi-axial 
approach (Wingert et al., 1989) to represent Lipoprotein Ontology based on five 
overarching sub-ontologies: Classification, Metabolism, Pathophysiology, 
Aetiology and Treatment, under which the associated concepts were identified 
and categorised in a hierarchical structure. We presented this work at the 22nd 
IEEE International Symposium on Computer-Based Medical Systems in August, 
2009 (Chen & Hadzic, 2009).  During this time, we evaluated our ontology and 
have since added one more sub-ontology Diagnostic Parameter to incorporate 
physiological measures for diagnostic purposes.  
 
We extended the initial conceptual model by extracting the concepts associated 
with the five key lipoprotein concepts. The search terms that were used to 
extract these concepts were: “classification of lipoproteins”, “lipoprotein 
metabolism”, “lipoprotein disorders”, “dyslipidaemia”, “causes”, “treatment”. This 
was carried out via the same literature review process described in the 
specification phase: by manually extracting these concepts from peer-reviewed 
journal articles and conference proceedings from the PubMed database, as well 
as other biomedical textbooks and articles.  
 
Simultaneously, we also reviewed the literature for various ontology building 
methodologies, as well as other established ontologies to structure our 
conceptual model in the most appropriate manner. At the early stages of 
concept building, it is imperative to develop the basic ontological framework 
towards modularity, for the purposes of reusability, maintenance and evolution 
(Rector, 2003). This can be done through the process of normalisation, which is 
a common procedure in databases for similar reasons. In developing our 
conceptual model, we adopted some features of the normalisation process 
according to (Rector, 2003). The key requirements of this process include: 
 
• The concepts to be reused can be identified and separated from the 
whole taxonomy. 
• Maintenance can be split amongst authors who can work independently. 
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• Concepts can evolve independently and new concepts can be added with 
minimal side effects. 
• The differences between various categories of information are 
represented explicitly for both human understanding and formal machine 
inference. 
 
With respect to these requirements, we define the Lipoprotein Domain Concept 
to include two general upper concepts: 
 
• Self-standing concepts: Broadly, self-standing concepts are “things” in the 
physical and conceptual world. By the same token, self-standing 
concepts of the Lipoprotein Domain Concept are “things” in the lipoprotein 
knowledge domain. Hence, we categorise the six lipoprotein sub-
ontologies discussed in the beginning of this section under the general 
category of Self Standing Concept. 
• Refining concepts: Value types and values which partition conceptual 
spaces e.g. “small, medium, large”, “mild, moderate, severe”, etc. For 
refining concepts:  
a) There should be a taxonomy of primitive “value types” which 
is disjoint;  
b) The primitive children of each value type should form a 
disjoint exhaustive partition, i.e. the values should “cover” the 
“value type”. 
 
At this stage, we also considered the use of these ontologies for other purposes 
such as enrichment of our ontology and ontology merging for future work (Noy & 
McGuinness, 2001; Spyns et al., 2008). 
 
We elaborate on this conceptual model and provide justifications for our choice 
of ontology structure in Chapter 6. 
 
5.4.2 Identification of Classes, Properties and Relations 
 
In the next step of the conceptualisation phase, we identified and described 
hundreds of concepts, their definitions and binary relationships between them in 
the form of theoretical axioms, using a Word document. From this, we defined 
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lipoprotein concepts as classes, arranged in a hierarchical structure under their 
respective sub-ontologies. The class hierarchy was developed by means of a 
combination of top-down and bottom-up classification strategies (Noy & 
McGuinness, 2001). Using a top-down approach, we initially began with the 
creation and description of the six sub-ontologies defined in the previous stage. 
Some of the relevant middle-level concepts then fall under their respective top-
level concepts via a top-down method. Others were formed using a bottom-up 
approach through which we first identified several specific concepts and then 
abstracted a more general and representative concept for them.  
 
Having established lipoprotein classes in a hierarchical structure, we 
subsequently assigned properties (relationships) to the corresponding 
lipoprotein classes (Noy & McGuinness, 2001; Spyns et al., 2008). The resultant 
model of classes and their relationships appear in the form of theory statements 
such as “A partOf B” or “X hasProperty Y”. As a result, relations between these 
classes are described in an unambiguous way and the possible values are filled. 
It must be reiterated that the process of knowledge acquisition occurs 
throughout the four stages, hence as new classes are identified, the associated 
properties and relations must be filled accordingly. We elaborate on this process 




The formalisation phase involves 2 sub-phases: 
 
• Formalisation of the conceptual model 
• Creation of instances 
 
5.5.1 Formalisation of the Conceptual Model 
 
To formalise the lipoprotein conceptual model from the previous phase, it is 
necessary to implement the ontology using an ontology language and its 
corresponding tool. As we have previously defined in Chapter 4.2, 
“formalisation” refers to the translation of the conceptualised knowledge into a 
machine-readable and formal language. Lipoprotein Ontology is represented by 
OWL as the ontology language due to its superiority compared to its preceding 
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languages (Grau et al., 2008; Horrocks et al., 2003). As an extension of RDF 
and DL, OWL balances expressivity with reasoning, which makes it the most 
suitable language for the purpose of Lipoprotein Ontology. OWL is the language 
used by prominent ontology editors, including Protégé. Most importantly, OWL is 
the standardised language of the Semantic Web.  
 
Ontology tools are capable of translating the concept definitions and 
descriptions into a predefined ontology language in an automatic way. We opted 
to develop Lipoprotein Ontology using the most recent version of the Protégé 
ontology editor at the writing of this thesis, Protégé 4.2. This tool allows us to 
store the specified concepts in a class hierarchy and facilitates the description 
and definition of their properties, constraints and describes the relationships with 
other concepts. The Protégé tool automatically translates concept definitions 
and descriptions into the formal OWL language. For example, the formal 
representation of “Chylomicron is a subclass of LipoproteinEntity and has 




  <rdfs:subClassOf rdf:resource=“http://www.owl-
ontologies.com/lipoprotein_ontology.owl#LipoproteinEntity”/> 
     <rdfs:subClassOf 
          <owl:Restriction> 
               <owl:onProperty 
rdf:resource=“http://www.owl-
ontologies.com/lipoprotein_ontology.owl#hasComponent”> 
               <owl:someValuesFrom 
rdf:resource=“http://www.owl-
ontologies.com/lipoprotein_ontology.owl#Cholesterol”/> 
          </owl:Restriction> 
     </rdfs:subClassOf> 
</owl:Class> 
 
Further details about the formalisation process of the conceptual framework are 




5.5.2 Creation of Instances 
 
In this step, we populate the ontology by creating instances for their given 
classes. Due to the extensive nature of Lipoprotein Ontology, we will be creating 
instances for the purpose of evaluation. We refer to our list of competency 




After the ontology has been developed, it must be evaluated for: 
 
 • Completeness: The concepts and relationships are explicitly stated and 
each definition is complete. 
 • Consistency: The definitions are consistent and do not include 
contradictory information. In addition, inferences need to be consistent 
with existing definitions and axioms, and should be clear and logical. 
 • Conciseness: The ontology does not store any unnecessary definitions. 
 • Extensibility: Users can add new definitions to the ontology and more 
knowledge to its definitions without altering the set of well-defined 
properties. 
 • Minimal encoding bias: Conceptualisations need to be specified at 
knowledge-level and not at a symbol or notation level. As such, the 
proper use of relations is necessary in order to maintain the integrity of 
the ontology. For example, for the superclass LPMetabolism, although it 
may appear to be more convenient to use the subclass relation “isA” 
instead of “partOf” expression, the “isA” relation is not the correct relation 
for its respective subclasses PhysicalEntity, OccurringEntity and 
ParticipantRole. Rather, we used the “partOf” relation in order to 
maintain the correct formal definition for their corresponding axioms. 
 
With respect to these criteria, the evaluation phase involves 3 sub-phases: 
 
 • Concept coverage 
 • Validation of competency questions 




5.6.1 Concept Coverage 
 
A test set, which consists of randomly selected abstracts of published papers 
from publication databases, can be used to evaluate the conceptual coverage of 
the designed ontology. The developed ontology is used to encode knowledge 
from this test set. Conceptual coverage evaluation can then be carried out by 
calculating the percentage of domain concepts, which are covered or 
represented by the ontology. 
 
5.6.2 Validation of Competency Questions 
 
The first step of the evaluation phase involved testing the complete Lipoprotein 
Ontology against the competency questions that were defined at the initial 
specification stage of ontology development. This was carried out in order to 
check that the model has successfully represented relationships present in the 
initial documents or definitions. How well does the model perform when it is 
faced with information that is not explicitly in the scope of its design? I.e. What 
inferences can we draw from it?  
 
5.6.3 Evaluation using Case Studies 
 
The established Lipoprotein Ontology was then evaluated using the concept 
coverage criterion (Hartmann et al., 2005); we developed two case studies or 
scenarios to evaluate whether the ontology represents the majority of 
lipoprotein-related concepts used in the literature. The lipoprotein-related 
concepts abstracted from these scenarios were given to the ontology tool. Then 
we calculated the percentage of concepts within the scenarios that had equal or 
similar concepts in Lipoprotein Ontology. In the later stages, new concepts will 
be added and created axioms will be further refined to ensure that the ontology 
meets the reusability, consistency, clarity coherence, minimal encoding bias, 
minimal ontological commitment, simplicity and correctness criteria (Brank et al., 
2005). The process of conceptual coverage method and our evaluation results 








In this chapter, we described the methodology used to develop Lipoprotein 
Ontology. This methodology incorporated different stages of other existing 
methodologies, and included the following processes: specification, 
conceptualisation, formalisation and evaluation. In the next chapter, we present 






Brank J., Grobelnik M., & Mladenić, D. (2005). A survey of ontology evaluation techniques. 
Paper presented at the Proceedings of the Conference on Data Mining and Data Warehouses 
(SiKDD 2005). 
Chen, M., & Hadzic, M. (2009). Lipoprotein ontology as a functional knowledge base. Paper 
presented at the Proceedings of the 22nd IEEE International Symposium on Computer-Based 
Medical Systems (CBMS 2009), New Mexico, USA. 
Grau, B. C., Horrocks, I., Motik, B., et al. (2008). OWL 2: the next step for OWL. Web Semantics: 
Science, Services and Agents on the World Wide Web, 6(4), 309–322. 
Hartmann, J., Sure, Y., Giboin, A., et al. (2005). Methods for ontology evaluation Knowledge web 
project deliverable 
Horrocks, I., Patel-Schneider, P. F., & van Harmelen, F. (2003). From SHIQ and RDF to OWL: 
the making of a web ontology language. Web Semantics: Science, Services and Agents on the 
World Wide Web, 1(1), 7–26. 
Noy, N. F., & McGuinness, D. L. (2001). Ontology development 101: a guide to creating your first 
ontology, from http://protege.stanford.edu/publications/ontology_development/ ontology101-noy-
mcguinness.html 
PubMed. (2013), from http://www.ncbi.nlm.nih.gov/pubmed 
Rector, A. L. (2003). Modularisation of domain ontologies implemented in description logics and 
related formalisms including OWL. Paper presented at the 2nd International Conference on 
Knowledge Capture, Florida, USA. 
Spyns, P., Tang, Y., & Meersman, R. (2008). An ontology engineering methodology for DOGMA 
Journal of Applied Ontology, 3(1-2), 13-39. 
 
Every reasonable effort has been made to acknowledge the owners of copyright material. I 













This chapter presents the conceptual framework for the representation of 
lipoprotein domain knowledge, and elaborates on some of the upper level 
concepts which are represented in Lipoprotein Ontology. Building on the 
literature review on lipoproteins we have thoroughly conducted in Chapter 2, we 
hereby present lipoprotein-related concepts in a structured hierarchy according 
to ontology principles defined in Chapter 5.4.1. The corresponding properties 
and restrictions of these concepts will be elucidated in Chapter 7 during the 
process of formalisation. Lipoprotein Ontology was developed and then 
implemented with Protégé 4.2. The visualisation of the lipoprotein conceptual 
framework and concept hierarchies will be presented in this chapter accordingly 
as figures.  
 
6.2 Overview of of Lipoprotein Ontology 
 
In this section, we describe the structure of Lipoprotein Ontology and outline the 
upper concepts that will be discussed in the remainder of the chapter. We refer 
to Chapter 4.6 for the definitions of these concepts in Lipoprotein Ontology. We 
will include the membership criteria to each class in an informal manner as part 
of the conceptualisation process, in order to organise lipoprotein concepts into 
their corresponding upper concepts. The attributes and relations of these 
concepts will be represented as a formal framework in the next chapter.  
 
First and foremost, we reiterate the definition of ontology as “the formal, explicit 
specification of a shared conceptualisation of a domain.” Therefore, it is 
important that we clearly establish our domain of interest at the initial stage of 
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ontology development. We have done this by creating two major subclasses 
under the main ontology concept Thing, which represents the class of all things 
(Figure 10): 
 
• LipoproteinDomainConcept: A set of lipoprotein concepts and relations 
that makes up the lipoprotein domain knowledge 
• MetaConcept: All other concepts that do not belong to the lipoprotein 
domain concept. 
 
Having defined LipoproteinDomainConcept as the class in which a set of 
lipoprotein concepts and relations are structured under, our next step was to 
organise the domain conceptual framework into two subclasses for the purpose 
of modularity, as discussed in Chapter 5.4.1. In order to preserve the integrity of 
the two upper concepts to the LipoproteinDomainConcept, we attached the 
prefix “LP” to these concepts to denote their unique associations with the 
lipoprotein domain. Thus, the two subclasses of LipoproteinDomainConcept 
are represented as follows (Figure 10): 
 
• LPSelfStandingConcept: “Things” or concepts in the lipoprotein domain 
domain.  
• LPRefiningConcept: Value types and values which partition conceptual 




Figure 10. Upper concepts of Lipoprotein Ontology, LipoproteinDomainConcept and 
MetaConcept with parent Thing. LipoproteinDomainConcept contains two subclasses 




Since LPSelfStandingConcept is the class in which concepts in the lipoprotein 
knowledge domain are organised under, it serves as the main conceptualisation 
of the lipoprotein domain knowledge, which can be represented by six sub-
ontologies (Figure 11). Similarly, we attached the prefix “LP” to these concepts 
to denote their unique associations with the lipoprotein domain. 
 
• LPClassification  
• LPMetabolism  
• LPPathophysiology  
• LPAetiology  
• LPTreatment  
• LPDiagnosticParameter 
 
Lipoprotein concepts and relations are organised under the corresponding sub-
ontologies, which we will discuss in the subsequent sections. These concepts 
are not mutually exclusive, and can be reused by more than one sub-ontology. 
This notion is particularly in alignment with the nature and role of lipoprotein 
components in the lipoprotein metabolism pathway. For example, the concept 
Cholesterol is used in two sub-ontologies: Metabolism and Classification. 
Cholesterol is a Sterol component classified under PhysicalEntity, which is a 
concept with partOf relation to Metabolism. At the same time, Cholesterol is 
also categorised in the Classification sub-ontology as one of the critical 
components of all classes of lipoproteins, collectively known as 
LipoproteinEntity, i.e. Chylomicron, VLDL, LDL, IDL and HDL.  
 
LPRefiningConcept is the top level concept which classifies value types and 
values which partition conceptual spaces. LPRefiningConcept for Lipoprotein 






Each of these concepts can be categorised further into their respective 
subclasses, and related to other concepts in the ontology, which we will discuss 






Figure 11. LipoproteinDomainConcept represented by two major subclasses, 




“Definition: Classification is defined as the classification of Lipoprotein Entity. 
Lipoprotein Entity is defined as a soluble complex of lipids and proteins. 
Depending on the lipid and protein content, lipoprotein entity are classified 
accordingly into various subclasses.”  
 
From the above, the sub-ontology LPClassification is defined as the 
classification of LipoproteinEntity. Respectively, LipoproteinEntity is defined 
as a soluble complex of lipids and proteins. LipoproteinEntity defines 
lipoprotein classes as follows (Figure 12): 
 
 • Chylomicron 
 • ChylomicronRemnant 
 • VeryLowDensityLipoprotein 
 • IntermediateDensityLipoprotein 
 • LowDensityLipoprotein 
 • HighDensityLipoprotein 







Figure 12. Sub-ontology of LPClassification with parent LPSelfStandingConcept and subclass 
LipoproteinEntity, with its respective subclasses. 
 
Lipoprotein classes are categorised accordingly under LipoproteinEntity based 
on several criteria that confer membership into the class: content, 
electrophoretic mobility and function. These attributes will be discussed further in 




As defined in Chapter 2.2.1, LipoproteinEntity is a soluble complex of lipids 
and proteins. Within the circulation, these components are in a state of constant 
flux, changing in composition and structure as lipoproteins are metabolised via 
various lipoprotein metabolism pathways. As lipoprotein contents are constantly 
being passed from one to another during metabolism, the distinction between 
classes is somewhat variable. Depending on the lipid and protein content, 
lipoprotein entities are classified accordingly into various types. Table 1 from 
Chapter 2.2.1 (Appendix A) summarises the lipid content and composition that 
constitute the major lipoprotein classes, Chylomicron, ChylomicronRemnant, 
VeryLowDensityLipoprotein, IntermediateDensity Lipoprotein, 




Because the lipoprotein divisions by density are arbitrary and vary somewhat 
within their own classes, they can also be classified according to their 
electrophoretic mobility on agarose gels into α, pre-β and β lipoproteins, 
corresponding to HDL, VLDL and LDL lipoprotein fractions respectively. 





The functions of the different lipoprotein classes are determined by their lipid 
and apolipoprotein components. Chylomicrons are synthesised in the intestines 
for the transport of dietary triglycerides to various tissues. VLDL are synthesised 
in the liver for the export of endogenous triglycerides, while IDL and LDL are 
derived from the metabolism of VLDL in circulation. The function of LDL is to 
deliver cholesteryl esters to the liver and peripheral tissues. HDL are 
synthesised and assembled in the liver and intestines or formed from the 
metabolism of other lipoproteins in circulation, and from cellular lipids at the cell 
membranes. HDL remove excess cholesterol from cells and transport it to liver 




“Definition: Lipoprotein Metabolism is defined as the chemical processes which 
involve the synthesis and/or catabolism of Lipoprotein Entity.” 
 
Up to this point, concept hierarchies were represented as hierararchical is-a 
relationships. For the concept of LPMetabolism, we represent the associative 
relationship between LPMetabolism and its corresponding concepts using the 
partOf relation. In Figure 13 below, we show the representation of the isA and 
partOf relations using different arrows. We will discuss the difference between 
these relations in the next chapter.  
 
 
Figure 13. Representation of hierarchical isA and associative partOf relations using empty and 
solid arrows, respectively. 
 
Understanding the metabolism of lipoproteins involves a clear elucidation of the 
components that participate in the lipoprotein metabolic pathways. This includes 
separating components from pathways, processes from location. The 
conceptualisation of the sub-ontology LPMetabolism can be categorised into 









Figure 14. Sub-ontology of LPMetabolism with parent LPSelfStandingConcept and subclasses 
PhysicalEntity, OccurringEntity and ParticipantRole. 
 
The upper concepts which belong to the LPMetabolism sub-ontology are 
derived from Systems Biology Ontology (Courtot et al., 2011), with some of the 
concept definitions referenced from MeSH (Lowe & Barnett, 1994). These 
concepts will be discussed in detail in the following sections. 
 
6.4.1 Physical Entity 
 
“Definition: Physical Entity is defined as the representation of an entity that may 
participate in an interaction, a process or a relationship of significance.” 
 





FunctionalEntity is a real thing involved in lipoprotein metabolism, defined by 
its properties or the function it performs. The list below is not fully exhaustive of 
all existing functional entities; for the purpose of this thesis, FunctionalEntity 















StructuralEntity is a real thing, defined by its physico-chemical structure, and 
can be further divided into two classes (Figure 15):  
 
• MacroOrganicStructure   
• MicroOrganicStructure 
 
Figure 15. Concept of PhysicalEntity with parent LPMetabolism and subclasses FunctionalEntity 
and StructuralEntity, with their respective subclasses. 
 
6.4.2 Occurring Entity 
 
“Definition: Occurring Entity is defined as the representation of an entity that 
manifests, unfolds or develops through time, such as a discrete event, or a 
mutual or reciprocal action or influence that happens between participating 
physical entities, and/or other occurring entities.” 
 
OccurringEntity can be further categorised into two classes:  
 




Process is defined as the representation of the action which brings about a 
change from one entity to another entity. In lipoprotein metabolism, these 



















Pathway is defined as the representation of a sequence of reactions which 
occurs whereby the products of one reaction are the substrates for subsequent 
reactions. In Chapter 2.2.2, we have identified three major pathways in 
lipoprotein metabolism as: 1. ExogenousPathway, dealing with the transport 
and metabolism of dietary lipids; 2. EndogenousPathway, dealing with the 
lipids that are synthesised in the liver, and; 3. ReverseCholesterolTransport, 
dealing with the synthesis and metabolism of HDL. However, in our ontology, we 
also include other pathways which are significant in the metabolism of various 
lipoprotein components. For example, we have included the HMG-
CoAReductasePathway concept as it is one of the target treatment pathways 
for dyslipidaemia. Therefore, the Pathway class includes the following concepts, 
















Figure 16. Concept of OccurringEntity with parent LPMetabolism and subclasses Process and 
Pathway, with their respective subclasses. 
 
6.4.3 Participant Role 
 
“Definition: Participant Role is defined as the function of a physical or conceptual 
entity, that is its role, in the execution of an event or process.”  
 
 143 
In order to assign roles to lipoprotein components, it is necessary to build a 
concept for this purpose. Therefore the ParticipantRole describes the function 
of various lipoprotein components and can be further categorised into six 










Figure 17. Concept of ParticipantRole with parent LPMetabolism and subclasses Reactant, 





“Definition: Pathophysiology is defined as the pathophysiology related to the 
dysregulation in lipoprotein disorders.” 
 
Dysregulation in lipoprotein metabolism occurs as a consequence of alterations 
in the kinetics of lipoproteins. To classify the sub-ontology LPPathophysiology, 
we separate concepts of the actual disorder from their physical indication into 
two classes using the associative partOf relationship (Figure 18).  
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Figure 18. Sub-ontology of LPPathophysiology with parent LPSelfStandingConcept and 





“Definition: Disorder is defined as disease or abnormality of function. Examples 
of  lipoprotein disorder are: Cardiovascular Disease, Diabetes.” 
 
Disorder associated with lipoprotein dysregulation can be further categorised 
into eight classes (Figure 19). Again, it should be noted that this list is not fully 
exhaustive of all disorders associated with lipoprotein dysregulation and can be 











As a number of definitions have been proposed to diagnose 
MetabolicSyndrome, we have included the most common definitions that are 






Figure 19. Concept of Disorder with parent LPPathophysiology and subclasses 
MetabolicSyndrome, InsulinResistance, LiverDisorder, RenalDisorder, LipidDisorder, 




“Definition: Symptom is defined as the subjective indication of a disorder or 
disease.” 
 
Symptom associated with lipoprotein dysregulation can be further categorised 














Figure 20. Concept of Symptom with parent LPPathophysiology, with subclasses Dyslipidaemia, 






“Definition: Aetiology is defined as the causes of lipoprotein disorder.” 
 
There are several contributing factors to dyslipidaemia. Dyslipidaemia can be 
the result of lifestyle, the interaction between genetic predisposition and 
environmental factors, or other diseases, or a combination of both. Drug 
interactions may also contribute to lipoprotein dysregulation. Therefore, 








Figure 21. Sub-ontology of LPAetiology with parent LPSelfStandingConcept and subclasses 




6.6.1 Lifestyle Cause 
 
“Definition: Lifestyle is defined as the causes of lipoprotein disorder due to 
lifestyle factors.” 
 
LifestyleCause of lipoprotein dysregulation can be further categorised into five 
classes(Figure 22). This list is not fully exhaustive of all lifestyle causes 









Figure 22. Concept of LifestyleCause with parent LPAetiology and subclasses Diet, Exercise, 
Smoking, Alcohol and EmotionalWellbeing. 
 
6.6.2 Genetic Cause 
 
“Definition: Genetic Cause is defined as the causes of lipoprotein disorder due to 
hereditary factors.”  
 
GeneticCause is further categorised into two types (Figure 23):  
 




Figure 23. Concept of Genetic with parent LPAetiology and subclasses Defect and Deficiency. 
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6.6.3 Disease State Cause 
 
“Definition: Disease State Cause is defined as the causes of lipoprotein disorder 
due to the disease states.” 
 
DiseaseStateCause is the concept given for disease states which cause 
lipoprotein disorders and will be explained further in the next chapter (Figure 24). 
 
Figure 24. Concept of DiseaseStateCause with parent LPAetiology. 
 
 
6.6.4 Drug Interaction 
 
“Definition: Drug Interaction is defined as the causes of lipoprotein disorder due 
to the action of other drugs” 
 
DrugInteraction is the concept given for the interaction of drug classes which 
causes lipoprotein disorders and will be explained further in the next chapter 
(Figure 25). 
 





“Definition: Treatment is defined as the treatment of lipoprotein disorder.”  
 
Treatment options to correct dyslipidaemia include drugs such as statins, 
fibrates, bile acid sequestrants and cholesterol absorption inhibitors, as well as 
lifestyle changes, or a combination of both. Therefore, LPTreatment can be 
further categorised into three classes, among others (Figure 26):  
 
• LifestyleChange 





Figure 26. Sub-ontology of LPTreatment with parent LPSelfStandingConcept and subclasses 
LifestyleChange, Pharmacotherapy and CombinationTherapy. 
 
6.7.1 Lifestyle Change 
 
“Definition: Lifestyle Change is defined as the treatment of lipoprotein disorder 
with changes in lifestyle.”  
 
Examples of these LifestyleChange concepts include but are not exclusive to 







Figure 27. Concept of LifestyleChange with parent LPTreatment and subclasses 




“Definition: Pharmacotherapy is defined as treatment of lipoprotein disorder with 
pharmacotherapy.” 
 
Pharmacotherapy of lipoprotein dysregulation include but are not exclusive to 









Figure 28. Concept of Pharmacotherapy with parent LPTreatment and subclasses Statin, 
Fibrate, NicotinicAcid and BileAcidSequestrant.  
 
6.7.3 Combination Therapy 
 
“Definition: Combination Therapy is defined as the treatment of lipoprotein 
disorder with a combination of treatment options.” 
 
CombinationTherapy is the concept given for the combination of treatment 




Figure 29. Concept of CombinationTherapy with parent LPTreatment. 
  
6.8 Diagnostic Parameters 
 
“Definition: Diagnostic Parameter is defined as the requirement of diagnosis 
specific to the characteristics of an individual.” 
 
In clinical practice, dyslipidaemia can be diagnosed by measuring lipoprotein 
components, and comparing these levels to established guidelines according to 
the gender and geographic ancestry of an individual. Since these concepts have 
been classified respective to their categories as discussed previously, the 
concept LPDiagnosticParameter includes the requirement of diagnosis specific 
to the characteristics of an individual. These are (Figure 30):  
 








Figure 30. Sub-ontology of LPDiagnosticParameter with parent LPSelfStandingConcept and 



















Figure 32. Concept of Ethnicity with parent LPDiagnosticParameter. 
 
6.8.3 Geographic Ancestry 
 
GeographicAncestry can be categorised into the following classes (Figure 33). 
This list is not fully exhaustive of all geographical locations and can be extended 














Figure 33. Concept of GeographicAncestry with parent LPDiagnosticParameter and subclasses 
Australia, Europe, NorthAmerica, SouthAmerica, Asia, MiddleEast, Africa, 





Patient is the concept given for the instances of patients that are classified or 
inferred by the ontology (Figure 34).  
 
  















In this chapter, we presented the conceptual framework for Lipoprotein Ontology 
using the ontology editor Protégé 4.2. First, we provided an outline of 
Lipoprotein Ontology and introduced the upper concepts of the ontology. We 
explained how these concepts are structured according to ontology principles 
defined in Chapter 5.4.1. Subsequently, we elaborated on the conceptualisation 
process of each of the six sub-ontologies of the lipoprotein domain knowledge, 
namely: Classification, Metabolism, Pathophysiology, Aetiology, Treatment and 
Diagnostic Parameter. These concept hierarchies were presented as figures. 
The corresponding properties and restrictions of these concepts will be 
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In the previous chapter, we presented the conceptual framework of Lipoprotein 
Ontology. We have opted to use Protégé 4.2 as our ontology development tool, 
and OWL as the ontology language for the implementation of Lipoprotein 
Ontology. This chapter explains how the conceptualisation process in the 
previous chapter was formalised using OWL and its operators. First, we provide 
an overview of KR languages and justify the rationale behind our choice of 
implementation tool and language. This is followed by a description of OWL 
components and the structure of OWL ontologies. Finally, visualisation of 
Lipoprotein Ontology is presented as screenshots from Protégé to represent 
various functions of concept classification, definition and description, using 
various OWL constructs. 
 
7.2 Knowledge Representation Languages 
 
In order to enable the sharing of information by software agents and facilitate the 
automatic processing of information, conceptual models have to be implemented 
in a formal language with well-defined syntax. As discussed in the Chapter 6, we 
have chosen to develop Lipoprotein Ontology using the ontology editor Protégé 
4.2. At the time of writing of this thesis, Protégé is the leading ontology editor 
across various disciplines, with a community of approximately 220,000 users 
internationally (http://protege.stanford.edu). 
 
Although various other KR languages exist, in this section we focus mainly on 
the formal language that is supported by Protégé, the Web Ontology Language 
2 (OWL 2). OWL 2 was developed by the World Wide Web Consortium (W3C) 
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as the standard to define ontologies on the Semantic Web (W3C, 2012), and is 
therefore a suitable language for the formalisation of Lipoprotein Ontology.  
 
This section introduces various KR languages associated with ontology building, 
such as Resource Descriptive Framework (RDF), Resource Descriptive 
Framework Schema (RDFS) and the Web Ontology Language (OWL).  
 
7.2.1 RDF and RDFS 
 
The Resource Descriptive Framework (RDF) (http://w3.org/RDF) is a language 
for representing information about resources on the World Wide Web (Berners-
Lee et al., 2001). RDF serves as a framework for metadata description and is 
represented as a machine-readable format of subject-predicate-object triplet 
from the English language. In contrast to object-oriented languages which are 
resource-centric, RDF is a property-centric language with an XML-based syntax 
(Baader et al., 2003). A resource-centric language requires the definition of 
concepts and their properties in a centralised method, which does not allow a 
property to be defined independently of its associated class. Thus, a new 
property cannot be defined unless it is represented by a predefined class or the 
creation of a new class for it. On the other hand, RDF is a semantic web 
language which allows the representation of information in a free manner, by 
providing the facility to define properties independently of the classes. Therefore, 
RDF has the capability to describe any class with any existing property. 
However, RDF has no vocabulary associated with it; as such, anything can be 
expressed in it as long as it follows a subject-predicate-object structure. 
 
The lack of vocabulary in RDF poses a problem for machine processing due to 
the insufficient context or meaning associated with the data model. Thus, RDF 
Schema (RDFS) (http://w3.org/TR/rdf-schema) was developed to extend RDF 
vocabulary to allow the description of concepts and attributes. This allows the 
creation of meaningful statements and facilitates the exchange of information 
between computer systems more efficiently due to the additional context. RDFS 
introduces the concept of classes, which allows classes to be specialised into 
subclasses that can inherit from multiple upper classes. Similarly, properties can 
be arranged in a hierarchical format from general to specific. RDF is then used 
to make actual statements using the structure described previously. In addition 
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to the class hiearchy, RDFS has other features such as such as providing the 
facility to set the domain and range of properties (Baader et al., 2003). RDFS 
also allows the creation of unions and intersections of classes, thereby 
effectively creating new classes. However, ontologies require greater vocabulary 
than one that RDF and RDFS offer, in addition to formal semantics. For this 
reason, the Web Ontology Language (OWL) was created on top of RDF and 
RDFS, and is our language of choice to represent Lipoprotein Ontology. 
 
7.2.2 OWL and OWL 2 
 
The modelling capabilities of RDF and RDFS allow vocabularies to be organised 
in hierarchies of class/subclass and property/subproperty relationships, operate 
domain and range restrictions and define instance memberships. However, they 
still lack other significant features of an ontology, such as cardinality restrictions, 
describing disjoint classes, among others. These shortcomings can be 
addressed by an ontology language.  
 
The Web Ontology Language (OWL) (http://w3.org/TR/owl-features) is a family 
of KR languages for authoring ontologies (W3C, 2012). Known in previous 
revisions as DAML (Stein, 2002), OIL (Horrocks, 2000), and their successor 
DAML+OIL (Horrocks, 2001), OWL extends the basic fact-stating function of 
RDF and the structuring capabilities of RDFS in various ways. In addition to 
declaring classes and properties, and organising them in a subsumption 
hierarchy accordingly, OWL has greater expressivity with the capability to 
provide restrictions on how properties behave that are local to a class. 
Furthermore, OWL also allows Boolean combinations such as intersectionOf, 
unionOf and complementOf, to combine both owl:Classes and class expressions 
(i.e. anonymous classes), or disjoint with other classes (W3C, 2009).  
 
To satisfy different requirements, OWL comes in three different forms:  OWL 
Lite, OWL DL and OWL Full. The difference between these types is their 
increasing expressiveness from simple constraints via computational 
completeness to syntactic freedom of RDF with no computational guarantees 





OWL Lite is used in situations where the features of RDFS are required with 
simple constraints (W3C, 2009). As OWL Lite offers the lowest formal 
complexity, such as setting cardinality values of 0 or 1, it allows a more tractable 
inference as well as provides a quick migration path from simple classification 
hierarchies such as taxonomies (W3C, 2009). Due to its low complexity, OWL 
Lite is considered to be too limited for our requirements.  
 
OWL DL is an extension of OWL Lite that offers maximum semantic 
expressiveness while retaining computational function which guarantees 
complete computation in finite time (W3C, 2009). OWL DL is based on DL, a 
family of logic-based KR languages that have formal semantics based on first 
order logic and allows automatic reasoning (Baader et al., 2003). As automatic 
reasoning is one of the requirements for Lipoprotein Ontology, OWL DL is 
suitable for developing our ontology.  
 
Out of the three OWL versions, OWL Full provides the greatest semantic 
expressiveness. However, as it lacks computational guarantees, it is not suitable 
for our requirements, as it is necessary that Lipoprotein Ontology be computable 
in finite time in order to be useful in its application.  
 
In 2009, OWL was extended with new features, thereby known as OWL 2 
(http://w3.org/TR/owl2-overview). OWL 2 is currently the standard ontology 
language recommended by W3C (W3C, 2012). Some of the new features of 
OWL 2 include the more user-friendly Manchester syntax, and a functional-style 
syntax which specifies the language structure and allows OWL 2 ontologies to 
be written in a compact form (W3C, 2012). 
 
OWL 2 is the ontology language supported by our chosen ontology editor, 
Protégé 4.2, and retains all the characteristics of OWL 1 in terms of its 
expressivity. It has two corresponding dialects to OWL 1: OWL 2 DL, which is 
used to refer to ontologies interpreted using Direct Semantics, and OWL 2 Full, 
which can only be interpreted under RDF-Based Semantics (W3C, 2012). 
Therefore, based on the purpose of our ontology and the need for reasoning 





In addition to automatic reasoning function, OWL 2 DL utilises Manchester 
syntax that can be used to make working with OWL easier. In the Semantic Web 
context, where users with a wide range of expertise might be expected to create 
or modify ontologies, readability and general ease of use are important 
considerations for an ontology language. This provides further justification 
towards our choice to use OWL 2 DL to develop our ontology.  
 
7.3 Components of OWL Ontologies 
 
OWL ontologies are composed of individuals, classes and properties. As 
discussed previously, we have opted to use OWL 2 to develop our ontology, 
which corresponds to SROIQ(D) logic. DL allow concepts to be defined and 
described using a rich set of operators such as intersection, union and negation, 
in addition to other property restrictions. Thus, complex concepts can be built up 
in definitions out of simpler concepts using the OWL components Classes, 




Individuals represent the objects in our domain of interest and can be referred 




Classes are concrete representation of concepts composed of formal 
descriptions that specify the conditions that must be satisfied by an individual for 
it to be a member of the class. For example, in Lipoprotein Ontology, the class 
Chylomicron contains all instances of chylomicron molecules. There are 
typically two types of classes in an ontology: primitive classes which are defined 
in terms of their necessary properties or attributes, and defined concepts which 
are defined in terms of properties which are both necessary and sufficient. We 









Properties represent the relations between two classes or individuals, and can 
also be placed in a subsumption (property/subproperty) hierarchy for the 
purpose of abstraction. There are three types of properties: 
 
• Object property links instances of one class to another class. E.g. The 
property hasComponent can be used to link the instances of Chylomicron 
and Cholesterol as “Chylomicron hasComponent Cholesterol”. 
• Datatype property specifies datatype values for individuals by linking 
them to an rdf literal or an XML Schema Datatype such as integer, float, 
string, Boolean etc. E.g. The datatype property hasSize can be used to 
describe the size range (between 75nm and 1200nm) that Chylomicron 
particles can fall under as  “Chylomicron hasSize some (integer[>= 75] 
and integer[<= 1200])”. As lipoprotein particles are classified into different 
classes according to the size range in diameter which is unique to that 
specific class, any particle that falls between the range specified in our 
example above is automatically classified as a chylomicron.  
• Annotation property is used for metadata description such as 
comments, references to resources, etc. E.g. The annotation property of 
the class Chylomicron is defined as “Comment: A class of lipoproteins 
that carry dietary cholesterol and triglycerides from the small intestines to 
the tissues.” 
 
7.3.3.1 Property Characteristics 
 
OWL allows the meaning of object properties to be enriched through the use of 
property chacteristics. In this section, we describe some of the property 
characteristics used in Lipoprotein Ontology and provide examples to illustrate 




Each object property may have a corresponding inverse property. For example, 
if the inverse property of hasComponent is isComponentOf, we can infer from 
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If a property is functional, there can be at most one unique value for each 
individual. For example, lipoproteins can be classified according to their 
electrophoretic mobility on agarose gels into α, pre-β and β lipoproteins, 
corresponding to HDL, VLDL and LDL lipoprotein fractions respectively. 
Chylomicrons remain at the electrophoretic origin. Therefore, for each subclass 
of LipoproteinEntity which has the corresponding functional property 
hasElectrophoreticMobilityValue, we can automatically infer the class that an 




If a property P is transitive and associates object X to object Y, and object Y to 
object Z, then object X is simultaneously associated with object Z via property P. 
For example, for the transitive property hasMetabolismProduct, if 
“VeryLowDensityLipoprotein hasMetabolismProduct 
IntermediateDensityLipoprotein” and “IntermediateDensity Lipoprotein 
hasMetabolismProduct LowDensityLipoprotein”, then we can infer that 




If object X is associated with object Y via property P, then object Y is associated 
with object X along the same property P. For example, the symmetric property 
isAssociatedWith is its own inverse property.  
 
7.3.3.2 Property Restrictions 
 
In addition to designating property characteristics, OWL also provides the facility 
to further constrain the range of a property through property restrictions. By 
assuming a restriction type as an abstract or anonymous class, we may 
describe a given class of individuals as a subclass of that anonymous class 
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which satisfies the restriction criteria. We have applied the following property 
restrictions to Lipoprotein Ontology and provide examples for each type of 
restriction.  
 
Quantifier restrictions  
 
Quantifier restrictions can be further categorised into existential restriction and 
universal restrictions.  
 
Existential restrictions, written in OWL as “someValuesFrom”, describe classes 
whose individuals are related, via a given property, to individuals of some other 
class. For example, the statement “Chylomicron hasComponent some 
Cholesterol” describes instances which belong to the class Chylomicron that 
have at least one (some) hasComponent relationship to members of the class 
Cholesterol. Here, the restriction “hasComponent some Cholesterol” can be 
abstracted as an anonymous class whose members are those individuals from 
the class Chylomicron that satisfy the restriction, that is, have at least one 
hasComponent relationship with Cholesterol.  
 
Universal restrictions, written in OWL as “allValuesFrom”, define classes of 
individuals that are associated only with individuals of another specified class 
along a certain property. For example, the statement “apoB-48 isAssociatedWith 
only Chylomicron” describes instances which belong to the anonymous class of 
individuals that only have isAssociatedWith relationship to the class 
Chylomicron. The universal restriction is rarely used in Lipoprotein Ontology 
since lipoprotein concepts are highly interrelated. 
 
Cardinality restrictions  
 
Cardinality restrictions allow us to describe the class of individuals that have at 
least, at most or exactly a specified number of relationships with other 
individuals or datatype values. For a given property P, a minimum cardinality 
restriction specifies the minimum number of P relationships that an individual 
must participate in. A maximum cardinality restriction specifies the maximum 
number of P relationships that an individual can participate in. A cardinality 
restriction specifies the exact number of P relationships that an individual must 
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participate in. Qualified cardinality restrictions are more specific than cardinality 
restrictions in that they state the class of the objects within the restriction.  
 
For example, the statement “MetabolicSyndrome hasSymptom min 3 Thing” 
describes the set of individuals that are members of the class 
MetabolicSyndrome and that have at least three hasSymptom relationships 
with other (distinct) individuals. This can also be applied to the various 
cardinality restriction types accordingly.  
 
hasValue restrictions  
 
A hasValue restriction describes the set of individuals that have at least one 
relationship along a specified property to a specified individual. For example, the 
hasValue restriction Patient hasGeographicAncestry Australia (where Australia 
is an individual) describes the set of individuals (the anonymous class of 
individuals) that belongs to the class Patient and has at least one relationship 
along the hasGeographicAncestry property to the specific instance Australia.  
 
7.3.4 Necessary and Sufficient Conditions 
 
Having described OWL properties, including property characteristics and 
restrictions, we will now discuss their usage in OWL classes to build up complex 
definitions from simpler definitions. Two types of OWL classes were 
implemented in Lipoprotein Ontology.  
 
Primitive class is a class that only has necessary conditions. For example, for 
the primitive class LipoproteinEntity, if an individual is a member of the class 
LipoproteinEntity then it must satisfy the condition. However, even if any 
(random) individual satisfies these necessary conditions, it cannot be 
automatically inferred as a member of the class LipoproteinEntity, as the 
conditions are not sufficient to be able to say this.  
 
Defined class is a class with at least one set of necessary and sufficient 
conditions, and can also be referred to as an equivalent class. For example, for 
the defined class Chylomicron, if an individual is a member of the class 
Chylomicron then it must satisfy the condition. On top of that, if any (random) 
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individual satisfies the conditions, then the individual must be a member of the 
class Chylomicron. Therefore, the conditions are not only necessary for 
membership of the class Chylomicron but also sufficient to determine that 
something which satisfies these conditions is also a member of the class. 
 
7.4 Structure of OWL Ontologies 
 
The relations between concepts or individuals (and their properties) can be 
categorised into two types: hierarchical and associative relationships.  
 
Hierarchical relationships organise concepts into “isA” or “partOf” hierarchies. 
The finite concepts in most of the ontologies are linked together using this type 
of relationship. Ontology-based representations are typically hierarchical 
models, following the natural tendency of the human mind to organise mental 
models through the formation of hierarchies. The value of the hierarchical 
structure is in its support of abstraction, which is the process whereby lower 
level, more specific concepts can be generalised into broader, upper level 
concepts to allow the automatic reasoning of subsumption (superclass/subclass) 
relationships (Rosch, 1978). Ontologies can also be represented as graph 
structures or trees or network models in order to meet the more complex 
requirements of an expert system (Helsper & van der Gaag, 2002). 
 
Associative relationships describe the dynamic interactions between entities and 
the influences that different components have on each other. Such influences 
can take various forms including causation, alteration, regulation, etc. In this 
regard, associative relationships in scientific domains should represent facts by 
identifying the existing connections between different concepts and describing 
the influences that those concepts have on each other through scientific 
evidence from the literature, rather than the consensus of domain experts (Smith 
et al., 2005). For example, an ontological statement such as “cell cycle 
checkpoint regulates cell cycle” in Gene Ontology (GO Consortium, 2000) is 
grounded in the scientific fact that the cell cycle is constantly and necessarily 
regulated by the cell cycle checkpoint (GO Consortium, 2000). Therefore, rather 
than defining ontology relationships through the agreement of domain experts, 
we have developed relations in Lipoprotein Ontology based on scientific 
evidence obtained from the literature.  
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7.5 Notation and Syntax 
 
In this thesis, the following conventions are used: 
 
• English text versions of definitions or concepts to be represented are 
written between double quotes “protein and lipid complex”. 
• Things that appear on the screen are given in a bold sans-serif font, e.g. 
LipoproteinOntology. 
• Classes (concepts) and property names (attributes, slots or roles) are 
written in camel back notation in bold and italics respectively, e.g. 
LipoproteinEntity, hasComponent. 
• Class names always begin with an uppercase letter, and with singular 
noun. Property names always begin with a lower case letter.  
 
Given these conventions, the representation of lipoproteins, defined as “protein 
and lipid complex”, is LipoproteinEntity. The relationship between 
chylomicrons, a kind of lipoprotein, and lipoprotein entity, is hierarchical and is 
represented by the “isA” property relation. Therefore, in Lipoprotein Ontology, 
the previous statement is written as: Chylomicron isA LipoproteinEntity. 
 
Protégé 4.2 follows the Manchester syntax, which is used when editing class 









Manchester OWL Syntax 
 
Example 
someValuesFrom ∃ some hasCause some X 
allValuesFrom ∀ only hasCause only X 
hasValue ∋ value hasCause value X 
minCardinality ≥ min hasCause min 3 
cardinality = exactly hasCause exactly 3 












Manchester OWL Syntax 
 
Meaning 
intersectionOf ⊓ and Female and Patient 
unionOf ⊔ or Male or Female 
complemenOf ¬ not not 
 
 
7.6 Formalisation of Lipoprotein Concepts 
 
In the previous section, we discussed the various components of OWL 
ontologies and the types of relations that OWL ontologies hold. Here, we 
describe the process of formalising Lipoprotein Ontology with OWL components 
of Classes, Properties and Individuals. The relationships between Lipoprotein 
Ontology concepts will be shown as figures throughout this chapter. Due to 
space constraints, we cannot link every single concept that has been defined in 
our ontology on these diagrams; however, wherever possible, we have shown 
how concepts from different sub-ontologies were reused, in order to view them 
within context. In addition, for some concepts, we include screenshots of the 
properties frame in Protégé to illustrate the properties and restrictions 
associated with the corresponding classes.  
 
The underlying DL formalism of our chosen implementation language OWL DL 
allows the use of a reasoner to check that the statements and definitions in the 
ontology are mutually consistent, ensuring the integrity of the ontology 
throughout the development process. Therefore, we have chosen to present the 
inferred model of our ontology, as it can be seen as a formal validation method 
to check for inconsistencies in the ontology implementation. In addition, the 
inferred model also provides a greater level of detail and relationships in some 
cases.  
 
The differences between various reasoners were reviewed in (Dentler et al., 
2011). In this thesis, we have used the Protégé built-in HermiT 1.3.7 reasoner, 
as it has the capability to determine the consistency of an ontology, identify 
subsumption relationships between concepts, among other features (Dentler et 
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al., 2011). In addition, it provides support for Semantic Web Rule Language 
(SWRL), which can be applied to the ontology at a much later stage to provide 
additional rules on top of the OWL knowledge base (Dentler et al., 2011; 
O’Connor, 2006).  
 
The upper concepts and class hierarchy of LipoproteinDomainConcept are 




Figure 35. LipoproteinDomainConcept represented by two major subclasses, 
LPSelfStandingConcept and LPRefiningConcept, with their respective subclasses. 
 
In the subsequent sections, we discuss the upper classes of 
LPSelfStandingConcept, which we refer to as sub-ontologies of Lipoprotein 
Ontology, as they contain the majority of lipoprotein domain knowledge. These 
include LPClassification, LPMetabolism, LPPathophysiology, LPAetiology, 




In this section, we formalised the various subtypes of lipoproteins according to 
several criteria which confer membership into the class such as content, 
electrophoretic mobility and function. These criteria were defined by various 
object and datatype properties which link concepts between LPClassification 
and LPMetabolism sub-ontologies. The sub-ontology LPClassification 
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contains the subclass LipoproteinEntity, which defines different lipoprotein 
classes as follows:  
 
 • Chylomicron 
 • ChylomicronRemnant 
 • VeryLowDensityLipoprotein 
 • IntermediateDensityLipoprotein 
 • LowDensityLipoprotein 
 • HighDensityLipoprotein 
 • Lipoprotein(a) 
 
LipoproteinEntity is linked to different subclasses of FunctionalEntity, which 
is asserted to be partOf LPMetabolism via the hasComponent property. In other 
words, for an individual to belong to the class LipoproteinEntity, it has to fulfil 
the following conditions: hasComponent some Triglyceride, Cholesterol, 
CholesterylEster, Phospholipid and Apolipoprotein.  
 
Due to the subsumption rule, all subclasses of LipoproteinEntity inherit the 
properties of the concept accordingly; however, it is not sufficient to classify 
different subtypes of LipoproteinEntity. Hence, we defined each individual 
subclass of LipoproteinEntity according to their respective characteristics. 
Figure 36 shows the concept Chylomicron. As we have discussed extensively 
in the literature review, the lipoprotein metabolism process involves a highly 
dynamic and constant remodelling of particles where lipid and apolipoprotein 
components are exchanged and/or catabolised, which results in the 
transformation of one lipoprotein particle to another. For example, in the 
endogenous pathway, the triglycerides in VLDL are hydrolysed as VLDL is 
metabolised into IDL and subsequently LDL. Because each lipoprotein subclass 
can be defined according to the content of their lipid and apolipoprotein 
components, referred to as percentage weight (that is, a VLDL cannot have the 
same lipid and apolipoprotein content as an LDL), the most appropriate 
definition of the different lipoprotein subclasses would be according to their 
lipid/apolipoprotein content. Hence, for a lipoprotein particle to be classified as a 
certain type of lipoprotein, it has to meet the necessary and sufficient conditions 







• hasPhospholipidPercentageWeight  




Figure 36. Formalisation of the concept Chylomicron. 
 
In addition, the class Chylomicron is linked to other concepts in the sub-
ontology LPMetabolism via properties such as:  
 
• isAssociatedWith (symmetric property). For example, if Chylomicron 




• hasProduct (transitive property and inverse of the property isProductOf). 
Given Chylomicron hasProduct ChylomicronRemnant, this assertion 





• hasDensity (datatype property) 
• hasSize (datatype property) 
 
The Figure above also shows the inherited properties from the superclass 
LipoproteinEntity, under SubClassOf (Anonymous Ancestor). 
 
Similarly, we have defined necessary and sufficient conditions for the other 
subclasses of LipoproteinEntity: ChylomicronRemnant, 
VeryLowDensityLipoprotein, IntermediateDensityLipoprotein, 




LPMetabolism concepts are commonly reused across the different Lipoprotein 
Ontology sub-ontologies, such as LPClassification, discussed in the previous 
section. In fact, LPMetabolism can be seen as the core of Lipoprotein Ontology, 
as it contains and describes the various atomic components of lipoprotein 
physiology, and relates these components to other aspects of lipoprotein 
research. In order to model lipoprotein metabolism in context of the biological 
domain as a whole, we categorised important components of LipoproteinEntity 
according to their appropriate classes. We refer to this process as normalisation, 
where we categorised concepts according to a structured hierarchy which allows 
for the easy extension and/or modification to a particular concept. For this 
reason, we separated the following concepts, defined to be partOf 
LPMetabolism as: 
 
• PhysicalEntity: An entity which participates in a process or relationship 
• OccurringEntity: An event or entity which develops through time 
• ParticipantRole: The role of an entity 
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We note that the concept names above are derived from Systems Biology 
Ontology (Courtot et al., 2011), with some of the concept definitions referenced 
from MeSH (Lowe & Barnett, 1994}. This gives us the potential to merge 




As its name suggests, PhysicalEntity contains the various components 
associated with LPClassification, categorised into the following classes:  
 
• FunctionalEntity: Defined by its properties or functions 
• StructuralEntity: Defined by its structure 
 
In Chapter 6.4.1, we presented all the subclasses of FunctionalEntity and 
StructuralEntity respectively. Figure 37 illustrates how some of these concepts 
are related to Chylomicron in LPClassification as follows: 
 
Figure 37. Relations between LPClassification concepts and LPMetabolism concepts. 
 
In the Figure above, class names are represented in rounded boxes, and their 
attributes or relationships to other classes are described along a line and 
arrowhead pointing towards the direction of the property that is being described.  
 
The relation isA naturally confers a hierarchical or subsumption relationship 
between two concepts. This implies that if "Cholesterol isA Lipid isA 
FunctionalEntity isA PhysicalEntity", then "Cholesterol isA PhysicalEntity". 
The subsumption relationship also leads to the inheritance of the properties of 
the superclass. Therefore, if "LipoproteinEntity hasComponent Cholesterol" 
and "Chylomicron isA LipoproteinEntity", then the equivalent is true: 
"Chylomicron hasComponent Cholesterol". 
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Although the diagram illustrates a clear representation of the binary relationships 
between any two concepts, we are unable to show every single relation they 
contain, due to space constraints. For example, we have defined the property 
hasComponent to have an inverse property isComponentOf. Hence, based on 
the statement: "LipoproteinEntity hasComponent Cholesterol", the reasoner 





OccurringEntity is categorised into the following classes:  
 
• Pathway: Defined as the representation of a sequence of reactions 
• Process: Defined as the action that causes a change from one entity to 
another 
 
As metabolic pathways are extremely complex, highly dynamic and involve 
many different components from the concept PhysicalEntity, it is practically 
impossible to formalise these two concepts in a stand-alone manner. Hence, 
rather than presenting the formal definition of concepts of OccurringEntity 
individually, we illustrate the formalisation process of the three lipoprotein 
metabolism pathways: 
 
• Exogenous pathway: The transport and metabolism of dietary lipids 
(Figure 38) 
• Endogenous pathway: The metabolism of hepatically synthesised lipids 
(Figure 39) 
• Reverse cholesterol transport: The synthesis and metabolism of HDL 
(Figure 40) 
 
Class names are represented in rounded boxes, and their attributes or 
relationships to other classes are described along a line and arrowhead pointing 
towards the direction of the property that is being described. Dotted boxes 
represent Process or Pathway concepts which are used to describe the 
relationship between one entity to another. Enlarged versions of the figures 
below are shown in Appendix I, J and K.  
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Due to the complexity of these pathways and space constraints, we are unable 
to show every single concept, but have represented the most interesting and 
relevant concepts involved in lipoprotein metabolism. Although the diagrams 
demonstrate a clear representation of the binary relations between two concepts 
in the context of their respective metabolism pathways, we are unable to show 





Figure 38. Formalisation of the concept ExogenousPathway. 
 
 
The concept ExogenousPathway describes the transport of dietary lipids, 
defined to be "Cholesterol isA Lipid and isComponentof DietaryFat" and 
"Triglyceride isA Lipid and isComponentof DietaryFat". After a meal, the 
hydrolysis of triglycerides into monoglycerides and free fatty acids is described 
as "Triglyceride hasProduct Monoglyceride and FreeFattyAcid" via 
"hasProcess Hydrolysis". The resynthesis of monoglycerides and free fatty 
acids is described as "Monoglyceride and FreeFattyAcid isProductOf 
Triglyceride" via "hasProcess Synthesis". Here, we note that the property 
hasProduct has an inverse property isProductOf; this is to keep the properties of 
the concepts consistent, which allows it to be used in different context.  
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Triglycerides are subsequently combined with cholesterol, cholesteryl ester, 
triglycerides, apo B-48 and apo As to form nascent chylomicrons in the 
enterocytes: "Triglyceride, Phospholipid, Cholesterol and CholesterylEster 
isComponentOf LipoproteinEntity" and "hasLocation Enterocyte". As 
"NascentChylomicron isA LipoproteinEntity", this confers exactly the same 
properties. This is logically appropriate as every instance of  LipoproteinEntity 
has to have the components Triglyceride, Phospholipid, Cholesterol and 
CholesterylEster. However, apolipoproteins are slightly different. With the 
exception of the principal apolipoproteins (ApoB-100, ApoB-48, ApoA-I And 
ApoA-II), apolipoproteins are exchanged and transferred between the different 
subtypes of lipoproteins. Hence, we used the relation "isAssociatedWith", 
defined to be a symmetric property (illustrated by double arrows), which allows 
the reasoner to infer the association between apolipoproteins to their respective 
classes. For example, "ApoA-I isAssociatedWith NascentChylomicron" infers 
the symmetric statement "NascentChylomicron isAssociatedWith ApoA-I". 
 
Nascent chylomicrons are then secreted into the circulation where they acquire 
apoCs and apoE from HDL, and referred to as chylomicrons. This is described 
as "NascentChylomicron hasProduct Chylomicron", "Chylomicron 
isAssociatedWith ApoB-48, ApoA-I, ApoA-II, ApoA-IV, ApoA-V, ApoC-I, 
ApoC-II, ApoC-III and ApoE" and "hasLocation Circulation". We defined the 
process of apolipoprotein transfer between chylomicrons and HDL as "ApoC-I, 
ApoC-II and ApoC-III isAssociatedWith HighDensityLipoprotein" and 
"hasProcess Transfer". 
 
ApoC-II activates lipoprotein lipase located in adipose and muscle tissues, 
where triglycerides in chylomicrons are hydrolysed into free fatty acids and 
glycerol by the action of lipoprotein lipase. This process is inhibited by apoC-III. 
In formal language, we describe the statement as: "ApoC-II activates 
LipoproteinLipase", "ApoC-III inhibits LipoproteinLipase" and 
"LipoproteinLipase hasLocation AdiposeTissue and MuscleTissue". 
"Triglyceride hasProduct Glycerol and FreeFattyAcid" and "isMetabolisedBy 
LipoproteinLipase" and "hasProcess Hydrolysis". As triglycerides are 
hydrolysed, chylomicrons gradually shrink to form chylomicron remnants, during 
which ApoAs and ApoC-II are transferred to HDL. We describe this as 






Figure 39. Formalisation of the concept EndogenousPathway. 
 
 
The EndogenousPathway describes the transport of lipids synthesised in the 
liver as "Liver hasProduct Cholesterol and Triglyceride" and "hasProcess 
Synthesis". VLDL carry triglycerides, cholesterol, apoB-100, and acquire 
cholesteryl esters, apoCs and apo E from HDL. This is described as "ApoC-I, 
ApoC-II, ApoC-III and ApoC-III isAssociatedWith VeryLowDensityLipoprotein 
and HighDensityLipoprotein" and "hasProcess Transfer".  
 
The metabolism of VLDL is facilitated by apoC-II and inhibited by the apoC-III 
content of the lipoprotein particles, where triglycerides are hydrolysed into 
grlycerol and free fatty acids by lipoprotein lipase. This process has been 
defined previously as "ApoC-II activates LipoproteinLipase", "ApoC-III inhibits 
LipoproteinLipase" and "LipoproteinLipase hasLocation AdiposeTissue and 
MuscleTissue". "Triglyceride hasProduct Glycerol and FreeFattyAcid" and 
"isMetabolisedBy LipoproteinLipase" and "hasProcess Hydrolysis". As VLDL 
lose triglycerides, they form IDL, and subsequently LDL through the same 
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process. Therefore, "VeryLowDensityLipoprotein hasProduct 
IntermediateDensityLipoprotein" and "IntermediateDensityLipoprotein 
hasProduct LowDensityLipoprotein". Because essentially all 
"VeryLowDensityLipoprotein hasProduct LowDensityLipoprotein", we have 
defined the property hasProduct to be transitive to infer as such.  
 
VLDL that are not metabolised to form IDL are taken up by the remnant 
receptor, while IDL that are not metabolised to form LDL are taken up by the 
LDL receptors, which is activated by apoB-100 and apoE. LDL also binds to LDL 
receptors, which is activated by apoB-100. Therefore, the uptake of VLDL, IDL 
and LDL are defined as follows: "VeryLowDensityLipoprotein isMetabolisedBy 
RemnantReceptor"; "IntermediateDensityLipoprotein isMetabolisedBy 
LDLReceptor", "isActivatedBy ApoB-100 and ApoE" and "hasProcess Uptake"; 
and "LowDensityLipoprotein isMetabolisedBy LDLReceptor", "isActivatedBy 





Figure 40. Formalisation of the concept ReverseCholesterolTransport. 
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The ReverseCholesterolTransport describes the removal of excess 
cholesterol from cells from the circulation back to the liver by HDL. HDL is 
synthesised in the liver and small intestines and released into the circulation as 
nascent HDL, which contains apoAs and phospholipid. This is defined as "Liver 
and SmallIntestine hasProduct NascentHighDensityLipoprotein" and 
"hasProcess Synthesis".  
 
Nascent HDL then acquires cholesterol from cell membranes, which is mediated 
by membrane transport protein, described as "Cholesterol isTransferredFrom 
Cell" and "isMediatedBy MembraneTransportProtein" and "hasProcess 
Transfer", as well as triglycerides from other lipoproteins, described as 
"Triglyceride isTransferredFrom Chylomicron, VeryLowDensityLipoprotein, 
IntermediateDensityLipoprotein and LowDensityLipoprotein", 
"isMediatedBy CETP" and "hasProcess Transfer". The transfer of these 
components to nascent HDL leads to mature HDL: 
"NascentHighDensityLipoprotein hasProduct HighDensityLipoprotein".  
 
Free cholesterol in mature HDL is esterified into cholesteryl esters by 
lecithin:cholesterol acyltransferase (LCAT) upon activation by apoA-I. This 
process is described as "Cholesterol hasProduct CholesterylEster", 
"hasProcess Esterification", "isMediatedBy LCAT" and "LCAT isActivatedBy 
ApoA-I".  
 
Cholesteryl esters can then be taken up by hepatocytes or transferred to apoB-
containing lipoproteins such as VLDL, IDL and LDL, by cholesterol ester transfer 
protein (CETP) in exchange for triglycerides. This process is defined as 
"CholesterylEster isTransferredTo Chylomicron, 
VeryLowDensityLipoprotein, IntermediateDensityLipoprotein and 
LowDensityLipoprotein", "isMediatedBy CETP" and "hasProcess Transfer". 
Earlier, we described the maturation process of nascent HDL to mature HDL to 
involve the transfer of triglycerides. Hence, we demonstrate the relationship 









Last but not least, for modularity purposes, we have created the concept 
ParticipantRole to describe the function or role of a PhysicalEntity. Figure 41 
shows an example of how subclasses of ParticipantRole are used to relate 
concepts under PhysicalEntity. An enlarged version of the figure is shown in 
Appendix L. 
 
Figure 41. Relations between ParticipantRole concepts and PhysicalEntity concepts in 
LPMetabolism and LPTreatment. 
 
 
Although classified under the same functional group, many physiological 
components have different and sometimes opposing functions, and interact 
differently to the same substance. A very good example of this is the different 
types of apolipoproteins. Although "Apolipoprotein isA Protein", they have 
completely different effects on enzymes. We define them as follows: 
 
• ApoC-I hasRole Activator and activates LCAT 
• ApoC-I hasRole Inhibitor and inhibits CETP 
• ApoC-II hasRole Activator and activates LipoproteinLipase 
• ApoC-III hasRole Activator and activates CETP 
• ApoC-III hasRole Inhibitor and inhibits LCAT, LipoproteinLipase and 
HepaticLipase 
 
In addition, the ParticipantRole concept is used to describe the role of other 
classes in general, such as "Pharmacotherapy hasRole DrugActionRole", 





The sub-ontology LPPathophysiology contains concepts that are used to 
define the dysregulation of lipoprotein metabolism. These concepts are primarily 
used to describe the diagnostic requirements in the class Patient. To define the 
sub-ontology LPPathophysiology, we separate concepts of the actual disorder 
from their physical indication into two classes using the assosiative partOf 
relationship: 
 
• Disorder: Defined to be a disease 




Figure 42. Relations between Disorder concepts in LPMetabolism and LPTreatment. 
 
 
Figure 42 illustrates the link between Disorder concepts in LPMetabolism and 
LPTreatment. An enlarged version of the figure is shown in Appendix M. The 
class Disorder contains disease concepts that are related to the dysregulation 
of lipoprotein metabolism. Although this condition is usually referred to as 
"dyslipidaemia", we stress that the concept of lipoprotein dysregulation is not 
necessarily ONLY present in patients with dyslipidaemia. Rather, lipoprotein 
dysregulation can also (and commonly occur) in patients suffering from 
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cardiovascular disease, diabetes, and other disorders. Therefore, we defined the 











For the purpose of this thesis, we will only discuss Dyslipidaemia in the context 
of lipoprotein dysregulation, although the concepts above have been properly 
defined in our full ontology. These concepts can also serve as linkage to their 
respective ontologies for fine-grained details of the corresponding concepts, in 
the case of ontology merging. 
 
Dyslipidaemia is defined to be a LipidDisorder. Primary dyslipidaemia, which 
is caused by genetic factors, is defined to have the subclasses 
Hypolipoproteinaemia and Hyperlipoproteinaemia. Again, a these 
subclasses have been defined in our ontology, we will select an example to 
illustrate how the process was carried out, as well as the link between the 
different sub-ontologies, highlighted in bold. As shown in the figure above, 
HyperlipoproteinaemiaTypeI contains two subclasses:  
 
• HyperlipoproteinaemiaTypeIa  
• HyperlipoproteinaemiaTypeIb  
 
We have defined in LPMetabolism (Chapter 7.6.2.2.2 EndogenousPathway) 
that "ApoC-II activates LipoproteinLipase", "Triglyceride isMetabolisedBy 
LipoproteinLipase" and "Triglyceride isComponentOf Chylomicron". 
Therefore, if we defined "HyperlipoproteinaemiaTypeIa hasDeficiency 
LipoproteinLipase" and "HyperlipoproteinaemiaTypeIb hasDeficiency ApoC-
II", then "HyperlipoproteinaemiaTypeIa and HyperlipoproteinaemiaTypeIb 
canIncreaseConcentrationOf Triglyceride and Chylomicron". 
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Dyslipidaemia can also be caused by factors other than genetic causes, referred 
to as secondary dyslipidaemia. We distinguish the difference between primary 
dyslipidaemia (described above) and secondary dyslipidaemia by creating a 
separate statement for the latter as "DyslipidaemicPatient hasDisorder 






Figure 43. Relations between Symptom concepts and Disorder concepts in LPPathophysiology 
and LPDiagnosticParameter. 
 
Figure 43 demonstrates the relationship between Symptoms and Disorder 
concepts in LPMetabolism and LPTreatment. An enlarged version of the figure 
is shown in Appendix N. For the purpose of this thesis, the concept Symptom 









These concepts are linked to the type of Patient associated with a particular 
symptom. For example, "DyslipidaemicPatient hasSymptom Dyslipidaemia", 
"ObesePatient hasSymptom CentralObesity", "HyperglycaemicPatient 
hasSymptom Hyperglycaemia" and "HypertensivePatient hasSymptom 
Hypertension". The properties of DyslipidaemicPatient, ObesePatient, 
HyperglycaemicPatient and HypertensivePatient, i.e. values that define the 
classification of a symptom according to individual characteristics according to 
the NCEP/ATP III guideline are discussed in detail in LPDiagnosticParameter. 
 
Furthermore, since the metabolic syndrome is defined to have three out of the 
four criteria above, we have applied a cardinality restriction on the concept 
MetabolicSyndromePatient hasSymptom min 3 Symptom. Therefore, if an 
instance of a "Patient hasSymptom Dyslipidaemia, CentralObesity and 
Hypertension" AND has fulfilled the necessary and suffficient conditions for 





The sub-ontology LPAetiology describes the different causes of lipoprotein 




• DiseaseStateCause  
• DrugInteraction 
 
Figure 44 illustrates some of the relations that these concepts have with 
concepts in other sub-ontologies. An enlarged version of the figure is shown in 
Appendix O. Here, we demonstrate the link between LPAetiology, 









One of the most common causes of lipoprotein dysregulation is LifestyleCause 
due to a sedentary lifestyle with lack of physical exercise and excessive dietary 
intake of saturated fat and cholesterol. Although LifestyleCause contains other 
subclasses which we have discussed in Chapter 6.6.1, we will be discussing the 
effect of diet on lipoprotein dysregulation. First, we define "DietaryFat isA Diet 
isA LifestyleCause". We have defined previously that "Chylomicron and 
Triglyceride isComponentOf DietaryFat". In LPAetiology, we state that "Diet 
canIncreaseConcentrationOf Chylomicron and VeryLowDensityLipoprotein" 
Inversely, "Dyslipidaemia hasIncreasedConcentrationOf Chylomicron and 
VeryLowDensityLipoprotein".  
 
In Chapter 7.6.3.1, we defined "Hypolipoproteinaemia and 
Hyperlipoproteinaemia isA Dyslipidaemia". Due to their genetic origins, we 
link these lipid disorders to the concept "isA GeneticCause" in LPAetiology. 
Similarly, we stated that "Diabetes, ThyroidDisease, RenalDisorder and 
LiverDisorder isA Disorder". Hence, in this section, we define the same 
concepts to be "isA DiseaseStateCause". DrugInteraction is a rather 
ambitious class, which has the potential to offer much inferential capability in 
future work. For the purpose of this thesis, we have associated the concepts 
"Thiazide and BetaBlocker hasCause DrugInteraction" and "isA 
Pharmacotherapy isA LPTreatment". For the time being, we have only 
selected six types of pharmacotherapy medication to treat lipoprotein 
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dysregulation. However, there are many different drugs that exist that can be 
included in the superclass Pharmacotherapy for the treatment of different 
Disorder that have been or can be added to our ontology. With a much larger 
subset of treatment options defined in the ontology, it will be possible to create 
restrictions such that, if a certain drug is mixed with another type, then a drug-
drug interaction can occur which may have negative implications on the patient, 




The sub-ontology LPTreatment describes treatment options to manage 






Figure 45 illustrates some of the links that these concepts have with concepts in 
other sub-ontologies. An enlarged version of the figure is shown in Appendix P. 
Here, we demonstrate the link between LPTreatment, LPClassification, 
LPMetabolism, LPPathophysiology and LPAetiology concepts. 
 
Figure 45. Relations between LPTreatment, LPClassification, LPMetabolism, 
LPPathophysiology and LPAetiology concepts. 
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The first line of approach for treatment of dyslipidaemia is LifestyleChange, 
which is very closely related to LifestyleCause in LPAetiology. Although these 
concepts seem very similar at a glance, we created two separate concepts 
(LifestyleCause and LifestyleChange) in order to describe them within the 
context of aetiology and treatment. LifestyleChange is defined as the treatment 
of lipoprotein disorder with changes in lifestyle. Studies have found that fish oil 
consumption was shown to raise HDL cholesterol and reduce triglycerides, 
which would in turn decrease the concentration of chylomicron and VLDL. We 
descibe this as "FishOil isA DietarySupplement isA LifestyleCause", "FishOil 
canDecreaseConcentrationOf HighDensityLipoprotein" and "FishOil 
canDecreaseConcentrationOf Triglyceride".  Similarly, "Diet, 
PhysicalExercise and WeightLoss canDecreaseConcentrationOf 
Cholesterol". As we have defined "Cholesterol and Triglyceride 
isComponentOf Chylomicon and VeryLowDensityLipoprotein", a decreased 
concentration of cholesterol and triglyceride implies the decrease in chylomicron 
and VLDL.  
 
The concept Pharmacotherapy contains four drug classes that have been 
shown to have different lipid lowering properties due to different actions on 
different receptors. For example, we make the following statement: "Statin 
inhibits HMG-CoAReductase". Given "AcetylCoA hasProduct Mevalonate", 
"isActivatedBy HMG-CoAReductase" and "hasProduct Cholesterol", the 
inhibition of HMG-CoAReductase would mean that "Statin 
canDecreaseConcentrationOf Mevalonate". Since the property hasProduct is 
defined to be transitive, it would imply that "Statin canDecreaseConcentrationOf 
Cholesterol". We also state "Fibrate canDecreaseConcentrationOf 
Triglyceride" and "NicotinicAcid canDecreaseConcentrationOf 
FreeFattyAcid". "BileAcidSequestrant canIncreaseConcentrationOf 
LDLReceptor". As "LowDensityLipoprotein isMetabolisedBy LDLReceptor" 
and "hasProcess Uptake", and increase in LDL receptor would therefore imply 
faster metabolism of LDL. 
 
For the purpose of this thesis, we have applied a cardinality restriction on 
CombinationTherapy, defined as "hasPotentialTreatment min 2". Therefore, 
any instance with at least two relations containing hasPotentialTreatment, then it 





The sub-ontology LPDiagnosticParameter contains the subclasses Gender, 




For the class Gender, we created two subclasses Female and Male, with 
equivalent classes hasGender Female and hasGender Male, respectively. We 
will be applying these concepts to the class Patient to distinguish different lipid 
parameters according to different genders. In addition, it is imperative that we 
defined the necessary and sufficient conditions as such, in order for the 




For the purpose of our ontology, we created three subclasses of Ethnicity: 
Asian, Caucasian and Other, with equivalent classes hasEthnicity Asian, 
hasEthnicity Caucasian and hasEthnicity Other. This is with respect to the 
lipoprotein guideline we have opted to use for Lipoprotein Ontology, which lists 
different lipid measurements for two ethnicities of Patient: Asian and 
Caucasian. Therefore, we created the concept Other for all other ethnicities, 
which can be can easily be extended to include other ethnic groups. Again, the 
necessary and sufficient conditions allow us to infer the ethnicity of the Patient 
accordingly. 
 
7.6.6.3 Geographic Ancestry 
 
The class GeographicAncestry expands the concept Ethnicity a little further 
and serves as a more realistic view of the world. We created a list of 
geographical regions which can be linked with the class Patient and Ethnicity 
via the object property hasEthnicity to define the origins of the individual. This list 
is in no way complete, but can be extended further to refine the concept 
GeographicAncestry. At this stage, it is beyond the scope of this thesis, but 
this concept can potentially be linked to the Gene Ontology to infer the possible 
genetic profile of an individual based on their ethnicity and/or geographic 
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ancestry. This has implications in genetic testing, and determining different 




For the class Patient, we created various subclasses which link their respective 
instances to the subclasses of Symptom (under the sub-ontology 
LPPathophysiology) via the object property hasSymptom. We focused 
specifically on the definition of the MetabolicSyndrome as well as the 
formalisation process of the different risk value indicators for dyslipidaemia, 
classified as RiskValuePartition. 
 
7.6.6.4.1 Classification of Metabolic Syndrome Patients 
 
As we have elaborated in Chapter 2.3.3, several guidelines exist towards the 
identification of the metabolic syndrome, such as the NCEP/ATP III (NCEP, 
2001), WHO (WHO, 1998) and IDF (IDF, 2005) definitions. For the purpose of 
this thesis, we have used the NCEP/ATP III guideline (Table 8), as it is the most 
commonly used definition for the metabolic syndrome (Huang, 2009). 
Furthermore, as the next update (NCEP/ATP IV) is anticipated to be released 
shortly, it remains to be the most current guideline for diagnostic purposes in a 
clinical setting (Martin et al., 2012).   
 




Based on the NCEP/ATP III guideline, a person is classified as a metabolic 
syndrome patient if s/he suffers from any three of the following symptoms: 
central obesity, hyperglycaemia, dyslipidaemia and hypertension. Hence, we 
had to clearly identify patients which fall under each criteria as ObesePatient, 
HyperglycaemicPatient, DyslipidaemicPatient and HypertensivePatient 
respectively, prior to defining the concept MetabolicSyndromePatient. As an 
example, Figure 46 shows the concept ObesePatient, for which we defined to 
have the necessary and sufficient conditions to infer that instances of 
ObesePatient hasSymptom CentralObesity. In addition, we have also defined 
ObesePatient to have datatype property hasWaistCircumference for instances 
which are restricted along the object properties hasEthnicity as well as 
hasGender in order to correctly classify the gender and ethnicity of patients 




Figure 46. Formalisation of the concept ObesePatient in Protégé. 
 
 
Similarly, we have defined necessary and sufficient conditions for the concept 
HyperglycaemicPatient, for which they are linked to the property hasSymptom 
to Hyperglycaemia, as well as the datatype property 
hasFastingPlasmaConcentration.  
 
For the concept DyslipidaemicPatient, we have defined necessary and 
sufficient conditions which include the property hasSymptom Dyslipidaemia, as 
well as datatype properties hasTriglycerideConcentration and 
hasHDLConcentration. The datatype property hasHDLConcentration is 
restricted along the object properties hasEthnicity as well as hasGender in order 
to correctly classify the gender and ethnicity of patients according to the 
NCEP/ATP III criteria.  
 
Correspondingly, we have defined necessary and sufficient conditions for the 
concept HypertensivePatient to include the property hasSymptom 
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Hypertension, as well as datatype properties hasBloodPressureSystolicValue 
and hasBloodPressureDiatolicValue. 
 
As the class MetabolicSyndromePatient contains individuals who suffer from 
three or more of the criteria defined above, we applied the cardinality restriction 
hasSymptom min 3 Thing to specify the minimum number (3) of hasSymptom 
relationships that an instance must have order to be inferred as a 
MetabolicSyndromePatient. In other words, MetabolicSyndromePatient has 
the equivalent class Patient and (hasSymptom min 3 Thing).  
 
7.6.6.4.2 Risk Value Partition  
 
In Chapter 2.4.1, we presented various guidelines which are used for the 
diagnosis of dyslipidaemia, such as the NCEP/ATP III (NCEP, 2001), AHA  
(Miller et al., 2011) and AACE (Jellinger et al., 2012). The guidelines provide an 
indication of risk (normal, borderline risk, high risk, very high risk) for various 
plasma levels of total triglycerides, cholesterol, LDL cholesterol and HDL 
cholesterol. Again, as the NCEP/ATP III guideline is the most frequently used 
guideline for dyslipidaemia management, we have incorporated this 
classification in our ontology (Table 9). 
 
Table 9. NCEP/ATP III lipid profile classification of risk factors (NCEP, 2001). 
  
 
To formalise and define the concept of risk value indicators associated with 
different plasma levels of total triglycerides, cholesterol, LDL cholesterol and 
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HDL cholesterol, we created the class RiskValuePartition, which contains the 
subclasses Normal, BorderlineRisk, HighRisk and VeryHighRisk, disjoint to 
one another.  
 
We defined concepts for Normal (Figure 47), BorderlineRisk, HighRisk and 
VeryHighRisk based on the guideline above using necesssary and sufficient 
conditions: object property hasRiskValue, as well as datatype properties 
hasTotalTriglycerideConcentration, hasTotalCholesterolConcentration, 




Figure 47. Formalisation of the concept Normal in Protégé. 
 
Having defined the subclasses of RiskValuePartition, we subsequently created 
a covering axiom for RiskValuePartition such that RiskValuePartition is 
covered by the classes Normal, BorderlineRisk, HighRisk and VeryHighRisk. 
This is necessary due to the open world assumption feature of ontologies; a 
covering axiom ensures that a member of RiskValuePartition must be a 




This chapter discussed the formalisation process of the lipoprotein conceptual 
framework described in Chapter 6. First, we provided an overview of KR 
languages associated with ontology building, and the justification behind our 
choice of implementation tool and language. This is followed by a brief 
introduction to the components of OWL ontologies and how they were utilised in 
Lipoprotein Ontology. We then discussed the structure of OWL ontologies, as 
well as the notation and syntax used throughout this chapter. We concluded this 
chapter by presenting a visualisation of Lipoprotein Ontology in figures and 
screenshots from Protege to represent various functions of concept 
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In this chapter, we evaluate Lipoprotein Ontology against several criteria. There 
are a number of evaluation methods for ontologies which include comparison to 
a "golden standard", functional performance, conceptual coverage, among 
others (Brank et al., 2005; Gangemi et al., 2005; Gruninger & Fox, 1995; 
Hartmann et al., 2005). It is important to note that the validity of an ontology 
might vary between different users or different domains. In this thesis, we have 
used three strategies to evaluate Lipoprotein Ontology as follows: 
 
• Evaluation of the syntactic quality of Lipoprotein Ontology 
• Evaluation of the conceptual coverage of Lipoprotein Ontology 
• Evaluation of the practical application of Lipoprotein Ontology through the 
validation of competency questions and case studies 
 
8.2 Ontology Evaluation Aspects 
 
Different evaluation methods are used for different purposes and applications. 
As ontologies are complex structures, it is often more practical to evaluate 
different aspects of the ontologies separately rather than focusing on the 
ontologies as a whole (Brank  et al., 2005). Broadly, these aspects include:  
 
• Syntactic level: An ontology which was manually constructed can be 
evaluated at the syntactic level by using syntactic considerations such as 
the presence of natural-language documentation, as well as the 
adherence towards several design criteria, which we will discuss further 




• Conceptual or lexical level: The vocabulary used to represent classes, 
instances and axioms in the ontology is evaluated through comparisons 
with various sources of data concerning the domain of interest such as 
domain-specific text corpora. This method is also referred to as the 
concept coverage method. 
 
• Contextual or application level: The context of the ontology can be 
evaluated through the use of competency questions that were set out in 
at the initial stages of ontology development. The ontology can also be 
evaluated at the application level through the use of case studies and the 
capability of the ontology to answer scenarios.  
 
8.3 Evaluation of the Syntactic Quality of Lipoprotein Ontology 
 
The basis of Lipoprotein Ontology was syntactically derived from rigorous 
literature review of peer-reviewed scientific journals and biomedical textbooks in 
the lipoprotein domain, which was documented in Chapter 2 of this thesis. 
General aspects of lipoprotein research were extracted and identified as upper 
self-standing concepts of Lipoprotein Ontology such as Classification, 
Metabolism, Pathophysiology, Aetiology, Treatment and Diagnostic Parameter. 
The quality of Lipoprotein Ontology was evaluated at the syntactic level using 
the five design criteria as follows (Brank  et al., 2005) 
 
 • Completeness: Concepts in Lipoprotein Ontology along with their 
relationships with other concepts are explicitly stated, and their properties 
restricted accordingly. Each definition is documented in natural language 
but described as formal axiom in the ontology. Most of the definitions in 
Lipoprotein Ontology are defined with necessary and sufficient conditions 
with respect to their scientific definitions, but some of the simpler 
concepts are defined with only necessary conditions, in order to build 
complex definitions out of atomic concepts.   
 
 • Consistency: The definitions in Lipoprotein Ontology are consistent and 
do not include contradictory information. In order to ensure the 
consistency of the concepts in the ontology, a single term is given to 
every lipoprotein concept; where acronyms, synonyms and abbreviations 
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exist which refer to the same concept, we have included these terms in 
the annotation property of the concept respectively. In addition, 
inferences are found to be satisfactorily consistent with existing 
definitions and axioms, described in Chapter 8.5.1. 
 
 • Conciseness: Lipoprotein Ontology does not store any unnecessary 
definitions. Every concept is linked to at least one other concept in 
Lipoprotein Ontology and contains the respective properties and 
restrictions.  
 
 • Extensibility: Despite the conciseness of Lipoprotein Ontology, users 
can add new definitions to the ontology and more knowledge to the 
definitions based on the existing vocabulary, without altering the set of 
well-defined properties and/or definitions. Also, due to the hierarchical 
structure and normalised design of Lipoprotein Ontology, new concepts 
can be added under existing concepts without affecting neighbouring 
concepts and their properties. From these new concepts, we can then 
build even more complex definitions in the ontology. 
 
 • Minimal encoding bias: Conceptualisations are specified at knowledge-
level and not at a symbol or notation level. As such, the proper use of 
relations is necessary in order to maintain the integrity of the ontology. 
For example, for the superclass LPMetabolism, although it may appear 
to be more convenient to use the subclass relation “isA” instead of 
“partOf” expression, the “isA” relation is not the correct relation for its 
respective subclasses PhysicalEntity, OccurringEntity and 
ParticipantRole. Rather, we used the “partOf” relation in order to 
maintain the correct formal definition for their corresponding axioms. 
 
8.4 Evaluation of the Conceptual Coverage of Lipoprotein Ontology 
 
One of the most common methods of ontology evaluation is through its concept 
coverage. This evaluates the ontology at the lexical or vocabulary level as 
described in the previous section, and can be done by determining the 




Our evaluation method involves the comparison of concepts contained in 
Lipoprotein Ontology against a selected data source from the lipoprotein 
research domain. Articles were extracted from PubMed, the largest online 
repository for biomedical literature, selected and analysed for evaluation of 
Lipoprotein Ontology. On 9th March 2013 we searched for the keyword 
"lipoprotein" in the PubMed database. The search engine originally returned a 
total of 157,964 articles; we narrowed down our search to  “humans” by applying 
a filter on the database to only include articles on human subjects, which 
reduced the result to 115,815 articles. From this set of articles, 90 article 
abstracts were randomly selected according to the core lipoprotein concepts in 
Lipoprotein Ontology, namely Classification, Metabolism, Pathophysiology, 
Aetiology, Treatment and Diagnostic Parameter. Please refer to Appendix Q for 
the complete list of the abstract titles. 
 
In the next phase, we examined these 90 article abstracts and extracted their 
lipoprotein-related concepts. Lipoprotein Ontology is then used to encode the 
knowledge from this test set. Determining the conceptual coverage includes the 
calculation of the percentage of sentences that can be fully represented by 
Lipoprotein Ontology. 
 
For example, we analysed the sentence "VLDL, the main secretory lipoprotein of 
the liver, contains cholesterol, phospholipid, triglyceride, newly synthesized B-
100 and small amounts of E and C apopeptides" (Olson, 1998) from one of the 
randomly selected abstracts, in terms of its lipoprotein-related concepts. From 
this statement, we identified a number of lipoprotein concepts such as 
VeryLowDensityLipoprotein, Liver, Cholesterol, Phospholipid, 
Triglyceride, ApoB-100, ApoE and ApoC. These concepts were categorised 
under the various sub-ontologies of Lipoprotein Ontology accordingly. For 
example, VeryLowDensityLipoprotein was classified under LPClassification, 
and the following were classified under LPMetabolism: Liver, Cholesterol, 
Phospholipid, Triglyceride, ApoB-100, ApoE and ApoC. Figure 48 illustrates 






Figure 48. The mapping of lipoprotein concepts in an article abstract to Lipoprotein Ontology 
(Olson, 1998). 
 
Table 10 shows the results of concept mapping for the abstract that was 
randomly selected.  
 







To calculate the concept coverage of Lipoprotein ontology, we used the 
following formula (Olson, 1998). Coverage(S) is defined as the measure of the 
level of coverage of a set of concepts S in a given ontology. Specifically, 
Coverage({C1,…,Cn}) was computed using the following formula (with |O| being 
the size of the ontology O given as the number of concepts included in O): 
 
Coverage({C1,…,Cn}) = |{Covered(C1) ∪ … ∪ Covered(Cn)}| 
    |O| 
 
Table 11 presents a summary of our evaluation results from the mapping 
process of the 90 randomly selected article abstracts in the lipoprotein domain. 
 




Our results indicate that we were able to match almost all of the extracted 
lipoprotein concepts under our lipoprotein sub-ontologies, namely 
LPClassification, LPMetabolism, LPPathophysiology, LPAetiology, LPTreatment 
and LPDiagnosticParameter. Therefore, these sub-ontologies can serve as 
upper-level categories for lipoprotein-related concepts from other biomedical 
ontologies. 
 
8.5 Evaluation of the Practical Application of Lipoprotein Ontology 
 
The practical application of Lipoprotein Ontology was evaluated at the context 
level using two methods: 
 
• Validation of competency questions 




8.5.1 Validation of Competency Questions 
 
We evaluated Lipoprotein Ontology against the list of competency questions that 
were defined at the specification stage of ontology development. The 
competency questions encompass the six sub-ontologies of Lipoprotein 
Ontology: Classification, Metabolism, Pathophysiology, Aetiology, Treatment 
and Diagnostic Parameter. Validating the competency questions was carried out 
in order to check that the ontology has successfully represented relationships 





Can the ontology identify lipoprotein particles based on their properties? 
 
To address this competency question, we created two unknown instances 
LipoproteinX and LipoproteinY, which belong to the general class Thing, and not 
to any LipoproteinEntity subclass. Without asserting the lipoprotein class these 
unknown instances belong to, we assigned properties from which the reasoner 
can automatically classify these instances to belong to their respective classes. 
Based on this, we initially verified that the ontology is capable of identifying all 
instances of the class LipoproteinEntity. As we have described in the previous 
chapter, each LipoproteinEntity subclass contains instances that were 
asserted to be members of their respective classes. This serves as a baseline 
measure for us to verify the correct identity of the unknown instances. 
 




Figure 49. Query result for LipoproteinEntity. 
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In the first example, shown in Figures 50 A, B and C below, we queried the 
ontology from the most general, narrowing down to more specific properties, 
such as the size of the lipoprotein particle, apolipoprotein content and 
electrophoretic mobility value.  
 
DL Query (A): LipoproteinEntity and (hasSize some integer[>=75, <=1200])  
DL Query (B): LipoproteinEntity and (hasSize some integer[>=75, <=1200]) 
and (isAssociatedWith some ApoB-48) 
DL Query (C): LipoproteinEntity and (hasSize some integer[>=75, <=1200]) 
and (isAssociatedWith some ApoB-48) and (hasElectrophoreticMobility some 
Origin) 
 
             
A.        B.       C. 
Figure 50. Query result for competency question Classification – Size.  
 
Referring to our table of major lipoprotein classes in Appendix A, the 
corresponding sizes of the three lipoprotein classes are as follows: 
Chylomicron (75mm-1200nm), ChylomicronRemnant (30-80nm) and 
VeryLowDensityLipoprotein (30-80nm). Based on the example above, Query 
A returned instances which have the datatype property hasSize between 75nm 
and 1200nm: Chylomicron (78nm), ChylomicronRemnant (80nm), 
VeryLowDensityLipoprotein (77nm) and LipoproteinX (79nm). This narrowed 
down the identity of LipoproteinX to be either of these four lipoprotein classes. If 
another query parameter was added to Query B, such as the object property 
isAssociatedWith a certain type of apolipoprotein, e.g. ApoB-48, the query 
results automatically returned the instances Chylomicron, ChylomicronRemnant 
and LipoproteinX, thus excluding VeryLowDensityLipoprotein, as it does not 
contain ApoB-48. To narrow down our search further, we applied an additional 
query parameter to Query C, the object property hasElectrophoreticMobility only 
Origin. As we have restricted the property to have the universal restriction "only" 
along the class/value Origin, we can satisfactorily infer that LipoproteinX is a 
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Chylomicron. This was verified by the query results, which also returned the 
instance Chylomicron.  
 
The second example, shown in Figures 51 A and B below, is similar to the first, 
where we queried the ontology from the most general, narrowing down to more 
specific properties, such as the density of the lipoprotein particle and 
apolipoprotein content.  
 
DL Query (A): LipoproteinEntity and (hasDensity some float[>=1.063f, 
<=1.21f])  
DL Query (B): LipoproteinEntity and (hasDensity some float[>=1.063f, 
<=1.21f]) and (isAssociatedWith some ApoA-I) 
 
       
      A.            B.       
Figure 51. Query result for competency question Classification – Density. 
 
Referring to our table of major lipoprotein classes in Appendix A, the 
corresponding densities of the two lipoprotein classes are as follows: 
Lipoprotein(a) (1.050-1.120g/ml) and HighDensityLipoprotein (1.063-
1.210g/ml). Based on the example above, Query A returned instances which 
have the datatype property hasDensity between 1.063 and 1.210g/ml: 
HighDensityLipoprotein, Lipoprotein(a) and LipoproteinY. This narrowed down 
the identity of LipoproteinY to be either of these three lipoprotein classes. If 
another query parameter was added to Query B, such as the object property 
isAssociatedWith a certain type of apolipoprotein, e.g. ApoA-I, the query results 
automatically returned the instances HighDensityLipoprotein and LipoproteinX, 
thus excluding Lipoprotein(a) as it does not contain ApoA-I. Based on this, we 
can satisfactorily infer that LipoproteinY is a HighDensityLipoprotein. This is 








Can the ontology identify the apolipoprotein classes that are associated 
with their corresponding lipoprotein entities? 
 
First, we verified that the reasoner is capable of identifying all instances of the 
class Apolipoprotein.  
 





Figure 52. Query result for Apolipoprotein. 
 
The relationship between the subclasses of LipoproteinEntity and the 
subclasses of Apolipoprotein is described using the object property 
isAssociatedWith as follows: Chylomicron isAssociatedWith some ApoA-I, 
ApoA-II, ApoA-IV, ApoA-V, ApoB-48, ApoC-I, ApoC-II, ApoC-III, ApoE. It is 
important to note here that the object property isAssociatedWith was defined to 
be symmetric; thus, the subclasses of Apolipoprotein contain no additional 
properties. In Figures 53 A and B below, we illustrate the inferencing capability 
of the symmetric property, isAssociatedWith.  
 
DL Query (A): Apolipoprotein and (isAssociatedWith some Chylomicron])  





                
        A.      B.      
Figure 53. Query result for competency question Metabolism. 
 
As the figure above illustrates, due to the symmetric property isAssociatedWith 
that was asserted to describe the relationship between the class Chylomicron 
and its corresponding Apolipoprotein subclasses, the reasoner is able to infer 
the Apolipoprotein subclasses that are associated with the lipoprotein class 
Chylomicron along the symmetric property isAssociatedWith. Respectively, we 
show this relation with the lipoprotein class ChylomicronRemnant and 




Can the ontology identify metabolic sydrome based on a patient's 
symptoms? 
 
We used two unknown instances DisorderX and DisorderY, which belong to the 
general class Thing, and not to any Disorder subclass. Without asserting the 
classes of disorders these unknown instances belong to, we created properties 
from which the reasoner can automatically classify these instances to belong to 
their respective classes. We initially verified that the ontology is capable of 
identifying all instances of the class Disorder. This serves as a baseline 












Figure 54. Query result for Disorder. 
 
DisorderX contains the properties hasSymptom some Dyslipidaemia and 
Hypertension, whereas DisorderY contains the properties hasSymptom some 
Dyslipidaemia, Hypertension and Hyperglycaemia. Figure 55 shows the 
result of our query with the following statement.  
 








As we have defined metabolic syndrome to have the property hasSymptom min 
3 Thing, the reasoner has identified DisorderY to be an instance of metabolic 




Can the ontology identify patients who are at risk of developing 
dyslipidaemia based on their lifestyle and/or genetic predisposition? 
 
To address this competency question, we presented an example using two 
unknown individuals PatientX and PatientY, which belong to the general class 
Thing. Without indicating any symptoms and disorders, we created properties 
from which the reasoner can infer these individuals who are at risk of developing 
dyslipidaemia, which belong to the class PatientAtRisk. First, we verified that 
the ontology is capable of identifying all instances of the class PatientAtRisk, 
shown in Figure 56 below. 
 
DL Query: PatientAtRisk 
 
 
Figure 56. Query result for PatientAtRisk. 
 
DL Query (A): PatientAtRisk and (hasLifestyleCause some Smoking) 




                                
 
     A.         B.     
Figure 57. Query result for competency question Aetiology – LifestyleCause.  
 
In Figure 57 A, the individual PatientX has been identified to be an instance of 
PatientAtRisk due to a smoking habit. Figure 57 B shows instances of the 
anonymous class which contain the intersection of PatientAtRisk due to genetic 
factors: PatientY, HyperlipoproteinaemicPatient and 
HypolipoproteinaemicPatient. In order to identify the disorder that PatientY is 
suffering from, we query the ontology using a property that PatientY is 
associated with, shown in Figure 58 below. 
 
DL Query: PatientAtRisk and (hasCause some GeneticCause) and 




Figure 58. Query result for competency question Aetiology – GeneticCause. 
 
Therefore, based on the ontology query, PatientY is inferred to be a member of 




Can the ontology identify potential treatments for patients with high 
cholesterol, high triglyceride, and both? 
 
Figures 59 A, B and C illustrate the types of treatments that can be prescribed 
for patients with high cholesterol, high triglyceride and both, respectively. We 
present the evaluation results as classes instead of their instances in order to 




DL Query A: LPTreatment and (canDecreaseConcentrationOf some 
Cholesterol) 
DL Query B: LPTreatment and (canDecreaseConcentrationOf some 
Triglyceride) 
DL Query C: LPTreatment and ((canDecreaseConcentrationOf some 
Cholesterol) or (canDecreaseConcentrationOf some Triglyceride)) 
           
         A.              B.       C. 
Figure 59. Query result for competency question Treatment. 
 
According to the ontology reasoner, the ideal treatments for lowering cholesterol 
and triglyceride are CombinationTherapy, LifestyleChange, Statin and 
Fibrate. 
 
8.5.1.6 Diagnostic Parameter 
 
Can the ontology identify patients who are at risk of developing 
dyslipidaemia? 
 
The DiagnosticParameter sub-ontology was evaluated against several criteria. 
The first step in our evaluation is to determine if the reasoner is able to classify 
the different subclasses of the class Patient based on the necessary and 
sufficient conditions we have defined for certain classes. Figures 60 and 61 









Figure 61. Inferred model of the subclasses of the concept Patient in Protégé. 
 
In addition to the subclasses of Patient discussed in Chapter 7.6.6.4.1, we 
created another subclass of Patient, named PatientAtRisk, to classify the 
subset of patients which fall under the risk category (normal, borderline risk, high 
risk, very high risk) for various levels of total triglycerides, cholesterol, LDL 
cholesterol and HDL cholesterol. We also created the class RiskValuePartition, 
described in Chapter 7.6.6.4.2, which contains the subclasses Normal, 
BorderlineRisk, HighRisk and VeryHighRisk, to formalise and define the 
concept of risk value indicators associated with different plasma levels of total 
triglycerides, cholesterol, LDL cholesterol and HDL cholesterol.  
 
Based on the necessary and sufficient conditions that we have defined for each 
concept, the reasoner was then able to classify the ontology according to the 
respective definitions. Figure B above demonstrates that the concepts 
BorderlineRisk, HighRisk, VeryHighRisk, along with DyslipidaemicPatient 
are now classified under the concept PatientAtRisk, whereas the concept 
Normal is classified under the concept Patient.  
 
8.5.2 Evaluation of Lipoprotein Ontology Through Case Studies 
 
Another method of evaluating the practical usefulness of Lipoprotein Ontology is 
through the use of case studies or scenarios. For this purpose, we have 
developed a case study for evaluating the application of Lipoprotein Ontology 
specifically in clinical diagnosis and management of dyslipidaemia. 
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Consider the disease "metabolic syndrome", a clinical syndrome characterised 
by three or more criteria such as central obesity, hyperglycaemia, dyslipidaemia 
and hypertension (NCEP, 2001), as shown in Table 8 in Chapter 7.6.6.4.1 (Page 
185). For convenience, we included the table below. 
 
Table 8. NCEP/ATP III definition of the metabolic syndrome (NCEP, 2001). 
 
 
As the table illustrates, the criteria for central obesity differs between genders 
and ethnicities. The criteria for HDL cholesterol level is also different between 
men and women. Given that this information has been defined in Lipoprotein 
Ontology, we develop the following scenario.  
 
6 patients visit a clinic for a regular check up. Table 12 summarises each of the 
patient profile and the measurements taken:   
 
• Waist circumference 
• Total triglyceride concentration 
• Total cholesterol concentration 
• LDL cholesterol concentration 
• HDL cholesterol concentration 
• Fasting plasma glucose level  






Table 12. Patient profile according to ethnicity, waist circumference, total triglyceride 
concentration, total cholesterol concentration, LDL cholesterol concentration, HDL cholesterol 




Based on the measurements above with respect to their gender and ethnicity, 
they are shown to suffer from the associated conditions listed under the column 
"disorder". Given this scenario, we propose the questions:  
 
• Can the ontology identify the respective disorders associated with each 
patient, and identify the patient(s) suffering from the metabolic syndrome? 
• Can the ontology identify the risks associated with each individual?  
 
First, we created several asserted instances of Patient shown in Figure 62, 
which serve as baseline measures for us to verify the correct classification of the 
inferred instances of the class Patient. For example, asserted instances of 
MetabolicSyndrome include MetabolicSyndromeAsianMale, 
MetabolicSyndromeAsianFemale, MetabolicSyndromeCaucasianMale and 
MetabolicSyndromeCaucasianFemale. These instances were defined according 
to their respective object and datatype properties, and serve as baseline 
measures for us to verify the correct identity of the inferred instances of 
MetabolicSyndrome. Based on the necessary and sufficient conditions that we 
have defined for MetabolicSyndrome, any instance of Patient that has met the 






Figure 62. Query result to Patient. 
 
Without asserting the disorders they are suffering from, we created instances of 
Patient (John, Jane, Mark, Mary, Anthony and Amanda) with various object 
properties such as hasGender and hasEthnicity. In addition, for every instance 
we entered various datatype property values such as 
hasTriglycerideConcentration, hasHDLConcentration, hasWaistCircumference 
and hasBloodPressureValue (Table 9). In the first example, shown in Figures 63 
A, B, C and D below, we queried the ontology for instances of patients who 
suffer from a particular disorder, using different query parameters. 
 
DL Query (A): DyslipidaemicPatient  
DL Query (B): HyperglycaemicPatient 
DL Query (C): HypertensivePatient 
DL Query (D): ObesePatient 
 
              
A.              B.               C.                        D. 




Figures 63 A, B, C and D show the inference results to the corresponding 
queries, which match to the values in the "disorder" column that were not 
asserted for each individual. Figure 64 shows that based on the datatype 
property values that were entered for the instances, the ontology is capable of 
classifying individuals who belong to the class MetabolicSyndromePatient.  
 




Figure 64. Query result to MetabolicSyndromePatient. 
 
Based on the query results, we can then satisfy that Mark and Mary are both 
individuals suffering from the metabolic syndrome disorder. 
 
In addition to the inference of disorders according to the corresponding 
properties, the reasoner was also able to classify individuals who are at risk of 
developing dyslipidaemia according to different values (Normal, BorderlineRisk, 
HighRisk and VeryHighRisk) shown in Figure 65 A, B, C and D. 
 
DL Query (A): Normal  
DL Query (B): BorderlineRisk 
DL Query (C): HighRisk 






              
          A.                   B.               
 
           
       C.                                       D. 
 
Figure 65. Query result for individual risk indicator 
 
As the figures above illustrate, we were able to identify individuals according to 




This chapter presents the evaluation phase of Lipoprotein Ontology. Here, we 
evaluated our ontology using three measures. First, we evaluated the syntactic 
quality of our ontology using five design criteria which include: completeness, 
consistency, conciseness, extendibility and minimal encoding bias. 
Subsequently, the conceptual coverage of Lipoprotein Ontology was evaluated 
by mapping the concepts from 90 randomly selected abstracts from the PubMed 
database. Finaly, the practical usefulness of Lipoprotein Ontology was evaluated 
through the validation of competency questions, as well as a case study 
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This chapter provides a recapitulation of the work that was carried out in this 
thesis, with an emphasis on how our work has addressed the research 
objectives that were presented in Chapter 1. This is followed by a brief 
discussion on the significance of our research. We also elaborate on the 
limitations of Lipoprotein Ontology, and identify potential areas which can be 
developed further as future work. Finally, this thesis concludes with a reflection 
on the wider biomedical challenge. 
 
9.2 Summary of the Thesis 
 
In Chapter 1, we provided an overview of the lipoprotein research domain, which 
covers the classification of lipoproteins, lipoprotein metabolism, lipoprotein 
disorders (dyslipidaemia), causes and treatment of dyslipidaemia. We then 
discussed how existing literature fail to present an interrelated model of 
lipoprotein concepts or demonstrate the links between them. Subsequently, we 
highlighted some issues within the lipoprotein research domain, which serve as 
the motivation of our research. These issues include the complexity of 
lipoprotein metabolism pathways, the impact of dyslipidaemia on human health, 
causes of dyslipidaemia, as well as the diagnosis and treatment of 
dyslipidaemia. We followed this discussion by presenting the scope of the 
problem and the objectives of this thesis as follows: 
 
• Objective 1. To develop an overall methodology framework towards the 
development of Lipoprotein Knowledge Representation.  
 
• Objective 2. To conceptualise lipoprotein concepts and structure the 
lipoprotein domain into six sub-domains as follows: describing the 
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classification of lipoproteins in healthy individuals (Classification), 
modelling the complex metabolism of lipoproteins through systematic 
relationships between lipoprotein concepts (Metabolism), transferring this 
approach to the classification of lipoproteins in patients with lipoprotein 
disorders (Pathophysiology), mapping the causes of dyslipidaemia 
(Aetiology), modelling treatment options for lipoprotein disorders 
(Treatment) and providing a consistent representation of diagnostic 
parameters for dyslipidaemia (Diagnostic Parameter).  
 
• Objective 3. To formalise the conceptualisation of lipoprotein knowledge in 
OWL representation language in the following sub-ontologies: 
Classification, Metabolism, Pathophysiology, Aetiology, Treatment and 
Diagnostic Parameter. 
 
• Objective 4. To evaluate Lipoprotein Ontology through the use of case 
studies, which have been developed to evaluate the robustness and 
consistency of the lipoprotein knowledge framework.  
 
In Chapter 2, we presented the current state of research in the lipoprotein 
domain. First, we introduced various lipoprotein concepts, including the different 
lipoprotein classes, components and metabolism pathways. We then examined 
the implications of dyslipidaemia on health, by describing the key components in 
dyslipidaemia, clinical and metabolic features of dyslipidaemia, as well as the 
significance of dyslipidaemia in the metabolic syndrome. Subsequently, we 
elaborated on the management of dyslipidaemia in terms of the diagnostic 
parameters, causes and treatment of dyslipidaemia. We then described the 
nature of biomedical information and discussed KR techniques in the 
management of biomedical data. Accordingly, we introduced ontologies as the 
potential solution for knowledge management issues.  
 
Chapter 3 stated the main research issue identified in this thesis as the lack of a 
formal conceptualisation framework for the description, organisation and 
classification of lipoprotein-related information. We first defined the key concepts 
in the lipoprotein research domain and discussed challenges unique within the 
domain, which served as the motivation of study. The underlying research 
issues were identified, including the issues of information explosion and 
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unstructured domain knowledge, the heterogeneity of biomedical information, 
and difficulty in information retrieval. Based on these issues, we derived the 
following key research questions:  
 
1. How can we model lipoprotein concepts and relationships such that they 
can be used as a representation of the lipoprotein research domain? 
Specifically, how can we represent complex lipoprotein metabolism 
pathways in terms of concepts and relationships? 
2. How can the model be used to aid knowledge integration and management 
in the lipoprotein domain? How can we use this framework to infer 
knowledge to aid diagnosis of lipoprotein dysregulation?  
3. How can such a model faciliate collaboration between users? For instance, 
how can we develop this platform for easy transferrance of research output 
from different research groups?  
4. How can we validate our framework such that it is consistent and easily 
extensible? 
 
With these key research questions in mind, we discussed our choice of research 
approach towards the development of Lipoprotein Ontology, a formal framework 
for the description, organisation and classification of lipoprotein-related 
information. 
 
In Chapter 4, we provided an overview of the solution to the problem definition in 
Chapter 3. We introduced some ontology definitions and characteristics, and 
discussed the role of ontologies in addressing the corresponding research 
issues, by providing examples of current applications of ontologies in the 
biomedical domain. This is followed by a critical review of other biomedical 
ontologies, which do not fulfil the requirements for a specific lipoprotein ontology. 
We also reviewed existing methodologies on ontology development which serve 
as the justification towards our choice of methodology. Finally, this chapter 
concluded with an overview of Lipoprotein Ontology and defined the key 
concepts and relations in the ontology.  
 
In Chapter 5, we described the methodology that was used to develop 
Lipoprotein Ontology. This methodology was based on the Knowledge 
Engineering Methodology due to its focus on conceptual design. However, we 
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have also incorporated various aspects of other methodologies to suit the 
purpose of Lipoprotein Ontology, which were discussed accordingly. Our 
methodology incorporated different stages of other existing methodologies, and 
included the following processes: specification, conceptualisation, formalisation 
and evaluation. This chapter addressed Objective 1 presented in Chapter 1. 
 
Chapter 6 elaborated on the conceptual framework for the representation of 
lipoprotein domain knowledge, and elaborated on some of the upper level 
concepts which are represented in Lipoprotein Ontology. Essentially, this 
chapter served as the conceptual backbone for our ontology. Here, we 
organised lipoprotein-related concepts in a structured hierarchy using the 
ontology editor Protege 4.2, according to ontology principles that we have 
previously defined in an earlier section. We described the conceptualisation 
process of each of the six sub-ontologies of the lipoprotein domain knowledge, 
namely: Classification, Metabolism. Pathophysiology, Aetiology, Treatment and 
Diagnostic Parameter. Collectively, these sub-ontologies make up the lipoprotein 
conceptual framework, which is in alignment with Objective 2, namely: the 
classification of lipoproteins in healthy individuals (Classification), modelling the 
complex metabolism of lipoproteins through systematic relationships between 
lipoprotein concepts (Metabolism), transferring this approach to the classification 
of lipoproteins in patients with lipoprotein disorders (Pathophysiology), mapping 
the causes of dyslipidaemia (Aetiology), modelling treatment options for 
lipoprotein disorders (Treatment) and providing a consistent representation of 
diagnostic parameters for dyslipidaemia (DiagnosticParameter).  
 
In Chapter 7, we discussed the formalisation process of the lipoprotein 
conceptual framework described above. We have opted to use Protege 4.2 as 
our ontology development tool, OWL as the ontology language for the 
implementation of Lipoprotein Ontology and HermiT 1.3.8 as the reasoner. First, 
we provided an overview of knowledge representation languages associated 
with ontology building, and the justification behind our choice of implementation 
tool and language. This is followed by a brief introduction to the components of 
OWL ontologies and how they were utilised in Lipoprotein Ontology. We then 
discussed the structure of OWL ontologies, as well as the notation and syntax 
used throughout this chapter. This chapter concluded with a visualisation of 
Lipoprotein Ontology presented as screenshots from Protege to represent 
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various functions of concept classification, definition and description, using 
various OWL constructs. Therefore, Chapter 7 adequately addressed Objective 
3. At the time of writing, Lipoprotein Ontology contained 469 classes, 66 object 
properties, 25 data properties and 237 instances. Figure 66 shows the complete 




Figure 65. Ontrology metrics for Lipoprotein Ontology in Protégé. 
 
Chapter 8 served as the evaluation phase of Lipoprotein Ontology. We 
evaluated our ontology using three methods. First, the syntactic quality of the 
ontology was evaluated using five design criteria: completeness, consistency, 
conciseness, extendibility and minimal encoding bias. Next, we mapped the 
concepts from 90 randomly selected article abstracts from the PubMed 
database to Lipoprotein Ontology in order to evaluate its conceptual coverage. 
Our evaluation results indicate that there was an excellent match between the 
concepts from the selected articles and the Lipoprotein Ontology concepts, the 
best match being 100% and the lowest being 61.2%. Finally, we evaluated the 
practical application of Lipoprotein Ontology through the validation of the 
competency questions that were developed during our methodology phase, as 
well as a case study scenario. The results demonstrate that the ontology 
contained the necessary concepts and relations in addressing the competency 
questions, thus meeting Objective 4. 
 
9.3 Research Significance 
 
The development of Lipoprotein Ontology has significance for both lipoprotein 
and ontology domains. 
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• At the time of writing this thesis, Lipoprotein Ontology is the first ontology 
framework designed specifically for the lipoprotein research domain. 
Lipoprotein Ontology provides a formal framework for lipoprotein concepts 
and relationships that can be used to integrate, link and represent the 
disorganised and dispersed knowledge of lipoproteins in a systematic and 
meaningful way.  
 
• The development of a formal, explicit and common vocabulary framework 
for the lipoprotein domain enables interoperability between research 
groups, thereby allowing for more efficient retrieval and analysis of 
information, saving time and resources. 
 
• Lipoprotein Ontology has the potential to provide an overview of various 
research subjects and empirical findings such that different concepts and 
empirical results can be categorised accordingly and viewed in relation to 
one another. Therefore, through the unified structure of Lipoprotein 
Ontology, some previously undiscovered relationships among different 
theories and concepts can be revealed, which can serve as a motivation 
for researchers to carry out studies to address gaps in the literature.  
 
• Lipoprotein Ontology can serve as a basis for the design of ontology-driven 
tools and applications for various information retrieval, analysis and data 
mining purposes. For example, Lipoprotein Ontology can be applied to 
Semantic Web search engines through which information can be retrieved, 
managed and analysed in an intelligent way. This initiative is particularly in 
alignment with recent worldwide attempts to develop and replace the 
current form of web with Semantic Web. 
 
• Lipoprotein Ontology can be used as the basis for the development of 
applications for the diagnosis and treatment of lipoprotein disorders. By 
incorporating specific aspects of lipoprotein research in Lipoprotein 
Ontology, not only in terms of the classification of lipoproteins, but also 
understanding the metabolic pathway, pathophysiology, causes of 
lipoprotein dysregulation and treatment options for lipoprotein disorders 




9.4 Limitations and Future Work 
 
Lipoprotein Ontology is an ambitious endeavour and much of its potential has 
been discussed in this thesis, however there are a number of limitations. Some 
of these issues are discussed below and pave the way for future work. 
 
9.4.1 Limitations in Conceptual Representation 
 
As discussed previously in this thesis, the challenge of maintaining a 
comprehensive repository of lipoprotein knowledge is beyond the capability of a 
single person, and the success of an ontology ultimately depends on the end 
users. Although we consider Lipoprotein Ontology to offer sufficient formal 
representation of lipoprotein concepts for the purpose of this thesis, ontology 
development is a subjective process. Therefore, characteristic of all ontologies, 
the work is not presented as a complete task. There is a need for collaboration 
with domain experts for further development and maintenance of the ontology 
for further use. In view of this limitation, we have designed our ontology to be 
easily extensible to accommodate new concepts without compromising the 
original framework with respect to future work. This includes the possibility of 
exporting the ontology to other forms, such as UML. 
 
9.4.2 Lack of Collaboration 
 
The metabolism of lipoproteins involves many different enzymes, receptors and 
other components interacting in various pathways, all occurring in tandem, and 
with one reaction frequently affecting the rate of a previous or subsequent 
reaction. However, delving further into these processes and components would 
require additional knowledge from domain experts in their respective fields. 
Deciding the granularity of the ontology was a challenge we faced initially, but 
the evaluation process has shown that the ontology contains all the necessary 
lipoprotein concepts to a satisfactory extent. Some of the advantages of an 
ontology include having an open world assumption as well as extensibility. 
Hence, if necessary, the ontology can be extended to include other finer entities 
(concepts) involved in lipoprotein metabolism. Having a fine-grained view of the 
overall sequence of events and the reaction rates of the various pathways can 
potentially extend the inferential power of the ontology in predicting the effect of 
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disease states or an agent such as drug on fat absorption. For this to occur, 
there needs to be collaboration between lipoprotein specialists in the field of 
physiology, biochemistry, molecular biology and pharmacology. 
 
9.4.3 Parameters for Lipoprotein Kinetics 
 
Lipoprotein kinetics involves breaking down lipoprotein metabolism pathways 
into separate compartments and applying mathematical formulas to determine 
the rates of reaction which occur in different compartments (Chan et al., 2004). 
Having lipoprotein kinetics mathematically annotated to the ontology will greatly 
improve the reasoning capabilities of the ontology; the end-user will be able to 
harness the computational power of the ontology in a relatively straightforward 
manner once the concepts and rules have been built in. Due to constraints on 
the scope of Lipoprotein Ontology, we have decided to exclude lipoprotein 
kinetics from the ontology, but this can certainly be included in our future work. 
 
9.4.4 The Notion of Time 
 
Despite the processing power of OWL, the language does not provide any 
support for the representation of temporal information (O’Connor & Das, 2011). 
The notion of time is particularly relevant in biomedical data and clinical 
applications of ontologies as the ability to infer patterns over time has 
tremendous potential. Some of these promising applications which come to mind 
include analysing longitudinal studies and mining for patterns and trends, 
extrapolating risk factors given the patient’s history, current lifestyle habits and 
diagnostic parameters, as well as monitoring the success of a treatment course. 
Several systems have been developed which address the temporal dimension 
such as the Time Oriented Database (Wiederhold, 1981) and the Arden Syntax 
(Hripcsak et al., 1994), which allow the extraction of information according to 
certain temporal patterns by associating an instant timestamp with particular 
records. A lightweight yet expressive temporal model has also been developed 
to facilitate the consistent representation as well as querying of temporal 
information in OWL ontologies (O’Connor & Das, 2011). As the model was 
designed to be integrated with existing ontologies, applying this model to 
Lipoprotein Ontology could have potential benefits in the inference of patterns 




9.4.5 Sociological Limitations 
 
As with any endeavour, the challenge to the adoption of Lipoprotein Ontology is 
largely sociological. Although the biomedical community has been moving 
steadily forward towards an age of bioinformatics and biomedical ontologies, the 
success of Lipoprotein Ontology is dependent on its acceptance by the 
community. As much as possible, we have engineered the development of 
Lipoprotein Ontology as a response towards issues within the lipoprotein 




We conclude this thesis by presenting a summary of our work, with an emphasis 
on how we have addressed our objectives. We have developed an ontological 
framework for the formal representation of lipoprotein concepts in terms of their 
Classification, Metabolism, Pathophysiology, Aetiology and Treatment. By 
providing formal specifications of lipoprotein concepts in a system of hierarchical 
and associative relations, Lipoprotein Ontology serves as the semantic 
framework for the computable modelling of lipoprotein domain knowledge. The 
integration of knowledge is particularly important in translating research outputs 
from experimental studies into clinical care. Lipoprotein Ontology is designed to 
bridge the gap between lipoprotein research and clinical practice by providing a 
controlled terminology which enables researchers and practitioners to integrate 
and relate heterogeneous information in lipoprotein research, as well as link 
research findings to disease patterns. Associating research data with ontology 
terms also enables effective retrieval and intelligent querying of information. 
Furthermore, successful collaboration between research groups or software 
agents would benefit from a common platform of shared and agreed knowledge. 
On a more ambitious outlook, Lipoprotein Ontology can serve as the basis for 
the design of intelligent applications such as semantic search engines and tools 
for the diagnosis and treatment of dyslipidaemia. It is not anticipated that such 
applications could perform better than human experts; however they could play 
an important role in filtering the flood of data to the point where human experts 
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Appendix A. Major Lipoprotein Classes 
 
A comparison of density, size, electrophoretic mobility, percentage of total mass that is triglyceride (TG), cholesterol (C), 








Appendix B. Summary of Lipoprotein Metabolism Processes 
 









Appendix C. Major Human Apolipoproteins 
 
Major human apolipoproteinsa, lipoprotein classes, molecular weight, concentration in plasma, synthesis site and function 
 
Abbreviations: apo, apolipoprotein, VLDL, very low density lipoprotein; IDL, intermediate density lipoprotein; LDL, low density lipoprotein; HDL, high 
density lipoprotein; Lp(a), lipoprotein (a); ABCA1, ATP-binding cassete transporter; TG, triglycerides; TRL, triglyceride-rich lipoprotein; LPL, 
lipoprotein lipase; HL, hepatic lipase; LDLr, LDL receptor; LCAT, lecithin-cholesterol acyltransferase; CETP, cholesteryl ester transfer protein; LSR, 
lipolysis-stimulated lipoprotein receptor ; * To a lesser extent 
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Appendix D. Clinical Definitions of The Metabolic Syndrome 
 
Clinical definitions of metabolic syndrome from WHO, World Health Organization; NCEP/ATP III, National Cholesterol 





Appendix E. Classification of Cardiovascular Risk Factors 
 
Classification of risk factors of various lipids according to LDL-cholesterol, total plasma cholesterol, total plasma 




Abbreviations: NCEP/ATP III, National Cholesterol Education Program Adult Treatment Panel III; AACE, American Association of Clinical 
Endocrinologists; AHA, American Heart Association  
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Appendix F. Fredrickson/WHO Classification of Primary Hyperlipidaemia 
 
Fredrickson/WHO classification of primary hyperlipidaemia according to type with respect to its synonym, type of defect, 
electrophoresis patter, lipoprotein abnormality, concentrations of plasma cholesterol and triglycerides, clinical features as 




Abbreviations: VLDL, very low density lipoprotein; IDL, intermediate density lipoprotein; LDL, low density lipoprotein 
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Appendix G. Pharmacotherapy Effects on Lipoprotein Metabolism 
 















































Appendix H. Article Abstracts for the Evaluation of Lipoprotein Ontology 
 
No.	   Title	  of	  Paper	  
1.	   2009	  Canadian	  Cardiovascular	  Society	  Canadian	  guidelines	  for	  the	  diagnosis	  and	  treatment	  of	  dyslipidemia	  and	  prevention	  of	  
CVD	  in	  adults	  
2.	   A	  receptor-­‐mediated	  pathway	  for	  cholesterol	  homeostasis	  
3.	   A	  simplified	  approach	  to	  lipoprotein	  kinetics	  and	  factors	  affecting	  serum	  cholesterol	  and	  triglyceride	  concentrations	  
4.	   Additional	  cardiovascular	  risk	  factors	  associated	  with	  excess	  weight	  in	  children	  and	  adolescents.	  The	  Belo	  Horizonte	  Heart	  Study	  
5.	   An	  ABC	  of	  apolipoprotein	  C-­‐III:	  A	  clinically	  useful	  new	  cardiovascular	  risk	  factor?	  
6.	   Analysis	  for	  cholesterol	  in	  all	  lipoprotein	  classes	  by	  single	  vertical	  ultracentrifugationof	  fingerstick	  blood	  and	  controlled-­‐
dispersion	  flow	  analysis	  
7.	   Apolipoproteins	  and	  metabolism	  in	  atherosclerosis	  
8.	   Characterization	  of	  electrophoretic	  lipoprotein	  fractions:	  Immunochemical	  and	  electron	  microscopic	  studies	  
9.	   Characterization	  of	  plasma	  lipoproteins	  separated	  and	  purified	  by	  agarose-­‐column	  chromatography	  
10.	   Cholesterol	  metabolism,	  LDL,	  and	  the	  LDL	  receptor	  
11.	   Cholesterol	  metabolism	  
12.	   Chylomicron	  metabolism	  
13.	   Classification	  of	  hyperlipidaemias	  and	  hyperlipoproteinaemias	  
14.	   Classification	  of	  lipoproteins	  and	  lipoprotein	  disorders	  
15.	   Comparison	  of	  the	  efficacy	  and	  safety	  of	  rosuvastatin	  versus	  atorvastatin,	  simvastatin,	  and	  pravastatin	  across	  doses	  (STELLAR	  
Trial)	  
16.	   Detection,	  evaluation	  and	  treatment	  of	  high	  blood	  cholesterol	  in	  adults	  (ATP	  III)	  
17.	   Diet	  and	  triglyceride	  metabolism	  
18.	   Dietary	  fiber	  and	  its	  interaction	  with	  drugs	  
19.	   Differences	  in	  apolipoprotein	  and	  lipid	  composition	  between	  human	  chylomicron	  remnants	  and	  very	  low	  density	  lipoproteins	  
isolated	  from	  fasting	  and	  postprandial	  plasma	  
20.	   Discovery	  of	  the	  lipoproteins,	  their	  role	  in	  fat	  transport	  and	  their	  significance	  as	  risk	  factors	  
21.	   Disorders	  of	  lipid	  metabolism	  
22.	   Disorders	  of	  lipoprotein	  metabolism	  
23.	   Drug	  interactions	  of	  lipid-­‐altering	  drugs	  
24.	   Drug	  interactions	  with	  lipid-­‐lowering	  drugs:	  Mechanisms	  and	  clinical	  relevance	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25.	   Dynamics	  of	  lipoprotein	  transport	  in	  the	  human	  circulatory	  system	  
26.	   Effects	  of	  alcohol	  on	  lipoprotein	  lipase,	  hepatic	  lipase,	  cholesteryl	  ester	  transfer	  protein,	  and	  lecithin-­‐cholesterol	  acyltransferase	  
in	  high-­‐density	  lipoprotein	  cholesterol	  elevation	  
27.	   Effects	  of	  alcohol	  on	  plasma	  lipoproteins	  and	  cholesterol	  and	  triglyceride	  metabolism	  in	  man	  
28.	   Effects	  of	  atorvastatin	  treatment	  on	  the	  oxidatively	  modified	  low	  density	  lipoprotein	  in	  hyperlipidemic	  patients	  
29.	   Efficacy	  and	  safety	  of	  controlled-­‐release	  niacin	  in	  dyslipoproteinemic	  veterans	  
30.	   ESC/EAS	  Guidelines	  for	  the	  management	  of	  dyslipidaemias	  
31.	   Exploring	  the	  lipoprotein	  composition	  using	  Bayesian	  regression	  on	  serum	  lipidomic	  profiles	  
32.	   Familial	  hypobetalipoproteinemia:	  A	  review	  
33.	   Functional	  overlap	  between	  “chylomicra”	  and	  “very	  low	  density	  lipoproteins”	  of	  human	  plasma	  during	  alimentary	  lipaemia	  
34.	   Functions	  and	  interrelationships	  of	  different	  classes	  of	  plasma	  lipoproteins	  
35.	   Genetic	  basis	  of	  lipoprotein	  disorders	  
36.	   Genetic	  factors	  affecting	  blood	  lipoproteins:	  The	  candidate	  gene	  approach	  
37.	   Genetic	  influences	  on	  susceptibility	  to	  atherosclerosis	  in	  the	  young	  
38.	   Genetic	  markers	  in	  atherosclerosis:	  A	  review	  
39.	   Heterogeneity	  of	  human	  plasma	  very	  low	  density	  lipoproteins.	  Separation	  of	  species	  differing	  in	  protein	  components	  
40.	   Hypertriglyceridemia:	  Its	  etiology,	  effects	  and	  treatment	  
41.	   Hypolipoproteinaemia	  
42.	   Influence	  of	  diet	  and	  physical	  exercise	  on	  plasma	  lipid	  
43.	   Joint	  distribution	  of	  lipoprotein	  cholesterol	  classes.	  The	  Framingham	  study	  
44.	   Lipid	  absorption	  and	  metabolism	  
45.	   Lipid	  composition	  of	  human	  serum	  lipoproteins	  
46.	   Lipid	  composition	  of	  lipoproteins	  of	  normal	  human	  plasma	  
47.	   Lipid	  depletion	  in	  atheromatous	  coronary	  arteries	  in	  rhesus	  monkeys	  after	  regression	  diets	  
48.	   Lipid-­‐lowering	  drugs	  
49.	   Lipid	  metabolism	  
50.	   Lipoprotein	  heterogeneity	  and	  apolipoprotein	  B	  metabolism	  
51.	   Lipoprotein	  kinetics	  in	  the	  metabolic	  syndrome:	  Pathophysiological	  and	  therapeutic	  lessons	  from	  stable	  isotope	  studies	  
52.	   Lipoprotein	  management	  in	  patients	  with	  cardiometabolic	  risk	  
53.	   Lipoprotein	  structure	  and	  metabolism	  
54.	   Lipoproteins	  and	  cardiovascular	  reactivity	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55.	   Lipoproteins	  and	  lipoprotein	  metabolism:	  A	  dynamic	  evaluation	  of	  the	  plasma	  fat	  transport	  system	  
56.	   Low-­‐density	  lipoprotein,	  non-­‐high-­‐density	  lipoprotein,	  and	  apolipoprotein	  B	  as	  targets	  of	  lipid-­‐lowering	  therapy	  
57.	   Low-­‐density	  lipoprotein	  subclasses:	  Mechanisms	  of	  formation	  and	  modulation	  
58.	   Metabolic	  relationships	  among	  the	  plasma	  lipoproteins	  
59.	   Metabolic	  syndrome:	  The	  danger	  signal	  in	  atherosclerosis	  
60.	   Molecular	  genetics	  of	  lipoprotein	  disorders	  
61.	   Pathophysiology	  of	  dyslipidaemia	  in	  the	  metabolic	  syndrome	  
62.	   Plasma	  lipid	  concentrations:	  The	  concept	  of	  normality	  and	  its	  implications	  for	  detection	  of	  high	  cardiovascular	  risk	  
63.	   Plasma	  lipids	  and	  lipoproteins	  in	  liver	  disease	  
64.	   Plasma	  lipoproteins:	  Genetic	  influences	  and	  clinical	  implications	  
65.	   Plasma	  lipoproteins,	  lipid	  transport,	  and	  atherosclerosis	  -­‐	  recent	  developments.	  
65.	   Plasma	  triglyceride	  determines	  structure-­‐composition	  in	  low	  and	  high	  density	  lipoproteins	  
66.	   Plasma	  or	  patient,	  paper	  electrophoresis	  or	  physician?	  The	  four-­‐P	  problem	  in	  classification	  of	  hyperlipidaemia	  
67.	   Postheparin	  plasma	  lipoprotein	  and	  hepatic	  lipase	  are	  determinants	  of	  hypo-­‐	  and	  hyperalphalipoproteinemia	  
68.	   Prediction	  of	  coronary	  heart	  disease	  using	  risk	  factor	  categories	  
69.	   Prevention	  and	  treatment:	  A	  tale	  of	  two	  strategies	  
70.	   Recommendations	  for	  the	  management	  of	  dyslipidemia	  2003	  update	  
71.	   Risk	  for	  myopathy	  with	  statin	  therapy	  in	  high-­‐risk	  patients	  
72.	   Separation	  of	  the	  main	  lipoprotein	  density	  classes	  from	  human	  plasma	  by	  rate-­‐zonal	  ultracentrifugation	  
73.	   Secondary	  hyperlipidaemia	  
74.	   Serum	  lipoproteins	  in	  four	  European	  communities:	  A	  quantitative	  comparison	  
75.	   Simple	  scoring	  scheme	  for	  calculating	  the	  risk	  of	  acute	  coronary	  events	  based	  on	  the	  10-­‐year	  follow-­‐up	  of	  the	  prospective	  
cardiovascular	  Münster	  (PROCAM)	  study	  
76.	   Standardization	  of	  measurements	  for	  cholesterol,	  triglycerides,	  and	  major	  lipoproteins	  
77.	   Statin	  safety	  and	  drug	  interactions:	  Clinical	  implications	  
78.	   Structural	  heterogeneity	  of	  apoB-­‐containing	  serum	  lipoproteins	  visualized	  using	  cryo-­‐electron	  microscopy	  
79.	   Studies	  of	  the	  mechanisms	  of	  carbohydrate-­‐induced	  lipaemia	  in	  normal	  man	  
80.	   Studies	  on	  the	  composition	  and	  structure	  of	  plasma	  lipoproteins:	  Distribution	  of	  lipoprotein	  families	  in	  major	  density	  classes	  of	  
normal	  human	  plasma	  lipoproteins	  
81.	   The	  anti-­‐coronary	  club:	  A	  dietary	  approach	  to	  the	  prevention	  of	  coronary	  heart	  disease	  -­‐	  a	  7	  year	  report	  
82.	   The	  distribution	  and	  chemical	  composition	  of	  ultracentrifugally	  separated	  lipoproteins	  in	  human	  serum	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83.	   The	  enterohepatic	  circulation	  of	  bile	  acids	  as	  they	  relate	  to	  lipid	  disordersx	  
84.	   The	  metabolic	  heterogeneity	  of	  human	  very	  low	  density	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Numerous methodologies have been proposed for ontology development. The 
following describes some of these methodologies, of which we have provided a 
comparison and critical review in Chapter 4.5. 
 
1.1 Knowledge Engineering Methodology 
 
A simple Knowledge Engineering Methodology was proposed by Noy & 
McGuinness to develop an ontology (Noy & McGuinness, 2001). Three 
fundamental rules serve as the basis for the methodology: 1. Modelling a 
domain depends on the application the ontology is built for; 2. Ontology 
development is an iterative process; 3. Concepts in the ontology should be as 
close to objects (nouns) and relationships (verbs) in the domain of interest. The 
methodology covers seven steps: purpose and scope identification, reusing 
existing ontologies if applicable, highlighting important terms in the ontology, 
defining the classes and class hierarchy, defining the properties of classes, 
defining restrictions, and creating instances. The first step defines the purpose 
and scope of the ontology by developing competency questions to which an 
ontology should be able to answer. These questions will also be used to validate 
the ontology later on. The second step involves refining and extending existing 
ontologies towards the domain of interest and intended purpose. This is 
particularly useful if the system is required to interact with other applications 
which have already committed to particular ontologies. The third step is the 
informal conceptualisation phase which consists of obtaining a comprehensive 
list of important terms and relations. In the fourth step, the concepts obtained 
from the previous stage are arranged in a class hierarchy. There are several 
possible approaches, which includes a top-down approach of defining the most 
general concepts in the domain and subsequent specialisation of the concepts, 
bottom-up approach of starting with the most specific concepts and subsequent 
grouping of these concepts into more general concepts, and a middle-out 
approach that combines the top-down and bottom-up approaches (Uschold & 
Gruninger, 1996). The fifth step involves defining the properties of the concepts 
that have been established in the previous step. The sixth step consists of 
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describing the value type (e.g. string or integer), allowed values, the number of 
values (cardinality) a property might have. The final step involves creating  
individual instances of the classes in the hierarchy. Defining an individual 
instance of a class requires allocating an individual instance to a class and 
describing its property.  
 
1.2 Uschold & King Methodology 
 
Uschold & King proposed a general methodology towards ontology 
development, based on the experience of creating Enterprise Ontology (Uschold 
& King, 1995). The methodology incorporates four main steps: purpose 
identification, ontology building, evaluation and documentation. In the initial 
stage, the ontology builder defines the purpose of the ontology and its intended 
applications. Competency questions can be drawn to assist in the clarification of 
the purpose, as well as serve as a reference document for validating the 
completed ontology. The ontology building stage includes three sub-phases: 
ontology capture, ontology coding and integration of available ontologies. 
Ontology capture involves identifying domain concepts and their relationships 
via a middle-out approach: by identifying the most general concepts, which are 
then used to branch out to upper and lower concepts by generalisation or 
specialisation respectively. In the coding phase, the concepts and relationships 
specified in the previous stage are formalised using a representation language. 
The integration task considers the possible incorporation of other existing 
ontologies into the ontology. In the third stage, the developed ontology is 
evaluated. The evaluation can be made with respect to reference criteria such 
as competency questions which were established in the initial phase, 
requirement specifications as well as compliance with the real world. The 
documentation stage prescribes the documentation of all underlying 
assumptions about the concepts in a given ontology in order to facilitate the 
process of effective knowledge sharing and reuse (Uschold & King, 1995). 







1.3 TOVE Methodology 
 
The TOVE methodology was originally developed to aid enterprise process 
modelling at the Toronto University (Gruninger & Fox, 1995). The process 
includes the use motivating scenarios as well as a set of competency questions 
to determine the scope of the ontology to be modelled, and aims to generate an 
enterprise model which is capable of deducing answers to users’ implicit 
queries. It places a special emphasis on the formulation of informal competency 
questions to which the ontology must be an answer. TOVE incorporates six 
stages: creating motivating scenarios, formulating informal competency 
questions, formalising terms extracted from the competency questions, 
developing formal competency questions, establishing first-order logic axioms, 
and validation using completeness theorems. In the motivating scenario stage, 
the ontology developer identifies and describes situations and applications to 
which ontology is expected to offer solutions. The proposed motivating scenario 
also incorporates a number of intuitively potential solutions to the identified 
problems as well as a rationale for including certain objects in the ontology. In 
the next stage, the requirements or questions to which ontology should provide 
answers are specified and described in an informal way. Subsequently, a set of 
terms are extracted from the informal competency questions and formally 
expressed in first-order logic or KIF language. The terminology specification 
relies on the identification of the objects, their attributes and relations in the 
given domain. In the next stage, the established ontology terminology is used to 
develop the formal competency questions. Through an iterative process, first-
order logic axioms are defined in order to provide semantics for the ontology 
terms and concepts. Axioms provide terms with appropriate definitions and 
impose restrictions on their interpretations. The process of axiom specification is 
basically directed by the predefined formal competency questions. Axioms are 
necessary and must adequately express the competency questions and their 
potential solutions. If an insufficient number of axioms have been proposed, then 
they must be refined and extended, and if necessary, other axioms added until 
there are adequate axioms for representing questions and solutions. In the final 
stage, called the completeness theorem, the expert will define the conditions 
under which the ontology has offered complete solutions to the competency 
questions. The formal competency questions, in this phase, is used to prove the 
completeness theorems of the established ontology (Gruninger & Fox, 1995). 
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1.4 DOGMA Methodology 
 
The DOGMA (Developing Ontology-Grounded Methods and Applications) 
methodology (Spyns et al., 2008) separates the conceptualisation of a domain 
(ontology base) from their application (commitment layer), which allows for 
reusability and scalability in reasoning about formal semantics. The 
methodology offers a special paradigm for the separation of the domain 
axiomatisation (the ontology base) from the application axiomatisation (the 
commitment layer) with the purpose of finding a solution for the trade-off 
problem which often exists between an ontology’s usability and its reusability. 
The advantage of DOGMA allows domain experts and users to have multiple 
views and requirements for different applications while using the same stored, 
meaning-independent conceptualisation (Spyns et al., 2008). Moreover, the 
DOGMA proposes the notion of the context which can be considered as an 
identifier to restrict the interpretation of each term to the specified concepts 




The METHONTOLOGY framework was developed by by Polytechnic University 
of Madrid, based on IEEE standards for Developing Software Life Cycle 
Processes, 1074-1995  (Fernández-López, M., & Gomez-Perez, A., 2002) The 
methodology basically enables the construction of ontologies at the knowledge 
level. METHONTOLOGY proposes three separate, yet overlapping set of 
activities to develop ontologies based on an evolving life cycle and prototype 
refinement: ontology development process, support activities and project 
management process. The developmental process in METHONTOLOGY 
incorporates the stages of requirement specification, domain conceptualisation, 
formalisation of the conceptual model in a formal language, implementation of 
the formal model and maintenance of the implemented ontology. The support 
actions may include knowledge acquisition, documentation, evaluation and 
integration of other ontologies. Finally, the project management activities 
concern the tasks of planning, control and quality assurance (Fernández-López, 
M., & Gomez-Perez, 2002). WebODE, which will be discussed in the next 





Developed at the Karlsruhe University, OnToKnowledge is a process-oriented 
methodology that focuses on knowledge management and maintenance in 
enterprises with respect to an analysis of usage scenarios (Staab et al., 2001). 
OnToKnowledge is based on a two-loop architecture: knowledge process and 
knowledge meta process. Knowledge process includes knowledge acquisition 
and evolution process. Knowledge meta process is a methodology of ontology 
development and consists of five steps: feasibility study, kick off, which includes 
specifying ontology requirements, identifying competency questions and 
considering the use of other ontologies; refinement, where a mature ontology is 
produced; evaluation, where the ontology is validated according to the initial 
requirements and competency questions; maintenance  (Fense et al., 1999).  
 
1.7 DILIGENT Methodology 
 
The DILIGENT methodology aims to support DIstributed, Loosely controlled and 
evolvInG Engineering of oNTologies (Pinto et al., 2004). It can be considered as 
an extension of ontology engineering methodologies such as OnToKnowledge 
or METHONTOLOGY with an emphasis on user centrality. It plans to integrate 
automatic agents in the ontology evolution process, allowing the ontology 
engineer to adapt to the unremitting change of domain knowledge. The 
DILIGENT methodology involves five major steps: building, local adaptation, 
analysis, revision and local update. In the building stage, the initial ontology is 
built by a small number of domain experts, users, ontology engineers and 
knowledge engineers. The ontology model at this stage need not be complete. 
After this preliminary ontology has been established, the users start working with 
it, developing their local ontologies by adapting it to their local requirements. The 
users are also able to modify the core ontology through a control board which 
records all modifications. At the analysis stage, local ontologies and the 
requests for change are analysed by the control board so that similarities among 
them can be discovered. After that, decisions will be made as to which 
modifications need to be applied to the core ontology to meet various users’ 
requirements. However, the new adaptations and localisation need to be revised 
in order to ensure that the core ontology has not lost its sharable quality. Hence, 
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the revision stage aims to adapt the ontology to various applicants’ 
requirements, enhancing its acceptance, consensuality and sharedness (Pinto 
et al., 2004). Experts from different areas take responsibility for the revision of 
the ontology. For example, users evaluate the usability and advantages of the 
ontology, providing feedback to ontology engineers through their requests and 
requirements. Respectively, the existence of factual mistakes and the degree to 
which the ontology represents the intended knowledge domain are assessed by 
domain experts. Correspondingly, knowledge engineers and ontology engineers 
evaluate the technical dimensions of the ontology such as its efficiency, logical 
properties or standard conformance, trying to update as well as hold the balance 
of different applied ontology modifications. Finally, at the stage of local update, 
applicants update their local ontologies to cope with the revisions which have 
been introduced to the modified core ontology  (Vrandecic et al., 2005). The 
DILIGENT methodology is particularly suitable for de-centralised knowledge 
management systems. It also offers flexibility in the use of ontology language or 
formalisms  (Vrandecic et al., 2005). 
 
1.8 KACTUS Methodology 
 
The KACTUS methodology involves building the ontology on the basis of a 
knowledge base through the process of abstraction, following a bottom-up 
strategy  (Bernaras et al., 1996). Initially, a knowledge base is built towards a 
specific application, but as more requirements are needed, the knowledge base 
is subsequently generalised into an ontology and adapted to the new 
applications. The more applications are built, the more general the ontology 
becomes. By applying this method recursively, the ontology gradually expands 
and represents consensual knowledge needed in all applications.  
 
1.9 SENSUS Methodology 
 
The SENSUS methodology derives domain-specific ontologies from large 
ontologies and enables reusability of knowledge since they have a common 
underlying structure (Swartout et al., 1997). The process involves the 
identification of “seed” terms which are relevant to a given domain, and linked 
manually to an upper ontology. All the concepts from the seed terms to the root 
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of the ontology are included; any missing term is added manually and the 
previous step is performed again to ensure completeness. In addition, nodes 
which have a large number of associations through them would have the entire 
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